

(10) Patent No.:

8,952,127 B2*

9.073.977 B2*

9,764,953 B2*

(56)

WO

p. 23-29.*

(45) Date of Patent:

US011739162B2

References Cited

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PUBLICATIONS Mahmoudi, Neda et al; "PEG-mimetic peptoid reduces protein

fouling of polysulfone hollow fibers." Colloids Surf. B (2017) 149

Seeman, Nadrian C., "DNA in a Material World," Nature 421.6921,

WO-2021030218 A1 * 2/2021 A61K 47/543

US 11,739,162 B2

2/2015 Chen C08G 69/10

7/2015 Zuckermann C07K 14/001

9/2017 Zuckermann C01B 25/455

Aug. 29, 2023

423/430

(12) United States Patent

Wang et al.

(54) SIDE CHAIN MODIFIED PEPTOIDS USEFUL AS STRUCTURE-STABILIZING COATINGS FOR BIOMATERIALS

- (71) Applicants: Brookhaven Science Associates, LLC, Upton, NY (US); The Regents of the University of California, Oakland, CA (US); The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); The Trustees of Columbia University in the City of New York, New York, NY (US)
- (72) Inventors: Shih-Ting Wang, Mastic, NY (US); Oleg Gang, Setauket, NY (US); Ronald N. Zuckermann, El Cerrito, CA (US); Carolyn R. Bertozzi, Menlo Park, CA (US)
- (73) Assignees: Brookhaven Science Associates LLC, Upton, NY (US); The Board of **Trustees of the Leland Stanford** Junior University, Stanford, CA (US); The Regents of the University of California, Oakland, CA (US); The Trustees of Columbia University in the City of New York, New York, NY (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 232 days.
- (21) Appl. No.: 17/015,532
- (22)Filed: Sep. 9, 2020

(65)**Prior Publication Data**

US 2021/0070886 A1 Mar. 11, 2021

Related U.S. Application Data

- (60) Provisional application No. 62/897,451, filed on Sep. 9, 2019.
- (51) Int. Cl.

С07К 7/06	(2006.01)
C07K 17/06	(2006.01)
A61K 47/69	(2017.01)
C07K 1/10	(2006.01)
B82Y 5/00	(2011.01)

- (52) **U** X 47/6923 (CO7K 7/06 (2013.01); *B82Y 5/00* (2013.01)
- (58) **Field of Classification Search** None See application file for complete search history.

J021 J/00	(2011.01)
U.S. Cl.	
CPC	C07K 17/06 (2013.01); A61B
(201	7.08): C07K 1/10 (2013.01): C

pp. 427-431 (2003).

Lin C, et al., "Designer DNA Nanoarchitectures," Biochemistry 48, pp. 1663-1674 (2009)

Pinheiro A V, et al., "Challenges and Opportunities for Structural DNA Nanotechnology," Nature Nanotechnology 6, pp. 763-772 (2011).

Rothemund, Paul WK. "Folding DNA to Create Nanoscale Shapes and Patterns," Nature 440.7082, pp. 297-302 (2006).

Mirkin, Chad A., et al. "A DNA-Based Method for Rationally Assembling Nanoparticles into Macroscopic Materials," Nature 382.6592, pp. 607-609 (1996).

Niemeyer, Christof M., et al., "Covalent DNA-Streptavidin Conjugates as Building Blocks for Novel Biometallic Nanostructures, Angewandte Chemie International Edition 37(16), pp. 2265-2268 (1998)

Keren, Kinneret, et al. "Sequence-Specific Molecular Lithography on Single DNA Molecules," Science 297.5578, pp. 72-75 (2002). Ford, William E., et al. "Platinated DNA as Precursors to Templated Chains of Metal Nanoparticles," Advanced Materials 13(23) pp. 1793-1797 (2001).

Alivisatos, A. Paul, et al. "Organization of 'Nanocrystal Molecules'

Minolo, A., Nature 382, 6592, pp. 609-611 (1996).
Nykypanchuk, Dmytro, et al. "DNA-Guided Crystallization of Colloidal Nanoparticles," Nature 451.7178, pp. 549-552 (2008).
Zhang, Yugang, et al. "A General Strategy for the DNA-Mediated College activity of Energy of the DNA-Mediated Strategy for the DNA-Mediated

Self-Assembly of Functional Nanoparticles into Heterogeneous Systems," Nature Nanotechnology 8(11), pp. 865-872 (2013).

Chandrasekaran, Arun Richard, et al., "DNA Nanocages," Chemistry of Materials 28(16), pp. 5569-5581 (2016).

Schneider, Ann-Kathrin, et al., "DNA Surface Technology: From Gene Sensors to Integrated Systems for Life and Materials Sciences," Angewandte Chemie International Edition 57(52), pp. 16959-16967 (2018).

Zhu, Bing, et al. "Precisely Tailored DNA Nanostructures and Their Theranostic Applications," The Chemical Record 17(12) pp. 1213-1230 (2017).

(Continued)

Primary Examiner - Fred H Reynolds

(74) Attorney, Agent, or Firm - Baker Botts LLP

(57)ABSTRACT

The current invention pertains compositions and methods to generate compositions providing stability to biomolecules, including providing physiologically stable and functional DNA origami-based drug/gene delivery carriers by surface coating with the oligo-ethylene glycol conjugated peptoids of Formulas (I), (II), and (III).

2 Claims, 78 Drawing Sheets

Specification includes a Sequence Listing.

(56) **References Cited**

OTHER PUBLICATIONS

Zhang, Yuezhou, et al. "Programmable and Multifunctional DNA-Based Materials for Biomedical Applications," Advanced Materials 30(24) 1703658 (2018).

Fu, Jinglin, et al. "Spatially-Interactive Biomolecular Networks Organized by Nucleic Acid Nanostructures," Accounts of Chemical Research 45(8) pp. 1215-1226 (2012).

Li, Jiang, et al. "Smart Drug Delivery Nanocarriers with Self-Assembled DNA Nanostructures," Advanced Materials 25(32) pp. 4386-4396 (2013).

Amir, Yaniv, et al. "Universal Computing by DNA Origami Robots in a Living Animal," Nature Nanotechnology 9(5) pp. 353-357 (2014).

Douglas, Shawn M., et al., "A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads," Science 335.6070, pp. 831-834 (2012).

Bujold, Katherine E., et al., "Optimized DNA "Nanosuitcases" for Encapsulation and Conditional Release of siRNA," Journal of the American Chemical Society 138(42), pp. 14030-14038 (2016).

Schuller, Verena J., et al. "Cellular Immunostimulation by CpG-Sequence-Coated DNA Origami Structures," ACS Nano 5(12) pp. 9696-9702 (2011).

Grossi G, et al., "Control of Enzyme Reactions by a Reconfigurable DNA Nanovault," Nat Commun 8:992, pp. 1-8 (2017).

Ora A, et al. (2016) Cellular delivery of enzyme-loaded DNA origami. Chem Commun 52:14161-14164.

Jiang, Qiao, et al. "DNA Origami as a Carrier for Circumvention of Drug Resistance," Journal of the American Chemical Society 134(32) pp. 13396-13403 (2012).

Zhang, Qian, et al. "DNA Origami as an In Vivo Drug Delivery Vehicle for Cancer Therapy," ACS Nano 8(7), pp. 6633-6643 (2014).

Sun W, et al. "Cocoon-Like Self-Degradable DNA Nanoclew for Anticancer Drug Delivery," Journal of the American Chemical Society 136, pp. 14722-14725 (2014).

Douglas S. M., et al. "Self-Assembly of DNA into Nanoscale Three-Dimensional Shapes," Nature 459.7245, pp. 414-418 (2009). Hahn, Jaeseung, et al. "Addressing the Instability of DNA Nanostructures in Tissue Culture," ACS Nano 8(9), pp. 8765-8775 (2014).

Kielar C, et al. "On the Stability of DNA Origami Nanostructures in Low-Magnesium Buffers," Angew Chemie Int Ed 57, pp. 9470-9474 (2018).

Kim, Hyojeong, et al., "Stability of DNA Origami Nanostructure under Diverse Chemical Environments," Chem Mater 26, pp. 5265-5273 (2014).

Benson E, et al. "Effects of Design Choices on the Stiffness of Wireframe DNA Origami Structures," ACS Nano 12, pp. 9291-9299 (2018).

Benson E, et al., "DNA Rendering of Polyhedral Meshes at the Nanoscale," Nature 523.7561, pp. 441-444 (2015).

Veneziano, R., et al. "Designer Nanoscale DNA Assemblies Programmed from the Top Down," Science 352.6293 pp. 1534-1534 (2016).

Gerling T, et al., "Sequence-Programmable Covalent Bonding of Designed DNA Assemblies," Science Advances 4: eaau1157 (2018). Cassinelli, Valentina, et al. "One-Step Formation of "Chain-Armor"-Stabilized DNA Nanostructures," Angewandte Chemie International Edition 54.27, pp. 7795-7798 (2015).

Ponnuswamy N, et al. "Oligolysine-Based Coating Protects DNA Nanostructures from Low-Salt Denaturation and Nuclease Degradation," Nat Commun 8:15654 (2017).

Kiviaho J.K., et al. "Cationic Polymers for DNA Origami Coating— Examining Their Binding Efficiency and Tuning the Enzymatic Reaction Rates," Nanoscale 8, pp. 11674-11680 (2016).

Agarwal, N.P., et al., "Block Copolymer Micellization as a Protection Strategy for DNA Origami," Angew Chemie Int Ed 56, pp. 5460-5464 (2017).

Mikkila J, et al. "Virus-Encapsulated DNA Origami Nanostructures for Cellular Delivery," Nano Lett 14, pp. 2196-2200 (2014). Auvinen H, et al. Protein Coating of DNA Nanostructures for Enhanced Stability and Immunocompatibility, Advanced Healthcare Materials, 6:1700692 (2017).

Sun, Jing, et al., "Peptoid Polymers: A Highly Designable Boinspired Material," ACS Nano 7.6, pp. 4715-4732 (2013).

Figliozzi G.M., et al. "[25] Synthesis of N-Substituted Glycine Peptoid Libraries," Methods in Enzymology 267, pp. 437-447 (1996).

Webster A.M., et al. "Recent Advances in the Synthesis of Peptoid Macrocycles," Chemistry—A European Journal 24.30. pp. 7560-7573 (2018).

Miller, Susan M., et al. "Proteolytic Studies of Homologous Peptide and N-Substituted Glycine Peptoid Oligomers," Bioorganic & Medicinal Chemistry Letters 4.22, pp. 2657-2662 (1994).

Wender, Paul A., et al. "The Design, Synthesis, and Evaluation of Molecules that Enable or Enhance Cellular Uptake: Peptoid Molecular Transporters." Proceedings of the National Academy of Sciences 97.24 pp. 13003-13008 (2000).

Rothbard, Jonathan B., et al. "Arginine-Rich Molecular Transporters for Drug Delivery: Role of Backbone Spacing in Cellular Uptake," Journal of Medicinal Chemistry 45.17, pp. 3612-3618 (2002).

Schroder, Tina, et al. "Peptoidic Amino-and Guanidinium-Carrier Systems: Targeted Drug Delivery Into the Cell Cytosol or the Nucleus," Journal of Medicinal Chemistry 51.3, pp. 376-379 (2008). Murphy, John E., et al. "A Combinatorial Approach to the Discovery of Efficient Cationic Peptoid Reagents for Gene Delivery." Proceedings of the National Academy of Sciences 95.4 (1998): 1517-1522.

Tian, Y, et al. "Prescribed Nanoparticle Cluster Architectures and Low-Dimensional Arrays Built Using Octahedral DNA Origami Frames," Nature Nanotechnology 10, pp. 637-644 (2015).

Tian, Ye, et al. "Lattice Engineering Through Nanoparticle-DNA Frameworks," Nature Materials 15.6, pp. 654-661 (2016).

Statz, Andrea R., et al. "New Peptidomimetic Polymers for Antifouling Surfaces," Journal of the American Chemical Society 127. 22, pp. 7972-7973 (2005).

Xuan, Sunting, et al. "Synthesis and Characterization of Well-Defined PEGylated Polypeptoids as Protein-Resistant Polymers," Biomacromolecules 18.3, pp. 951-964 (2017).

Dragan, A. I., et al. "SYBR Green I: Fluorescence Properties and Interaction with DNA," Journal of Fluorescence 22.4, pp. 1189-1199 (2012).

Zipper, Hubert, et al. "Investigations on DNA Intercalation and Surface Binding by SYBR Green I, its Structure Determination and Methodological Implications," Nucleic Acids Research 32.12, pp. e103-e103 (2004).

Krishnamoorthy, G., et al., "Structure and Dynamics of Condensed DNA Probed by 1, 1 '-(4, 4, 8, 8-Tetramethyl-4, 8-Diazaundecamethylene) bis [4-[[3-Methylbenz-1, 3-Oxazol-2-yl] Methylidine]-1, 4-Dihydroquinolinium] Tetraiodide Fluorescence," Biochemistry 41.51, pp. 15277-15287 (2002).

Guarnieri, Frank, et al., "Simulated Annealing of Chemical Potential: A General Procedure for Locating Bound Waters. Application to the Study of the Differential Hydration Propensities of the Major and Minor Grooves of DNA," Journal of the American Chemical Society 118.35, pp. 8493-8494 (1996).

Spink, Charles H., et al., "Effects of Hydration, Ion Release, and Excluded Volume on the Melting of Triplex and Duplex DNA," Biochemistry 38.1, pp. 496-508 (1999).

Tateishi-Karimta, et al., "Control of Stability and Structure of Nucleic Acids Using Cosolutes," Methods 67.2, pp. 151-158 (2014). Miyoshi, Daisuke, et al. "Hydration Regulates Thermodynamics of G-Quadruplex Formation Under Molecular Crowding Conditions" Journal of the American Chemical Society 128.24, pp. 7957-7963 (2006).

Munkholm, Christiane, et al., "Intramolecular Fluorescence Self-Quenching of Fluoresceinamine," Journal of the American Chemical Society 112.7, pp. 2608-2612 (1990).

Hu, Lianzhe, et al. "Highly Sensitive Fluorescent Detection of Trypsin Based on BSA-Stabilized Gold Nanoclusters," Biosensors and Bioelectronics 32.1, pp. 297-299 (2012).

(56) **References Cited**

OTHER PUBLICATIONS

Xiao, Han, et al. "Precision Glycocalyx Editing as a Strategy for Cancer Immunotherapy" Proceedings of the National Academy of Sciences 113.37, pp. 10304-10309 (2016).

* cited by examiner





FIG. 1B







FIG. 2A



FIG 2B



FIG. 3A



FIG. 3B



FIG. 3C



FIG. 3D



FIG. 3E



FIG. 3F



FIG. 4A



FIG. 4B



FIG. 4C



FIG. 4D



FIG. 4E



FIG. 4F







FIG. 5A



FIG. 5B



FIG. 6A



FIG. 6B



FIG. 6C



FIG. 6D



FIG. 7A



FIG. 7B



FIG. 8A







FIG. 8C

OC/PE8-Tz

OC/PE9-Tz



FIG. 8D





FIG. 9A



FIG. 9B



FIG. 10


FIG. 11





FIG. 13B







FIG. 13G



FIG. 14A







FIG. 14E



FIG. 14F



FIG. 14G





FIG. 15B







FIG. 18A

dsDNA/PE2, N/P =							
8	4	2	1	0.5	0.25	0.125	0

FIG. 18B



FIG. 19A





FIG. 19C









FIG. 21B



2 0 1







. С Ц





Н С 20







0 L







Aug. 29, 2023

S C L





FIG. 34A





FIG. 35A



С С С С С




FIG. 37A



р С С С



FIG. 38A



FIG. 38B



FIG. 39



FIG. 40



FIG. 41



Ц С С



FIG. 43

SIDE CHAIN MODIFIED PEPTOIDS USEFUL AS STRUCTURE-STABILIZING COATINGS FOR BIOMATERIALS

STATEMENT OF GOVERNMENT RIGHTS

This invention was made with government support under DE-SC0012704 and DE-AC02-05CH11231 awarded by Department of Energy. The government has certain rights in the invention(s).

FIELD OF THE INVENTION

This invention relates to stabilizing biomaterials for biomedical applications. 15

BACKGROUND OF THE INVENTION

DNA nanotechnology allows to program self-assembly of synthetic oligonucleotides into structures with prescribed 20 topologies and spatial configurations. One of such approaches is called DNA origami. Advancement in DNA origami design and synthesis with high-precision structural controls has enabled potential biomedical applications, including smart drug/gene delivery carriers and biomolecu- 25 lar devices at the cellular level. Additionally, DNA origamis designed with controlled shape, biocompatibility and responsiveness toward other biomolecules (e.g., proteins, lipids, DNAs, and RNAs), may serve as a reliable molecular interface and augment functionalities of the hybrid bio/nano 30 system. This technology applies a bottom-up approach in nanocarrier design and synthesis that may bring potential solutions in targeted drug/gene delivery and biomedical imaging and sensing, in which translation of nanoformulation carriers into clinical applications has remained chal- 35 lenging due to the difficulty to regulate interfaces between the nanocarriers and biological systems.

There are some roadblocks to maximizing this technology, however. For example, biomedical applications of DNA origamis with precisely defined nanostructures are 40 often incompatible with the comparatively high content (10-20 mM) of magnesium ions required for the DNA origami self-assembly and its long-term stability. In fact, low transfection due to poor structural integrity of DNA origamis in physiological fluids, which typically contain low 45 content of the magnesium ions (~1 mM), has been identified as a major challenge. Moreover, change in solution components and pH as well as nuclease degradation have also been shown to affect the DNA origami superstructures. It is therefore crucial to stabilize DNA origami structures under 50 the damaging factors in order for them to be effectively used for broader biomedical applications.

Therefore, there is a need to overcome these obstacles and create a composition which can stabilize a biomaterial, such as pre-defined nucleic acid based nanostructures (e.g., DNA 55 origami).

SUMMARY OF THE INVENTION

The present invention relates to compositions and meth- $_{60}$ ods for the stabilization of biomaterials.

In some embodiments, the invention relates to a composition for stabilizing a biomaterial, said composition including a compound of Formula (I).

$$T_{1} [A_{m} - E_{n}]_{b1} [G_{p} - J_{q}]_{b2} [L_{r} - M_{s}]_{b3} [Q_{r} - U_{u}]_{b4} T_{2}$$
(I

wherein

A is

$$T_{I}$$
 R_{I} O R_{I} R_{I} O R_{I} R_{I









J is



L is

$$J = \begin{bmatrix} R_5 & O \\ I & M_5 \end{bmatrix} M;$$

M is



Q is



U is

65



m, n, p, q, r, s, t, and u are independently 0, 1, 2, 3, 4, or 5;

- b1, b2, b3, and b4 are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20;
- R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ are independently H, OH, (C₁-C₈)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₈) alkoxy, (C_1-C_6) alkylene-O--- (C_1-C_6) alkyl, (C_1-C_6) al- ⁵ kylene-O— (C_1-C_6) alkylene-O— (C_1-C_6) alkyl, $-((CH_2)_{1-8}-O)_{1-14}-CH_3, -((CH_2)_{1-8}-O)_{1-14}-al$ kyl, $(C_1 - C_8)$ alkylene-C(O)OH, $(C_1 - C_8)$ alkylene-SO₁₋₃ H_{1-2} , (C_1-C_8) alkylene- $PO_{1-3}H_{1-2}$, (C_1-C_8) alkylene- SO_2 —NH₂, (C₁-C₈)alkoxy, (C₁-C₆)alkylene-(NH) 10 $NR_{10}R_{11}$, (C_1-C_8) alkylene- $NR_{12}R_{13}$, (C_1-C_8) alkylene- $C(O)NR_{14}R_{15}$, or $-(C_1-C_6)$ alkylene- R_{16} , where alkyl, alkenyl, alkynyl, alkylene, and alkoxy are optionally substituted with one or more substituent each independently selected from (C1-C3)alkyl, oxo, NH2, 15 -COOH, halogen, hydroxyl, methoxy, ethoxy, N₃, biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, succinimide, or maleimide;

$$\Gamma_1$$
 is





$$U \begin{bmatrix} T_{2,1} & O \\ I \\ N \\ T_{2,2} \end{bmatrix},$$

H, —OH, or NH₂;

- $T_{1.1}$, $T_{1.2}$, $T_{1.3}$, $T_{2.1}$, and $T_{2.2}$ are independently R_1 , R_8 , $-(C_1-C_6)alkylene(NR_{17}R_{18}), -NR_{14}R_{15}, (C_1-C_6)al$ kylene-C(O)R₁₆, $-C(O)(C_1-C_6)alkyl,$ -C(O)NR₁₇R₁₈, SO₂, —OH, —SH, —COOH, —(C₁-C₆) alkylene-N₃, --(C₂-C₆)alkynyl, or alkyl, alkenyl, 45 alkynyl, alkylene, or alkoxy that is substituted with at least one of biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, halo, succinimide, and maleimide;
- R₁₆ is partially or fully saturated (C₃-C₈)carbocyclic, phenyl, 4- to 8-membered heterocycle containing 1 to 50 4 heteroatoms each independently selected from O, S, or N, 5- to 7-membered heteroaryl containing 1 to 3 heteroatoms each independently selected from O, N, or S, where R_{16} is optionally substituted with one or more substituents each independently selected from (C_1-C_3) 55 alkyl, (C1-C3)alkyl-NH2, (C1-C3)alkoxy, halogen, hydroxyl, --C(O)NH₂, --COOH, or --CN; and
- $R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}$, and R_{18} are each independently H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C₆)alkynyl, or halo-substituted (C₁-C₆)alkyl; wherein 60 R₁-R₈, each defines a submonomer, and wherein Formula (I) defines a peptoid.

In some embodiments, the invention relates to a composition for stabilizing a biomaterial, said composition includes a compound of Formula (II). 65

$$T_1 - [X_{b1} - Y_{b2} - Z_{b3}]_n - T_2$$
 (II)

4

wherein X is









20





35





T₂ is



H, —OH, or NH₂;

wherein,

n is 1, 2, 3, 4, or 5;

- b1, b2, and b3 are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, and 20;
- R1, R2, R3, R4, R5, R6, are independently H, OH, (C1- C_8)alkyl, (C_2 - C_6)alkenyl, (C_2 - C_6)alkynyl, (C_1 - C_8) alkoxy, (C_1-C_6) alkylene-O-(C_1-C_6)alkyl, (C_1-C_6) alkylene-O-(C₁-C₆)alkylene-O-(C₁-C₆)alkyl,

 $-((CH_2)_{1-8}-O)_{1-14}-CH_3, -((CH_2)_{1-8}-O)_{1-14}-al$ kyl, (C_1-C_8) alkylene-C(O)OH, (C_1-C_8) alkylene-SO₁₋₃ $C(O)NR_{14}R_{15}$, or $-(C_1-C_6)$ alkylene- R_{16} , where alkyl, alkenyl, alkynyl, alkylene, and alkoxy are optionally substituted with one or more substituent each independently selected from (C1-C3)alkyl, oxo, NH2, -COOH, halogen, hydroxyl, methoxy, ethoxy, N₃, biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, succinimide, or maleimide;

- R₁₆ is partially or fully saturated (C₃-C₈)carbocyclic, phenyl, 4- to 8-membered heterocycle containing 1 to 4 heteroatoms each independently selected from O, S, or N, 5- to 7-membered heteroaryl containing 1 to 3 heteroatoms each independently selected from O, N, or 10 S, where R₁₆ is optionally substituted with one or more substituents each independently selected from (C1-C3) alkyl, (C_1-C_3) alkyl-NH₂, (C_1-C_3) alkoxy, halogen, hydroxyl, -C(O)NH₂, -COOH, or -CN;
- $T_{1.1},\,T_{1.2},\,T_{1.3},\,T_{2.1},$ and $T_{2.2}$ are independently $R_1,\,R_6,\,$ 15 $-(C_1-C_6)$ alkylene(NR₁₇R₁₈), $-NR_{14}R_{15}$, (C₁-C₆)alkylene-C(O) R_{16} , —C(O)(C₁-C₆)alkyl, -C(O)NR₁₇R₁₈, SO₂, -OH, -SH, -COOH, -(C₁-C₆) alkyl azide, --(C2-C6)alkynyl, or alkyl, alkenyl, 20 alkynyl, alkylene, or alkoxy that is substituted with at least one of biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, halo, succinimide, and maleimide; and
- $R_{10},\,R_{11},\,R_{12},\,R_{13},\,R_{14},\,R_{15},\,R_{16},\,R_{17},$ and R_{18} are each independently H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2- 25 C_6)alkynyl, or halo-substituted (C_1 - C_6)alkyl; wherein R_1 - R_6 , each defines a submonomer, and wherein Formula (II) defines a peptoid.

In some embodiments, the invention relates to a composition for stabilizing a biomaterial, said composition including a compound of Formula (III).



wherein r is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 50, 100, or 200;

 T_1 is





T₂ is

$$\begin{bmatrix} T_{2,1} & O \\ I \\ N \\ T_{2,2} \end{bmatrix},$$

H, —OH, or NH₂;

- wherein $T_{1,1}$, $T_{1,2}$, $T_{1,3}$, $T_{2,1}$, and $T_{2,2}$ are independently $-(CH_2)$ —NH₂, $-((CH_2)_2$ —O)₃—CH₃, $-(C_1$ -C₆)al-kylene(NR₁₇R₁₈), $-NR_{14}R_{15}$, $(C_1$ -C₆)alkylene-C(O) R₁₆, $-C(O)(C_1$ -C₆)alkyl, $-C(O)NR_{17}R_{18}$, SO₂, -OH, -SH, -COOH, $-(C_1$ -C₆)alkylene-azide, $(C_1 C_2)$ -COH, $-(C_1 C_2)$ -C(D) $-(C_2-C_6)$ alkynyl, or alkyl, alkenyl, alkynyl, alkylene, or alkoxy that is substituted with at least one of biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, halo, succinimide, and maleimide; and
- $R_{14},\ R_{15},\ R_{16},\ R_{17},$ and R_{18} are each independently H, $(C_1 - C_6)$ alkyl, $(C_2 - C_6)$ alkenyl, $(C_2 - C_6)$ alkynyl, or halosubstituted $(C_1 - \overline{C}_6)$ alkyl; wherein formula (III) defines a peptoid.

In some embodiments, the invention relates to a drug delivery carrier having a pre-defined nucleic acid nanostructure and a compound of Formula (I), (II), or (III).

In some embodiments, the invention relates to a stabilized complex having a pre-defined nucleic acid nanostructure; a compound of Formula (I), (II), or (III); and a drug molecule or protein.

In some embodiments, the invention relates to a method of stabilizing a pre-defined nucleic acid nanostructure, said method including (i) complexing a pre-defined nucleic acid nanostructure with a composition comprising a compound of Formula (I), (II), or (III).

In some embodiments, the invention relates to a stabilized ³⁵ nanoparticle complex having a nanoparticle; and a compound according to Formula (I), (II), or (III).

BRIEF DESCRIPTION OF THE DRAWINGS

40 FIG. 1. (A) Chemical structures of peptoids designed to protect 3D octahedra-shaped DNA origamis (OC). Nae: (2-aminoethyl)glycine, Nte: N-2-(2-(2-methoxyethoxy) ethoxy)ethylglycine and Nme: N-(2-methoxyethyl)glycine. (B) Transmission electron microscope (TEM) image and 45 schematic view (inset) of the OC structure (scale bar: 50 nm). (C) Schematic view showing the different surface coating of the two types ("brush" and "block") of peptoids on the OC structure proposed in this work, which leads to varied protection effect.

50 FIG. 2. Fluorescence assay monitoring peptoid-stabilized duplex DNA (dsDNA). Real-time SYBR Green I (SG) fluorescence assay of a 15-bp dsDNA (500 µM) in the presence of peptoids at different ratios of peptoid amines to phosphate groups of the DNA (N/P). The fluorescence signals of (A) dsDNA/peptoid complexes at N/P of 4 and (B) dsDNA/PE2 complexes at different N/P are plotted against the increasing temperature.

FIG. 3 Molecular dynamics (MD) simulations of the interactions of PE1 and PE4 with dsDNA. Molecular rep-60 resentation of the most visited binding sites and structures of (A) PE1 and (B) PE4 with dsDNA. The most visited binding sites represented as occupancy volume areas (shown as transparent white) where the peptoids were present for at least 6% of total contact time. (C-F) Radial distribution 65 functions (RDF) of water near the (C, D) minor and (E, F)

major grooves of the dsDNA. RDFs were calculated on the H (donor) atoms of water and the N and O (acceptor) atoms

of (C, E) AT and (D, F) GC base-pairs. The structuring of water around DNA only is shown in FIG. **3**C-F, lines labeled DNA, while for the dsDNA/PE1 and dsDNA/PE4 complexes are shown in FIG. **3**C-F, lines labeled PE1-DNA and PE4-DNA, where the AT and GC base-pairs are distin- 5 guished by light and dark colors respectively.

FIG. 4. Analysis of peptoid-coated OCs in low Mg^{2+} solution. (A) Schematic view showing peptoid-coated OCs (OC/peptoid) was protected against Mg^{2+} depletion. (B, C) Agarose gel electrophoresis (AGE) was used to analyze the 10 structural integrity of OCs in TAE buffer at MgCl₂ concentrations of 12.5 mM (+) and 1.25 mM (-). In (c), the electrophoretic shift was measured from the reference band at 0.5 kb and the relative value was calculated from that of the control OCs (n=3). (D) TEM imaging was performed on 15 OCs extracted from the agarose gels (bands a and b in B). Scale bars: 200 nm. The insets show magnified images of the OC structures (scale bars: 100 nm). (E) Dynamic light scattering (DLS) and (F) in situ small angle X-ray scattering (SAXS) spectra show bare OCs and OC/PE2 treated with 20 EDTA (5 or 10 mM) for 20-30 min at room temperature.

FIG. **5**. Analysis of peptoid-coated OCs in the presence of deoxyribonuclease (DN). (A) Schematic view showing peptoid-coated OCs (OC/peptoid) were protected against DN (image obtained from PDB: 2DNJ) degradation. (B) TEM 25 images show bare OCs and OC/peptoid (N/P: 0.5) in solution containing DN of 15 g/mL. Imaging was performed on samples extracted from the agarose gel (scale bars: 200 nm). The insets show magnified images of the OC structures (scale bars: 100 nm). 30

FIG. 6. Analysis of peptoid-coated OCs in cell media and presence of serum nuclease. TEM images show (A, C) bare OCs and (B, D) PE2-coated OCs (OC/PE2) in (A, B) Roswell Park Memorial Institute (RPMI) 1640 medium and (C, D) Dulbecco's Modified Eagle Medium (DMEM) con- 35 taining 0%, 5%, and 10% of fetal bovine serum (FBS) and incubated for 24 h at 37° C. The final concentrations of MgCl₂ were 1.25 mM. Imaging was performed on samples extracted from the agarose gels (scale bars: 200 nm). The insets show magnified images of the OC structures (scale 40 bars: 50 nm).

FIG. 7. Protection of protein-encapsulated in OCs by PE2 coating. (A) Schematic view showing that OC/PE2 reduce trypsin (image obtained from PDB: 1S0Q) digestion of fluorescein labeled BSA encapsulated in the OCs. (B) Fluo- 45 rescence kinetics show enhanced fluorescence of the fluorescein labeled BSA upon trypsin cleavage (λ_{ex} =490 nm and λ_{em} =525 nm, 37° C.).

FIG. **8**. Surface functionalization of peptoid-stabilized OCs with antibody and fluorophore. (A) Schematic view 50 showing alkyne-modified peptoids conjugates azide-modified cargos through click chemistry. Here, azide fluor 488 (AF) and Trastuzumab (Tz) were used as the presenting cargos (label 1). (B) Chemical structure of PE8 and PE9. (C) Fluorescence assay of bare OCs, OC/PE8-AF and OC/PE9-55 AF extracted from the agarose gel (λ_{ex} =485 nm and λ_{em} =510-800 nm). (D) TEM images show surface coating of OCs with PE8-Tz and PE9-Tz. The samples were labeled with immunogold (label 2 in A) prior to TEM imaging (scale bars: 50 nm).

FIG. 9. Stabilization of Au NPs by peptoid coating. (A) Schematic view showing the block-type peptoid Nae₆-Nte₁₂ was used to stabilize 20 nm citrated-capped gold nanoparticles (Au NPs). (B) UV-visible spectroscopy (UV-vis) showing stable Au NPs (0.5 nM) after coating with Nae₆- 65 Nte₁₂ block at different concentrations. The buffer was 10 mM phosphate, pH 7.0.

FIG. **10**. Peptoid stabilizes Au NPs in solution containing high salt concentration. UV-vis showing that Au NPs remains stable in solution containing 200 mM of sodium chloride after coating with Nae₆-Nte₁₂ block. Below 0.375 μ M of Nae6-Nte12 block, the extent of Au NP aggregation is dependent on the peptoid concentration.

FIG. **11** Cryogenic protection of peptoid stabilized Au NPs. (A) Pictures showing Nae_6 -Nte₁₂ block stabilizes the Au NPs at frozen (top) and melted (bottom) states.

FIG. 12 UV-vis showing stable Au NPs in the melted state with Nae_6 -Nte₁₂ block coating. Higher concentration of peptoid enables higher Au NP stability.

FIG. **13** Mass spectrometry of peptoids PE1-9 prepared by solid phase peptoid synthesis.

FIG. **14** Real-time SYBR Green I (SG) fluorescence assay of the 15-bp dsDNA in the presence of peptoids (A, B) PE1, (C, D) PE3, (E, F) PE4 and (G, H) PE5 at different N/P. Derivatives of the fluorescence intensities were plotted against the increasing temperature.

FIG. **15** Real-time SG fluorescence assay of peptoid only. (A) Fluorescence intensities and (B) derivatives of the fluorescence intensities were plotted against the increasing temperature.

FIG. **16** Real-time SG fluorescence assay of 15-bp dsDNA in the presence of (A) PE1-5 at N/P of 4 (B) PE2 at different N/P as in FIGS. **2**A and **2**B, respectively. Derivatives of fluorescence intensities were plotted against the increasing temperature.

FIG. 17 Fluorescence spectra of the 15-bp dsDNA in the presence of SG and PE2 at different N/P. Sample preparation and fluorescence measurements were performed at room temperature (λ_{ex} =495 nm and λ_{em} =510-650 nm). The concentration of PE2 only in solution was the same as that of N/P of 8, which was 1.85 µM.

FIG. **18** AGE shows the electrophoretic shift of dsDNA/ peptoid complexes. (A) dsDNA/peptoid of 0.5; (B) dsDNA/ PE2 at different N/P.

FIG. **19** Atomistic structures of the peptoid and dsDNA models used in the MD simulations. The peptoids (A) PE1 and (B) PE4 are shown in FIG. **19**A and FIG. **19**B. (C) Molecular and (D) cartoon representation of the dsDNA model are shown in FIGS. **19**C and **19**D.

FIG. **20** Negative-stained TEM images show peptoidcoated OCs at N/P of 0.5, 0.25 and 0.1 (scale bars: 200 nm). The insets show magnified images of the OC structures (scale bars: 100 nm).

FIG. **21** (A) Chemical structure of the Nae6-Nte16 block peptoid and (B) negative-stained TEM images of Nae₆-Nte₁₆ block-coated OCs at N/P of 0.5 (scale bar: 200 nm). The inset shows magnified image of the OC structures (scale bar: 100 nm).

FIG. **22** Top: Molecular structure of PE6. Bottom: Negative-stained TEM images of PE6-coated OC structures at N/P of (A) 2, (B) 1 and (C) 0.5 (scale bars: 200 nm). The insets show magnified images of the OC structures (scale bars: 100 nm).

FIG. 23 Top: molecular structure of PE7. Bottom: negative-stained TEM images of PE7-coated OCs at N/P of (A) 2, (B) 1 and (C) 0.5 (scale bars: 200 nm). The insets show
magnified images of the OC structures (scale bars: 100 nm).

FIG. **24** AGE showing the electrophoretic shift of peptoid-coated OCs (4.3 nM). Lanes 1-3: N/P of 0.5, 0.25, and 0.1, respectively; Lane 4: peptoid/OC=1; and Lane 5: OC only.

FIG. **25** AGE of OC/peptoid in TAE buffer. The final concentration of $MgCl_2$ was 1.25 mM. The result was used in the calculation of electrophoretic shift in FIG. **4**C.

FIG. 26 Negative-stained TEM images of (A) bare OCs and OC/PE2 at (B) N/P of 0.1 and (C) N/P of 0.5. The final concentration of MgCl₂ in TAE buffer was 1.25 mM. TEM samples were extracted from the agarose gels (scale bars: 200 nm). The insets show magnified images of the OC $^{-5}$ structures (scale bars: 100 nm).

FIG. 27 Negative-stained TEM images of peptoid (PE1, PE3, PE4, and PE5)-coated OCs in TAE buffer. The final concentrations of MgCl₂ were 12.5 mM (TAE-Mg²⁺) and 1.25 mM (TAE low Mg^{2+}). TEM samples were extracted from the agarose gels (scale bars: 200 nm). The insets show magnified images of the OC structures (scale bars: 100 nm).

FIG. 28 Real-time SG fluorescence assay of bare and peptoid-coated OCs (1 nM, N/P: 0.125) in PBS buffer. 15 Derivatives of the fluorescence intensities were normalized to 0-1 range and plotted against the increasing temperature.

FIG. 29 Negative-stained TEM images of OCs in the presence of different amounts of EDTA: (A) 12.5 mM, (B) 10 mM, (C) 6.25 mM, (D) 3.5 mM and (E) 0 mM. The 20 concentration of MgCl₂ in TAE buffer was 12.5 mM. EDTA was added to the OC solution and left undisturbed for ~4 h at room temperature prior to TEM samples preparation (scale bars: 200 nm). The insets show magnified images of the OC structures (scale bars: 100 nm).

FIG. 30 Kratky analysis of SAXS data in FIGS. 4F and G. Bare OCs appeared to be more flexible upon treatment with EDTA and did not plateau at higher q compared to the PE2-coated OCs.

FIG. 31 Left: AGE of bare and peptoid-coated OCs in PBS buffer. The final concentration of MgCl₂ was 1.25 mM. Right: TEM samples were extracted from the agarose gels (bands a-f). Scale bars: 200 nm. The insets show magnified images of the OC structures (scale bars: 100 nm).

FIG. 32 AGE of OCs in the presence of different concentrations of deoxyribonuclease I (DN). Degradation of OC nanostructures by DN was shown by the electrophoretic shift toward the end of lower molecular weight and the presence of new bands representing degraded OCs.

FIG. 33 TEM images of bare OCs and peptoid-coated OCs in the absence (left) and presence of DN (15 µg/mL, right). The samples were extracted from agarose gels. The concentration of MgCl₂ in TAE buffer was 12.5 mM (scale bars: 200 nm). The insets show magnified images of the OC 45 structures (scale bars: 100 nm). Among the peptoid sequences, only OC/PE2 showed protection of the OC nanostructures.

FIG. 34 DLS of (A) bare and (B) PE2-coated OCs (N/P: 0.5) in the presence of DN. The extent of size reduction 50 wherein represents degradation of the OC nanostructures by DN.

FIG. 35 Negative-stained TEM images of (A) bare OCs and (B) PE2-coated OCs in DMEM cell media containing FBS (0%, 5%, and 10%). The final concentration of MgCl₂ was 1.25 mM. TEM samples were extracted from the 55 agarose gels (scale bars: 200 nm). The insets show the magnified images of the OC structures (scale bars: 100 nm).

FIG. 36 UV-vis spectra of step-wise functionalization of 10 nm gold nanoparticles (Au NPs) with Cys-Ala-Leu-Asp-Asp-Lys(N3) (SEQ ID NO: 127) (pep) and followed by a 60 DBCO-modified single-stranded DNA (ssDNA, 5'-TAT-GAAGTGATGGATGAT/3DBCO/), (SEQ ID NO: 1) which complemented with the eight ssDNAs located in the OCs.

FIG. 37 (A) AGE and (B) TEM images show PE2 coated and Au NP-encapsulated OCs in DMEM media containing 65 FBS (0%, 5%, and 10%). AGE was performed and imaged by white light (top) and UV light (bottom). TEM samples

were extracted from the agarose gels (scale bars: 200 nm). The insets show magnified images of the OC structures (scale bars: 50 nm).

FIG. 38 (A) Fluorescence spectrum of doxorubicin (Dox, 100 µM) in PBS buffer. Excitation and emission wavelengths were measured at 485 nm and 510-800 nm, respectively. (B) Fluorescence signals at 597 nm were plotted against Dox concentrations ([Dox]). A linear relationship between fluorescence signal and [Dox] was observed below 3.2 µM.

FIG. 39 Plot showing the total Dox release from bare OCs and OC/PE2 (n=2). The Dox release was determined by the remaining fluorescence of OCs after incubating in PBS buffer at 37° C. for 48 h. A reduction of total Dox release from the OC/PE2 compared to bare OCs was observed at both pH 7 and 5.5.

FIG. 40 Fluorescence enhancement of fluorescein labeled BSA (80 nM) in the presence and absence of trypsin (50 nM). The concentration of MgCl₂ in TAE buffer was 12.5 mM. The solution was incubated overnight (>12 h) at 37° C. prior to fluorescence measurement (λ_{ex} =490 nm and λ_{em} =510-800 nm).

FIG. 41 Fluorescence spectra of fluorescein-labelled BSA encapsulated in bare and PE2-coated OCs (20 nM) in the $_{25}$ presence and absence of trypsin (50 nM). The concentration of MgCl₂ in TAE buffer was 12.5 mM. The mixtures were incubated at 37° C. for ~15 h prior to fluorescence measurement (λ_{ex} =485 nm and λ_{em} =510-800 nm).

FIG. 42 TEM images of OC in the presence of different trypsin concentrations: (A) 5 µM, (B) 0.5 µM, (C) 0.1 µM and (D) 0 µM (scale bars: 200 nm). The insets show magnified images of the OC structures (scale bars: 100 nm).

FIG. 43 Site-specific modification of Trastuzumab. Top: schematic view of the modification. Bottom: ESI-LC/MS 35 analyses of the Trastuzumab-azide.

DETAILED DESCRIPTION

The present invention relates to compositions and meth- $_{40}$ ods for the stabilization of biomaterials.

As used herein, compositions of the present invention for stabilization of biomaterials are referred to as "peptoids". In other words, the peptoids of the present invention can also be referred to as a series of N-substituted glycines. Peptoids according to the present invention are exemplified by Formulas (I), (II), and (III) described herein.

In one embodiment, the composition of the invention includes a compound of Formula (I).

$$T_{1} [A_{m} E_{n}]_{b1} [G_{p} J_{q}]_{b2} [L_{r} M_{s}]_{b3} [Q_{r} U_{u}]_{b4} T_{2}$$
(I)

A is



E is









L is





Q is



$$Q = \begin{bmatrix} R_8 & O \\ I & \\ N & \\ T_2; \end{bmatrix}$$

3, 4, or 5;

- b1, b2, b3, and b4 are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20;
- R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ are independently H, OH, (C_1-C_8) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_8) 55 alkoxy, (C_1-C_6) alkylene-O-(C_1-C_6)alkyl, (C_1-C_6) alkylene-O— (C_1-C_6) alkylene-O— (C_1-C_6) alkyl,

 $-((CH_2)_{1-8}-O)_{1-14}-CH_3, -((CH_2)_{1-8}-O)_{1-14}-al$ kyl, (C_1-C_8) alkylene-C(O)OH, (C_1-C_8) alkylene-SO₁₋₃ $\begin{array}{l} H_{1-2}, \quad (C_1-C_8) alkylene-PO_{1-3}H_{1-2}, \quad (C_1-C_8) alkylene-60\\ SO_2--NH_2, \quad (C_1-C_8) alkoxy, \quad (C_1-C_6) alkylene-(NH)\\ NR_{10}R_{11}, (C_1-C_8) alkylene-NR_{12}R_{13}, \quad (C_1-C_8) alkylene-60\\ NR_{10}R_{11}, \quad (C_1-C_8) alkylene-NR_{12}R_{13}, \quad (C_1-C_8) alkylene-60\\ NR_{10}R_{10}R_{11}, \quad (C_1-C_8) alkylene-NR_{12}R_{13}, \quad (C_1-C_8) alkylene-60\\ NR_{10}R_{11}, \quad (C_1-C_8) alkylene-NR_{12}R_{13}, \quad (C_1-C_8) alkylene-60\\ NR_{$ $C(O)NR_{14}R_{15}$, or $-(C_1-C_6)$ alkylene $-R_{16}$, where alkyl, alkenyl, alkynyl, alkylene, and alkoxy are optionally substituted with one or more substituent each indepen- 65 dently selected from (C₁-C₃)alkyl, oxo, NH₂, -COOH, halogen, hydroxyl, methoxy, ethoxy, N3,

12

biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, succinimide, or maleimide;







15



25

30

35

40

45

- H, —OH, or NH₂;
- $T_{1.1},\,T_{1.2},\,T_{1.3},\,T_{2.1},$ and $T_{2.2}$ are independently $R_1,\,R_8,$ $-(C_1-C_6)$ alkylene(NR₁₇R₁₈), $-NR_{14}R_{15}$, (C₁-C₆)alkylene-C(O)R₁₆, $--C(O)(C_1-C_6)alkyl,$ -C(O)NR₁₇R₁₈, SO₂, -OH, -SH, -COOH, -(C₁-C₆) alkylene N₃, --(C₂-C₆)alkynyl, or alkyl, alkenyl, alkynyl, alkylene, or alkoxy that is substituted with at least one of biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, halo, succinimide, and maleimide;

wherein R1-R8, each defines a submonomer,

- R_{16} is partially or fully saturated $(C_3\text{-}C_8)\text{carbocyclic},$ phenyl, 4- to 8-membered heterocycle containing 1 to 4 heteroatoms each independently selected from O, S, or N, 5- to 7-membered heteroaryl containing 1 to 3 heteroatoms each independently selected from O, N, or S, where R₁₆ is optionally substituted with one or more substituents each independently selected from (C_1-C_3) alkyl, (C1-C3)alkyl-NH2, (C1-C3)alkoxy, halogen, hydroxyl, --C(O)NH2, --COOH, or --CN; and
 - $R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}$, and R_{18} are each independently H, (C_1-C_6) alkyl, (C_2-C_6) alkeyl, (C_2-C_6) alkyl, or halo-substituted (C_1-C_6) alkyl;

wherein Formula (I) defines a peptoid, and

wherein T_1 and T_2 define terminal groups.

For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms wherein m, n, p, q, r, s, t, and u are independently 0, 1, 2, 50 used in the singular will also include the plural and vice versa.

> As used herein, the term "alkyl" refers to a fully saturated branched or unbranched hydrocarbon moieties having up to 12 carbon atoms. Unless otherwise provided, alkyl refers to hydrocarbon moieties having 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms (i.e., (C1-C6)alkyl), or 1 to 3 carbon atoms (i.e., $(C_1-C_3)alkyl)$). Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, 3,3-dimethylpropyl, hexyl, 2-methylpentyl, and the like.

> As used herein, "alkylene" or "alkylenyl" refers to a branched or unbranched alkyl (as defined herein) chain having two free radicals available for bonding. Alkylene refers to divalent alkyl group as defined herein above having 1 to 12 carbon atoms. Unless otherwise provided, alkylene

refers to moieties having 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 3 carbon atoms. For example, methylene or methylenyl (e.g., $-CH_2$), ethylene or ethylenyl (e.g., $-CH_2$ — CH_2 — CH_2 — CH_2), propylene or propylenyl (e.g., $-CH_2$ — CH_2 — CH_3)— CH_3 — CH_2

As used herein, the term "alkenyl" refers to a monovalent group derived from a hydrocarbon having at least one carbon-carbon double bond. The term " C_2 - C_6 -alkenyl" refers to a monovalent group derived from a hydrocarbon 15 having two to six carbon atoms and comprising at least one carbon-carbon double bond. The alkenyl group can be unbranched or branched. Representative examples of alkenyl include vinyl, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 1-butenyl, 3-butenyl, and so on.

As used herein, the term "alkynyl" refers to a monovalent group derived from a hydrocarbon having at least one carbon-carbon triple bond. The term " (C_2-C_6) alkynyl" refers 25 to a monovalent group derived from a hydrocarbon having 2 to 6 carbon atoms and comprising at least one carboncarbon triple bond. The alkynyl group can be unbranched or branched. Representative examples include ethynyl, propynyl, butyn-1-yl, butyn-2-yl, and so on. 30

As used herein, the term "alkoxy" refers to —O-alkyl, wherein alkyl is as defined herein. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexy-loxy, cyclopropyloxy-, cyclohexyloxy- and the like. In some 35 embodiments, alkoxy groups may have about 1 to 8 carbon atoms. Typically, alkoxy groups have about 1 to 6 carbons, and more preferably about 1 to 3 carbons.

As used herein, the term "partially or fully saturated carbocyclic" (also referred to as "partially or fully saturated 40 cycloalkyl") refers to nonaromatic rings that are either partially or fully hydrogenated and may exist as a single ring of 3 to 8 members or bicyclic ring of 9 to 14 members. Unless specified otherwise, the carbocyclic ring is generally a 3- to 8-membered ring. In another embodiment, the 45 carbocyclic ring is a 3- to 6-membered ring. For example, partially or fully saturated carbocyclic rings (or cycloalkyl) include groups such as cyclopropyl, cyclopropenyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentyl, cyclopentyl, so norbornyl, norbornenyl, and the like. The term "cycloalkylene" refers to cycloalkyl as defined herein having two free radicals available for bonding.

As used herein, the term "heteroaryl" refers to a 5- to 14-membered monocyclic- or bicyclic- or tricyclic-aromatic 55 ring system, having 1 to 8 heteroatoms selected from N, O, or S. Typically, the heteroaryl is a 5- to 10-membered ring system (e.g., 5- to 7-membered monocycle or an 8- to 10-membered bicycle). A 5-7 membered monocyclic ring system preferably contains 1 to 3 heteroatoms each inde-60 pendently selected from O, N, or S. Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrssolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2, 65 3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, and 2-, 4-, or

5-pyrimidinyl. As used herein, the term "heteroarylene" refers to heteroaryl as defined herein having two free radicals available for bonding.

As used herein, the term "halogen" or "halo" refers to fluoro, chloro, bromo, and iodo. It is to be understood that the terminology oxo or C(O) refers to a —C=O group, whether it be ketone, aldehyde or acid or acid derivative. Similarly, S(O) refers to a —S=O group.

Submonomers

As used herein, the term "submonomer" refers to a substituent that is covalently bonded to the amino group of the peptoid backbone of Formulas (I), (II), and (III). More specifically, in the case of Formula (I), submonomer refers to R_1 - R_8 (individually or collectively); in the case of Formula (II), submonomer refers to R1- R_6 (individually or collectively); and in the case of Formula (III), submonomer refers to the groups bound to the amino group of the peptoid backbone (individually or collectively). More specifically, submonomers of Formula (III) include —(CH₂)₂NH₂, and —(CH₂)₂—O—(CH₂)₂O—(CH₂)₂O—CH₃.

In general, each of the submonomer moiety has a molecular weight of 1 to 250 daltons or 1 to 500 daltons. The submonomers can be positively charged, negatively charged, or neutrally charged. Submonomers may include functional groups that add functionality to the peptoid.

In some embodiments, the N-substitutions can include guanidoalkyl, alkylphenyl, indolylalkyl, alkoxyphenyl, hydroxyphenylalkyl, and halophenylalkyl and without limitation to (S, R)- α -methylbenzyl, benzyl, phenethyl, naphthylmethyl, methoxyethyl, (S)- α -methylnaphthylmethyl, N-pyrrolidinopropyl, furfurylmethyl, cyclohexylmethyl, 3,4,5-trimethoxybenzyl, phenylpropyl, 6-galactosyl, 3'-indolylethyl, p-methoxyphenylethyl, p-chlorophenylethyl, or p-hydroxyphenylethyl groups.

The submonomers may be protected by tert-butyloxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc), or allyloxycarbonyl (Aloc) and cleaved after the peptoid synthesis. Positively-Charged Submonomers

In some embodiments, the positively charged submonomers are aminoalkyl groups having about 1-20 carbon atoms. The N-substitutions can include guanidoalkyl, alkylphenyl, halophenylalkyl, indolylalkyl, alkoxyphenyl, hydroxyphenylalkyl and without limitation to (S, R)- α methylbenzyl, benzyl, phenethyl, naphthylmethyl, methoxyethyl, (S)- α -methylnaphthylmethyl, N-pyrrolidinopropyl, furfurylmethyl, cyclohexylmethyl, 3,4,5-trimethoxybenzyl, phenylpropyl, 6-galactosyl, 3'-indolylethyl, p-methoxyphenylethyl, p-chlorophenylethyl, or p-hydroxyphenylethyl groups. The cationic side chains can include the following: aminoethyl, aminopropyl, aminohexyl, 1,4-butadiamine (lysine mimic), (S)-1-methylethylenediamine, trimethylaminoethyl, quanidinoethyl, or quanidinopropyl.

The positively charged submonomers can include functional groups discussed herein.

Examples of positively charged submonomers are shown in Table 1.

TABLE 1





Wherein n is an integer between 1 and 100. Wherein X 45 represents the amino group of the peptoid backbone. Negatively-Charged Submonomers

In some embodiments, negatively charged submonomers are carboxyalkyl groups having 1-20 carbon atoms. The anionic side chain can include carboxyl, carbonyl, sulfonic⁵⁰ acid, sulfonamide, phosphate, and phosphonic acid-based submonomers. Similar to the positively charged submonomers, the N-substituted side chains can include functional groups discussed herein.

The negatively charged submonomers can include func-⁵⁵ tional groups discussed herein.

Examples of negatively-charged submonomers are shown in Table 2.

TABLE 2



Wherein n is an integer between 1 and 100. Wherein X represents the amino group of the peptoid backbone.

Neutrally-Charged Oligo-Ethylene Glycol Motifs:

The term "oligo" as in "oligo-ethylene glycol" includes without limitation to polymers, copolymers, and interpolymers of any length. In addition, the oligomers may consist of a single repeating monomer, two alternating monomer units, and two or more monomer units randomly or purposely spaced relative to each other. The oligo-ethylene glycol comprises at least 1 ethylene glycol unit (i.e., submonomer: methoxyethylamine) moiety, typically at least 2 repeating units (i.e., submonomer: 2-(2-methoxyethoxy) ethanamine) and preferably at least 3 repeating units (i.e., submonomer: 2-(2-(2-methoxyethoxy)ethanamine).

The water-soluble motifs can also be substituted with oligomers or polymers composed of α -methylbenzylamine which typically comprise 2 to 13 repeating units. Examples can be found in works by Kirshenbaum (44), Zuckermann (45), Barron (46) and their co-workers. Carboxyamide, taurine- and phosphonate-based submonomers may also be used (47-49).





Wherein n is an integer between 1 and 100. Wherein X represents the amino group of the peptoid backbone. Neutrally Charged Functional Submonomers:

The functional groups exhibit no net positive or negative charge. Functional groups include any group that allows for chemical conjugatison (or strong binding) to a chemical compound, imaging reagents, biomolecules, ligands, polymers, or glycans discussed above on the surfaces of DNA origami and nanoformulation carriers. Examples of a functional groups includes allowed on the surface of the surfaces of the string of the surface and function that the surface of the surfaces of the surface and func-

⁶⁵ tional group includes alkyne, azide, sulfhydryl, maleimide biotinyl, cyano, hydrazido, carbodiimide, halo, succinimide, and maleimide.

Examples of functional submonomers are shown in Table 4.



Wherein n is an integer between 1 and 100. Wherein X 20 represents the amino group of the peptoid backbone.

In one embodiment, the composition of the invention includes a compound of Formula (II).

$$T_1-[X_{b1}-Y_{b2}-Z_{b3}]_n-T_2$$
 (II) 25

wherein X is



















H, —OH, or NH₂;

wherein,

40

45

T₂ is

n is 1, 2, 3, 4, or 5;

- b1, b2, and b3 are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20;
- $T_{1.1},\,T_{1.2},\,T_{1.3},\,T_{2.1},$ and $T_{2.2}$ are independently $R_1,\,R_6,$ $-(C_1-C_6)$ alkylene(NR₁₇R₁₈), $-NR_{14}R_{15}$, (C₁-C₆)alkylene-C(O)R₁₆, $--C(O)(C_1-C_6)alkyl,$ -C(O)NR₁₇R₁₈, SO₂, —OH, —SH, —COOH, — $-(C_1 - C_6)$ alkylene-N₃, $-(C_2-C_6)$ alkynyl, or alkyl, alkenyl, alkynyl, alkylene, or alkoxy that is substituted with at least one of biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, halo, succinimide, and maleimide;
- R₁, R₂, R₃, R₄, R₅, R₆, are independently H, OH, (C₁- C_8)alkyl, (C_2 - C_6)alkenyl, (C_2 - C_6)alkynyl, (C_1 - C_8) alkoxy, (C1-C6)alkylene-O-(C1-C6)alkyl, (C1-C6)alkylene-O-(C1-C6)alkylene-O-(C1-C6)alkyl, --((CH₂)₁₋₈--O)₁₋₁₄--CH₃, --((CH₂)₁₋₈--O)₁₋₁₄-alkyl, (C1-C8)alkylene-C(O)OH, (C1-C8)alkylene-SO1-3 H_{1-2} , (C_1-C_8) alkylene- $PO_{1-3}H_{1-2}$, (C_1-C_8) alkylene- SO_2 —NH₂, (C₁-C₈)alkoxy, (C₁-C₆)alkylene-(NH) NR₁₀R₁₁, (C₁-C₈)alkylene-NR₁₂R₁₃, (C₁-C₈)alkylene-C(O)NR₁₄R₁₅, or --(C₁-C₆)alkylene-R₁₆, where alkyl, alkenyl, alkynyl, alkylene, and alkoxy are optionally substituted with one or more substituent each independently selected from (C1-C3)alkyl, oxo, NH2, -COOH, halogen, hydroxyl, methoxy, ethoxy, N3, biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, succinimide, or maleimide;
- R₁₆ is partially or fully saturated (C₃-C₈)carbocyclic, phenyl, 4- to 8-membered heterocycle containing 1 to 4 heteroatoms each independently selected from O, S, or N, 5- to 7-membered heteroaryl containing 1 to 3 heteroatoms each independently selected from O, N, or S, where R₁₆ is optionally substituted with one or more substituents each independently selected from (C_1-C_3) alkyl, (C_1-C_3) alkyl- NH_2 , (C_1-C_3) alkoxy, halogen, hydroxyl, --C(O)NH2, --COOH, or --CN; and
- $\begin{array}{l} R_{10},\,R_{11},\,R_{12},\,R_{13},\,R_{14},\,R_{15},\,R_{16},\,R_{17},\,\text{and}\,\,R_{18} \text{ are each} \\ \text{independently} \,\,H,\,\,(C_1\text{-}C_6)\text{alkyl},\,\,(C_2\text{-}C_6)\text{alkenyl},$ 50 C_6)alkynyl, or halo-substituted (C_1 - C_5)alkyl; wherein R_1 - R_6 , each defines a submonomer, wherein Formula (II) defines a peptoid, and wherein T_1 and T_2 define terminal groups.

In some embodiments, the peptoid of Formula (I) or 55 Formula (II) may include alternating submonomers across a portion of the peptoid sequence, or across the entirety of the peptoid sequence, excluding the terminal groups. For example, the peptoid may include submonomers that alter-60 nate between any combination of positive submonomers, negative submonomers, and neutral submonomers.

In one embodiment, the peptoid may include submonomers that alternate between positive submonomers and neutral submonomers. In one embodiment, the peptoid may 65 include submonomers that alternate between negative submonomers and neutral submonomers. In one embodiment, the peptoid may include submonomers that alternate

between positive submonomers and negative submonomers. In one embodiment, the peptoid may include submonomers that alternate between two types of negative submonomers, two types of positive submonomers, or two types of neutral submonomers.

In some embodiments, the peptoid sequence may include semi-alternating submonomers. For example, the peptoid sequence may alternate between one pair of submonomers for one portion of the peptoid sequence, and alternate between a second pair of submonomers for another portion 10 of the peptoid sequence.

As used herein, the term "repeat unit" or "repeating unit" corresponds to the smallest constitutional unit, the repetition of which constitutes a regular macromolecule (or oligomer molecule or block).

By way of example, with reference to Formula (I), " $[A_m, -E_n]$ " defines a repeat unit having two monomers; with reference to Formula (II), " $[X_{b1}-Y_{b2}-Z_{b3}]$ " defines a repeat unit, having three monomers.

By way of further example, in the case of peptoid PE1, the 20 repeat unit is $-(CH_2)_2-NH_2$ and $-((CH_2)_2-O)_3-CH_3$. By way of further example, in the case of peptoid PE3, the repeat unit is $-(CH_2)_2-NH_2$, $-((CH_2)_2-O)_3-CH_3$, $-(CH_2)_2O-CH_3$, and $-((CH_2)_2-O)_3-CH_3$, wherein one monomer is repeated in this repeat unit. In some 25 embodiments, the repeating unit may contain a sequence of four unique submonomers.

In one embodiment, the peptoid sequence may have alternating groups of submonomers, wherein each repeating unit includes a unique sequence of 2, 3, 4, 5, or 6 submono- 30 mers. By way of example, see peptoid PE3 of FIG. 1. In the case of PE3, group 1 includes two monomers, having the following submonomers — $(CH_2)_2$ — NH_2 , — $((CH_2)_2$ — $O)_3$ — CH_3 ; and group 2 includes two monomers having the following two submonomers — $(CH_2)_2O$ — CH_3 , and 35 — $((CH_2)_2-O)_3$ — CH_3 . In this way, peptoid PE3 alternates between group 1 and group 2 along its sequence.

In some embodiments, the peptoids of the present invention may have the charged submonomers distributed across the length of the peptoid. For example, the charged submonomers may be sporadically, evenly, or periodically distributed across the length of the peptoid. This type of peptoid structure is herein referred to as a brush structure.

In some embodiments, the peptoids of the present invention may have an uneven distribution of charged submono- 45 mers across the length of the peptoid. In some embodiments, positively-charged submonomers, negatively-charged submonomers, or neutrally-charged submonomers are clustered at the N-terminus, at the C-terminus, or internally, resulting in uneven charge distribution across the length of the pep- 50 toid. Such peptoids are referred to as having a block structure. In one aspect of this embodiment, positively-charged submonomers are clustered at the N-terminus. For example, in the case of a peptoid of Formula (I), submonomers R_1 - R_4 include at least one positive submonomer and no more than 55 four positive submonomers, and submonomers R₅-R₈ include no positive submonomers, or less submonomers than submonomers R_1 - R_4 . In another aspect of this embodiment, negatively-charged submonomers are clustered at the C-terminus.

Examples of peptoids having a brush structure and block structure are shown in FIG. 1. Accordingly, brush-type peptoids and block-type peptoids interact differently with the subject biomaterial. In the case of the brush-type peptoids, both termini of the peptoid are proximal to the 65 biomaterial (e.g., pre-defined nucleic acid nanostructure). In the case of block-type peptoids, one terminus is proximal to

the biomaterial (e.g., pre-defined nucleic acid nanostructure and one terminus is distal to the biomaterial (e.g., predefined nucleic acid nanostructure).

In some embodiments, the peptoids described herein may have a net positive charge. Such peptoids can interact with nucleic acid to facilitate their binding thereto.

In some embodiments, out of the total submonomers present in a peptoid of the invention, and described herein, 0-80%, 20-80%, 20-50%, 20-40%, 20-30%, 30-60%, 30-50%, or 30-40% of the submonomers are positively charged.

In some embodiments, out of the total submonomers present in a peptoid of the invention, and described herein, 0-80%, 20-80%, 20-50%, 20-40%, 20-30%, 30-60%, 30-50%, or 30-40% of the submonomers are negatively charged.

In some embodiments, out of the total submonomers present in a peptoid of the invention, and described herein, less than 20%, less than 25%, less than 30%, less than 25% of the submonomers are neutrally charged.

In some embodiments, the ratio of positive:neutral, negative:neutral, or positive:negative submonomers is 0.001:1, 0.01:1, 0.1:1, 0.5:1; 1:1, 1:3, 1:5, 1:10, or a range in between.

In some embodiments, the ratio of neutral submonomers to charged submonomers is approximately 1:1. In some embodiments, the ratio of neutral submonomers to charged submonomers is approximately 2-5:1.

In some embodiments, out of the total submonomers present in a peptoid of the invention, 20-80%, 30-80%, or 40-80% of the total submonomer content includes oligo-ethylene glycol.

In a preferred embodiment, N-substituted glycine, L-amino acid, D-amino acid and analogue thereof (e.g., aliphatic guanidines) are preferred to be incorporated as the charged motifs that facilitate peptoid interactions with the surfaces of drug/gene carriers. More specific to peptoid-DNA origami interactions, the positively charged submonomers are not limited to functional groups, including the amino, guanidino, hydrazido, and amidino groups. These functional groups can be aromatic or aliphatic and may include enantiomers (e.g., L-amino acid and D-amino acid).

The peptoid sequences can be chemically conjugated with polyalkylene glycol, in particular, polyethylene glycol is preferred and typically has a molecular weight from 2 to 50 kDa. The peptoid sequences can also be chemically conjugated to mono-, di-, or polysaccharide. This may include chitosan, alginate, heparin, hyaluronic acid, chondroitin sulfate, cyclodextrin, pectin, amylose, dextran and analog thereof. Finally, the peptoid designs also permit crosslinking between the polymers, for example, through disulfide bond at the terminating group or side chains.

The amount of neutrally charged functional groups in a peptoid sequence 12 repeating units can be less than 30% in order to ensure peptoid-DNA binding by the positively charged moieties and DNA origami stabilization by the oligo-ethylene glycol moieties. In some embodiments, a peptoid sequence having 12 repeating units the amount of neutrally charged functional groups is less than 35%. In some embodiments, a peptoid sequence having 12 repeating units the amount of neutrally charged functional groups is less than 35%.

25

In one embodiment, the composition of the invention includes a compound of Formula (III).

wherein r is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 50, 100, or 200;





JH

or H; and T_2 is



H, —OH, or NH₂; wherein

- $T_{1.1}$, $T_{1.2}$, $T_{1.3}$, $T_{2.1}$, and $T_{2.2}$ are independently -(C2-C6)alkynyl, or alkyl, alkenyl, alkynyl, alkylene, or alkoxy that is substituted with at least one of 55 biotinyl, sulfhydryl, cyano, hydrazido, carbodiimide, halo, succinimide, and maleimide; and
- R14, R15, R16, R17, and R18 are each independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, or halosubstituted (C1-C6)alkyl;

wherein formula (III) defines a peptoid, and

wherein T_1 and T_2 define terminal groups.

As used herein, and with reference to Formulas (I), (II), and (III), T₁ defines the N-terminus and T₂ defines the C-terminus. 65

In some embodiments, the peptoid includes 1, 2, 3, 4, or more functional groups. The functional groups may be located exclusively at a single terminus, both termini, internal to the peptoid sequence, or combinations thereof.

The peptoid sequences of the present disclosure can be up to 200 monomer units in length. Typically, the length of the peptoid sequence is at least 2 monomers; at least 3 monomers; more usually 4 monomers, more usually 6-12 monomers and preferably 24-48 monomers. In addition, the typical repeating units of peptoid sequences comprise 2 monomers including 1 positively-charged and 1 neutrally-10 charged monomer, 3 monomers including 1 positivelycharged and 2 neutrally-charged monomers, and 4 monomers including 2 positive-charged and 2 neutrally-charged monomers. As used herein, a "monomer" means one N-substituted glycine unit. By way of example, referencing For-15 mula (I), A_m , E_n , G_p , J_q , L_r , M_s , Q_r , and U_u each define a monomer.

In some embodiments, the present invention includes a peptoid according to Formula (I), (II), and (III), wherein a peptoid is conjugated to a chemical compound, imaging 20 reagent, targeting ligand, protein, peptide, aptamer, peptide nucleic acid, dendrimer, oligomer, polymer, antibody, antibody fragment, another peptoid, a biomaterial as disclosed herein, or combinations thereof. Examples of suitable chemical compounds for conjugation include hormones, steroids, estrogens, androgens, thyroid hormone, vitamins, or folic acid.

The conjugation may be by way of a functional group, as described herein and commonly known in the art.

Peptoid synthesis follows the solid-phase peptoid synthe-30 sis which is well known in the art, see, e.g., reference nos. 25, 26; where the designed functionality is incorporated during synthesis, enabling controlled peptoid components and architectures.

The peptoids disclosed herein can be prepared by solid-35 phase synthesis and polymerization methods. The solidphase synthesis includes methods developed by 1) Merrifield (36), which involves coupling amino acid units (commonly protected by Fmoc) to the growing chain anchored on a resin; and 2) the "submonomer method" 40 developed by Zuckermann (26), which builds peptoid sequences using acylation and nucleophilic displacement with bromoacetic acid and secondary amines. In the polymerization method, peptoids with high molecular weights can be synthesized through ring-opening polymerizations of 45 N-substituted N-carboxyanhydride monomers (37-40) or N-thiocarboxyanhydrides (41-43).

Regardless of type of peptoid monomers, the full-length peptoids described herein may be produced by the same general procedure which includes repeating a two-step or three step cycle wherein a new monomer unit is added in each cycle until a desired length is obtained.

With regards to Formulas (I), (II), and (III) as described herein. When the specific number denoting a chemical group is the integer 0 (zero), a bond is intended to link the adjacent groups onto which the said group is substituted. For example, " $(G1)(G2)_0(G3)$ " is equivalent to "G1-G3". Wherein G1 and G3 are adjacent to the subject chemical group G1 (wherein 0 is the specific number denoting the chemical group).

60 Stabilized Biomaterials

In some embodiments, the present invention provides a stabilized biomaterial and methods for generating the same. Biomaterials

As used herein, biomaterials include materials useful for biomedical applications. Examples of biomaterials include nucleic acid (DNA and RNA) based nano-structures; lipid based nanostructures; and nanoparticles.

35

The nucleic acid based nano-structure may be a predefined nucleic acid nanostructure. An example of a predefined nucleic acid nanostructure includes pre-defined DNA nanostructure. The terms "DNA origami" and "predefined DNA nanostructure" are used interchangeably 5 herein.

As used herein, pre-defined nucleic acid nanostructure includes a polynucleotide molecule that has been rationally designed to self-assemble into a pre-defined shape or structure.

The pre-defined nucleic acid nanostructure in accordance with the present disclosure has a size of 1 to 2000 nm, 1 to 1000 nm, 1 to 900 nm, 1 to 800 nm, 1 to 700 nm, 1 to 600 nm, 1 to 500 nm, 1 to 400 nm, 1 to 300 nm, 1 to 200 nm, 1 to 100 nm, or 1 to 50 nm. The size of the pre-defined 15 nucleic acid nanostructure is determined by the longest length of the structure.

As used herein, "self-assemble" refers to the ability of a single-strand of nucleic acid to anneal to itself or another single-strand of nucleic acid, in a sequence-specific manner, 20 in a predicted and non-arbitrary manner, and without external physical control.

In some embodiments, the nucleic acid based nanostructure is double stranded DNA.

In some embodiments, the pre-defined nucleic acid nano- 25 structure is an octahedral-shaped DNA structure having a size of approximately -60 nm. (29, 30)

In some embodiments, the pre-defined nucleic acid nanostructure is a lattice-based DNA structure that includes a template DNA and staple DNAs with defined shapes and 30 sizes.

In some embodiments, the pre-defined nucleic acid nanostructure is a large-scale DNA structure formed by selfassembly of several smaller pre-defined DNA nanostructures.

The term "lipid" as used herein refers to any suitable material resulting in a single to multi-layered structures such that a hydrophobic portion of the lipid material orients toward the inner lipid layer while a hydrophilic portion orients toward the aqueous phase. An example of a single 40 layer lipid structure includes micelle. Lipids include highly hydrophobic compounds such as triglycerides, phospholipids, glycolipids, and sterols such as cholesterol and amphipathic lipids. An example of a lipid-based structure includes liposomes. 45

As used herein, the terms "liposome" and "liposomes" refer to a spherical structure having at least one lipid bilayer. A liposome can be used for the administration of therapeutic agents. A liposome can comprise a combination of one or more phospholipids, an optional lipid that is not a phospho-50 lipid, such as sterols, glycolipids, amphipathic lipids, pegy-lated lipids, or a combination thereof. As used herein, a liposome may have a diameter of about 20 nm to about 3,000 nm. In one embodiment, the diameter of the liposomes is about 75 nm to about 600 nm. In certain embodiments, the 55 liposomes can have diameters precisely falling within 110 nm and 125 nm.

In one embodiment, the invention includes stabilized nanoparticles. The nanoparticles are metallic (e.g., monometallic, bimetallic, or polymetallic), and may be inorganic ⁶⁰ or organic. In some embodiments, the nanoparticles comprise gold, silver, copper, iron oxide, titanium nanoparticles, or alloys thereof, ceramics, carbon, or silica nano- or microparticles. In particular embodiments the nanoparticles are gold or silver nanoparticles. ⁶⁵

In some embodiments, the present invention includes a composition having a compound of Formula (I), Formula

(II), or Formula (III) and a biomaterial, wherein the compound of Formula (I), Formula (II), or Formula (III) is complexed with a biomaterial. In some embodiments, the complex further includes a small molecule therapeutic or protein. Such a complex defines a drug carrier complex according to the present disclosure.

In embodiments wherein the biomaterial is a nucleic acid, the complex between the peptoid of Formula (I), Formula (II), or Formula (III) and the biomaterial can be characterized as having a molar ratio of peptoid amines to nucleic acid phosphates (N/P).

The following values for N/P be combined in any manner to create a range with a minima and maxima for ratio necessary for a stable complex between the peptoid and nucleic acid biomaterial: 0.001, 0.01, 0.1, 0.125, 0.25, 0.5, 1, 2, 3, 4, 5, 8, and 10. As an example, the N/P may be

between 0.001 and 3, 0.001 and 2, 0.01 and 2, or 0.1 and 2. In some embodiments, the N/P is less than 4, less than 3, less than 2, or less than 1.

In some embodiments, the biomaterial is a pre-defined nucleic acid nanostructure and the complex with a peptoid of the present invention includes a N/P of less than 3 or less than 2.

In an embodiment of the invention, the peptoid sequences comprise 1 to 100 (or any range in between) of the repeating dimers, trimers or tetramers. Optionally, the designs are not limited to peptoid sequences that contain only the positively-, negatively- or neutrally charged monomers, excluding the terminal groups for specific purposes.

As used herein, the submonomers and peptoids are referenced as having a charge. The net charges are also determined by the solution pH, in which the physiologically relevant pH is at least 4 and is no more than 8.5. Method of Stabilizing

In some embodiments, the present invention includes a method of stabilizing a biomaterial, said method includes complexing with the biomaterial with a composition including a compound of Formula (I), (II), or (III), as described herein.

As used herein, "complexing" means forming a complex of two or more components. As used herein, "complex" refers to a combination of two or more components having intramolecular or intermolecular covalent or noncovalent interactions. The complexed components are said to be stabilized. As used herein, "stabilized" means that the component that is stabilized has improved properties as compared to properties of the non-stabilized or non-complexed component. By way of example, and as described herein, a biomaterial is stabilized if it has increased nuclease resistance. By way of further example, a stabilized pre-defined DNA nanostructure has increased structural integrity in environments with low salt or low monovalent or bivalent ions.

In one embodiment, complexing includes (i) contacting the biomaterial with a composition with a compound of Formula (I), (II), or (III). The contacting conditions include with compound of Formula (I), (II), or (III) for between 0.5 and 20, 10 and 20, 8 and 12, or 0.5 and 4 hours; and at a temperature of between 1° C. and 4° C., 20° C. and 40° C., or 2° C. and 10° C.

In one embodiment, the method includes a method of stabilizing a pre-defined nucleic acid nanostructure. In some aspects of this embodiment, the contacting and complexing include a ratio of Formula (I), (II), or (III) amines to nucleic acid phosphates is less than 20, less than 15, less than 10, less than 8, less than 5, or less than 2. In some aspects of this embodiment, the contacting includes a ratio of Formula (I),

-

(II), or (III) amines to nucleic acid phosphates of the pre-defined nucleic acid nanostructure is between 3 and 0.01, 3 and 0.1, or 2 and 0.2.

Formation of the origami nanostructures can include and without limitation to basically negatively charged "polynucleotide" or "nucleic acid", which refers to DNA, RNA, peptide nucleic acids and their analogues thereof. In addition, the nucleic acids may be single-stranded, doublestranded or combination of the two types of molecules.

Throughout this specification, quantities are defined by ranges having a lower boundary and upper boundary, and by lower or upper boundaries. Each lower boundary can be combined with each upper boundary to define a range. Two lower boundary values can be combined to define a range, and two upper boundary values can be combined to define a range. The lower and upper boundaries should each be taken as a separate element.

Examples

Materials

All single-stranded DNA (ssDNA) sequences were purchased from Integrated DNA Technologies and the M13mp18 ssDNA scaffold was purchased from Bayou Biolabs. 2-(2-(2-methoxyethoxy)ethoxy)ethanamine was purchased from Aurum Pharmatech. Rink Amide resin, 2-methoxyethylamine, propargylamine, magnesium chloride (MgCl₂), copper (II) sulphate (CuSO₄), aminoguanidine hydrochloride, DNase I, doxorubicin, agarose (medium ³ EEO), bovine serum albumin, trypsin and phosphate buffer saline (PBS) were purchased from Sigma Aldrich. Method

Preparation of octahedra-shaped DNA origamis (OCs). OCs were folded by mixing 20 nM of M13mp18 scaffold DNA and 100 nM of each staple oligonucleotides in TAE (1×) buffer containing 12.5 mM MgCl₂. The mixed solution was then cooled from 90° C. to room temperature over 20 hours to obtain the target OC structure. After synthesis, OCs were purified using the Amicon 100 k centrifugal filter units (Millipore Sigma) and centrifuged at 400 g and at 4° C. The purification process was repeated 6 times by adding fresh TAE (1×) buffer containing 12.5 mM MgCl₂ in each cycle. OC Sequence

OC-staple-1	(950	тп	NO ·	2)	
TCAAAGCGAACCAGACCGTTTTATATAGTC	(PEČ	тD	110:	2)	50
OC-staple-2	(CEO	TD	NO.	21	50
GCTTTGAGGACTAAAGAGCAACGGGGAGTT	(DEQ	10	140.	57	
OC-staple-3	(550	тп	NO.	4)	
GTAAATCGTCGCTATTGAATAACTCAAGAA	(DEQ	10	140.	ч)	55
OC-staple-4	(CEO	TD	NO.	E)	
AAGCCTTAAATCAAGACTTGCGGAGCAAAT	(DEQ	10	140.	5,	
OC-staple-5	(CEO	TD	NO.	6)	60
ATTTTAAGAACTGGCTTGAATTATCAGTGA	(SEQ	тD	110:	0)	
OC-staple-6	(CEO	TD	NO.	7)	
GTTAAAATTCGCATTATAAACGTAAACTAG	(SEQ	тр	NO:	')	65

28

	-continued					
	OC-STAPLE- /	(SEÇ	Q II	O NO	: 8)	
5	OC-staple-8					
	ATTGCGTAGATTTTCAAAACAGATTGTTTG	(SEÇ	Q II	оио	: 9)	
10	OC-staple-9					
	- TAACCTGTTTAGCTATTTTCGCATTCATTC	(SEQ	ID	NO:	10)	
	OC-staple-10					
15	- GTCAGAGGGTAATTGAGAACACCAAAATAG	(SEQ	ID	NO:	11)	
	OC-staple-11					
15	CTCCAGCCAGCTTTCCCCTCAGGACGTTGG	(SEQ	ID	NO :	12)	
	OC-staple-12					
20	GTCCACTATTAAAGAACCAGTTTTGGTTCC	(SEQ	ID	NO :	13)	
20	OC-staple-13					
	TAAAGGTGGCAACATAGTAGAAAATAATAA	(SEQ	ID	NO :	14)	
	OC-staple-14					
25	GATAAGTCCTGAACAACTGTTTAAAGAGAA	(SEQ	ID	NO :	15)	
	OC-staple-15					
	GGTAATAGTAAAATGTAAGTTTTACACTAT	(SEQ	ID	NO :	16)	
30	OC-staple-16	·			\	
	TCAGAACCGCCACCCTCTCAGAGTATTAGC	(SEQ	ID	NO :	17)	
	OC-staple-17	(-			
35	AAGGGAACCGAACTGAGCAGACGGTATCAT	(SEQ	ID	NO :	τs)	
	OC-staple-18	(680	TD	NO	10)	
	GTAAAGATTCAAAAGGCCTGAGTTGACCCT	(SEQ	ID	NO :	19)	
40	OC-staple-19	(CEO	TD	NO	201	
	AGGCGTTAAATAAGAAGACCGTGTCGCAAG	(SEQ	ID	110 :	20)	
	OC-staple-20	(950	тп	NO .	21)	
45	CAGGTCGACTCTAGAGCAAGCTTCAAGGCG	(DEQ	10	110.	21)	
	OC-staple-21	(SEO	тр	NO ·	22)	
	CAGAGCCACCACCCTCTCAGAACTCGAGAG	(520	10	110 .	22,	
50	OC-staple-22	(SEO	тр	NO :	23)	
	TTCACGTTGAAAATCTTGCGAATGGGATTT	£	10		,	
55	OC-staple-23	(CEO	тп	NO.	24)	
	AAGTTTTAACGGGGTCGGAGTGTAGAATGG	(SEQ		140 :	27)	
	OC-staple-24	(0.5.)	
60	TTGCGTATTGGGCGCCCGCGGGGGTGCGCTC	(SEQ	ΤD	NO :	25)	
	OC-staple-25					
	GTCACCAGAGCCATGGTGAATTATCACCAATCAGAA	(SEQ AAGCC	ID T	NO :	26)	
	OC-staple-26					

5 GGACAGAGTTACTTTGTCGAAATCCGCGTGTATCACCGTACG

(SEO ID NO: 27)

US 11,739,162 B2

-continued 0C-staple-27				-continued OC-staple-47		
(SEQ ID CAACATGATTTACGAGCATGGAATAAGTAAGACGACAATAAA	NO:	28)		(SEQ ID NO ATAATTAAAATTTAAAAAACTTTTTCAAACTTTTAACAAC	0: ·	48)
OC-staple-28			5	OC-staple-48		
(SEQ ID AACCAGACGCTACGTTAATAAAACGAACATACCACATTCAGG	NO:	29)		(SEQ ID NO GCACCCAGCGTTTTTTATCCGGTATTCTAGGCGAATTATTCA	0: ·	49)
OC-staple-29				OC-staple-49		
SEQ ID (SEQ ID) TGACCTACTAGAAAAAGCCCCAGGCAAAGCAATTTCATCTTC	NO:	30)	10	(SEQ ID NO GGAAGCGCCCACAAACAGTTAATGCCCCGACTCCTCAAGATA	: C	50)
OC-staple-30				OC-staple-50		
SEQ ID (SEQ ID) TGCCGGAAGGGGACTCGTAACCGTGCATTATATTTTAGTTCT	NO:	31)		(SEQ ID NO GTTTGCCTATTCACAGGCAGGTCAGACGCCACCACCACCACCACCACCACCACCACCACCAC	: C	51)
OC-staple-31			15	OC-staple-51		
SEQ ID) AGAACCCCAAATCACCATCTGCGGAATCGAATAAAAATTTTT	NO:	32)		(SEQ ID NO CGCGAGCTTAGTTTTTCCCAATTCTGCGCAAGTGTAAAGCCT	0:	52)
OC-staple-32				OC-staple-52		
SEQ ID (SEQ ID) GCTCCATTGTGTACCGTAACACTGAGTTAGTTAGCGTAACCT	NO:	33)	20	(SEQ ID NO AGAAGCAACCAAGCCAAAAGAATACACTAATGCCAAAACTCC	0:	53)
OC-staple-33			20	OC-staple-53		
SEQ ID (SEQ ID) AGTACCGAATAGGAACCCAAACGGTGTAACCTCAGGAGGTTT	NO:	34)		(SEQ ID NO ATTAAGTATAAAGCGGCAAGGCAAAGAAACTAATAGGGTACC	0:	54)
OC-staple-34				OC-staple-54		
SEQ ID (SEQ ID) CAGTTTGAATGTTTAGTATCATATGCGTAGAATCGCCATAGC	NO:	35)	25	(SEQ ID NO CAGTGCCTACATGGGAATTTACCGTTCCACAAGTAAGCAGAT	0:	55)
OC-staple-35				OC-staple-55		
SEQ ID) AAGATTGTTTTTTAACCAAGAAACCATCGACCCAAAAACAGG	NO:	36)		(SEQ ID NO ATAAGGCGCCAAAAGTTGAGATTTAGGATAACGGACCAGTCA	0:	56)
OC-staple-36			30	OC-staple-56		
SEQ ID) TCAGAGCGCCACCACATAATCAAAATCAGAACGAGTAGTAG	NO:	: 37)		(SEQ ID NO TGCTAAACAGATGAAGAAACCACCAGAATTTAAAAAAAGGCT):	57)
OC-staple-37				OC-staple-57		
SEQ ID) GATGGTTGGGAAGAAAAATCCACCAGAAATAATTGGGCTTGA	NO:	38)	35	(SEQ ID NC CAGCCTTGGTTTTGTATTAAGAGGCTGACTGCCTATATCAGA):	58)
OC-staple-38				OC-staple-58	_	
(SEQ ID CTCCTTAACGTAGAAACCAATCAATAATTCATCGAGAACAGA	NO:	39)		(SEQ ID NC CGGAATAATTCAACCCAGCGCCAAAGACTTATTTTAACGCAA):	59)
OC-staple-39			40	OC-staple-59	_	
(SEQ ID AGACACCTTACGCAGAACTGGCATGATTTTCTGTCCAGACAA	NO:	40)		(SEQ ID NC CGCCTGAATTACCCTAATCTTGACAAGACAGACCATGAAAGA	: C	60)
OC-staple-40				OC-staple-60	_	
(SEQ ID GCCAGCTAGGCGATAGCTTAGATTAAGACCTTTTTAACCTGT	NO:	41)	45	(SEQ ID NO ACGCGAGGCTACAACAGTACCTTTTACAAATCGCGCAGAGAA	0:	61)
OC-staple-41				OC-staple-61	_	
SEQ ID) CCGACTTATTAGGAACGCCATCAAAAATGAGTAACAACCCCA	NO:	42)		(SEQ ID NO CAGCGAACATTAAAAGAGAGTACCTTTACTGAATATAATGAA	0:	62)
OC-staple-42			50	OC-staple-62	_	
SEQ ID) GTCCAATAGCGAGAACCAGACGACGATATTCAACGCAAGGGA	NO:	43)		(SEQ ID NO GGACGTTTAATTTCGACGAGAAACACCACCACTAATGCAGAT	0:	63)
OC-staple-43				OC-staple-63		
SEQ ID) CCAAAATACAATATGATATTCAACCGTTAGGCTATCAGGTAA	NO:	44)	55	(SEQ ID NO AAAGCGCCAAAGTTTATCTTACCGAAGCCCAATAATGAGTAA	0:	64)
OC-staple-44				OC-staple-64		
(SEQ ID AACAGTACTTGAAAACATATGAGACGGGTCTTTTTTAATGGA	NO:	45)		(SEQ ID NG GAGCTCGTTGTAAACGCCAGGGTTTTCCAAAGCAATAAAGCC	: C	65)
OC-staple-45			60	OC-staple-65		
- (SEQ ID TTTCACCGCATTAAAGTCGGGAAACCTGATTTGAATTACCCA	NO:	46)		SEQ ID NO	: C	66)
0C-staple-46				0C-staple-66		
(SEQ ID	NO:	47)	65	(SEQ ID NO	: C	67)

US 11,739,162 B2

-continued				-continued
(SEQ ID	NO :	68)		OC-staple-87 (SEQ ID NO: 88)
			5	TATAAAGCATCGTAACCAAGTACCGCACCGGCTGTAATATCC
OC-staple-68 (SEQ ID	NO:	69)	5	OC-staple-88 (SEQ ID NO: 89)
AACAAAAATAACTAGGTCTGAGAGACTACGCTGAGTTTCCCT				ATAGCCCGCGAAAATAATTGTATCGGTTCGCCGACAATGAGT
OC-staple-69 (SEQ ID	NO:	70)		OC-staple-89
CATAACCTAAATCAACAGTTCAGAAAACGTCATAAGGATAGC			10	AGACAGTTCATATAGGAGAAGCCTTTATAACATTGCCTGAGA
OC-staple-70 (SEQ ID	NO :	71)		OC-staple-90
CACGACGAATTCGTGTGGCATCAATTCTTTAGCAAAATTACG				(SEQ ID NO: 91) AACAGGTCCCGAAATTGCATCAAAAAGATCTTTGATCATCAG
OC-staple-71 (SEQ ID	NO :	72)	15	OC-staple-91
CCTACCAACAGTAATTTTATCCTGAATCAAACAGCCATATGA				(SEQ ID NO: 92)
OC-staple-72 (SEQ ID	NO:	73)		0C-stanle-92
GATTATAAAGAAACGCCAGTTACAAAATTTACCAACGTCAGA			20	(SEQ ID NO: 93)
OC-staple-73 (SEO ID	NO ·	74)		TCAAAGGGAGATAGCCCTTATAAATCAAGACAACAACCATCG
AGTAGATTGAAAAGAATCATGGTCATAGCCGGAAGCATAAGT	110.	, _ ,		OC-staple-93 (SEQ ID NO: 94)
OC-staple-74 (SEO ID	NO.	75)	25	GTAATACGCAAACATGAGAGATCTACAACTAGCTGAGGCCGG
TAGAATCCATAAATCATTTAACAATTTCTCCCCGGCTTAGGTT	NO:	/5/	25	OC-staple-94 (SEO ID NO. 95)
OC-staple-75				GAGATAACATTAGAAGAATAACATAAAAAGGAAGGATTAGGA
(SEQ ID AAAGGCCAAATATGTTAGAGCTTAATTGATTGCTCCATGAGG	NO:	/6)		OC-staple-95
OC-staple-76			30	(SEQ ID NO: 96) CAGATATTACCTGAATACCAAGTTACAATCGGGAGCTATTTT
(SEQ ID CCAAAAGGAAAGGACAACAGTTTCAGCGAATCATCATATTCC	NO:	77)		OC-staple-96
OC-staple-77				(SEQ ID NO: 97) CATATAACTAATGAACAACAACATACGAGCTGTTTCTTTGGGG
(SEQ ID GAAATCGATAACCGGATACCGATAGTTGTATCAGCTCCAACG	NO :	78)	35	0C-stanle-97
OC-staple-78				(SEQ ID NO: 98)
(SEQ ID TGAATATTATCAAAATAATGGAAGGGTTAATATTTATCCCAA	NO :	79)		
OC-staple-79			40	CATT
(SEQ ID GAGGAAGCAGGATTCGGGTAAAATACGTAAAACACCCCCCAG	NO :	80)		OC-staple-98 (SEQ ID NO: 99)
OC-staple-80				GGGGTGCCAGTTGAGACCATTAGATACAATTTTCACTGTGTGAAATTGTT
(SEQ ID GGTTGATTTTCCAGCAGACAGCCCTCATTCGTCACGGGATAG	NO :	81)	45	ATCC
OC-staple-81				OC-staple-99
(SEQ ID CAAGCCCCCACCCTTAGCCCGGAATAGGACGATCTAAAGTTT	NO:	82)		(SEQ 1D NO: 100) CTTCGCTGGGCGCAGACGACAGTATCGGGGCACCGTCGCCATTCAGGCTG
OC-staple-82			50	CGCA
(SEQ ID	NO:	83)	50	OC-staple-100
OC storle 02				(SEQ ID NO: 101) TCAGAGCTGGGTAAACGACGGCCAGTGCGATCCCCGTAGTAGCATTAACA
(SEQ ID	NO:	84)		тсса
CATCCTATTCAGCTAAAAGGTAAAGTAAAAAGCAAGCCGTTT			55	oc starla 101
OC-staple-84 (SEQ ID	NO :	85)		(SEQ ID NO: 102)
CAGCTCATATAAGCGTACCCCGGTTGATGTGTCGGATTCTCC				TIAGUGIACAGAGUGGGAGAATTAACTGUGUTAATTTUGGAACCTATTA
OC-staple-85 (SEO ID	NO:	86)	60	TTCT
CATGTCACAAACGGCATTAAATGTGAGCAATTCGCGTTAAAT		,		OC-staple-102 (SEO ID NO: 103)
OC-staple-86	110	051		GATATTCTAAATTGAGCCGGAACGAGGCCCAACTTGGCGCATAGGCTGGC
(SEQ ID AGCGTCACGTATAAGAATTGAGTTAAGCCCTTTTTAAGAAAG	NO:	87)	65	TGAC

US 11,739,162 B2

66		C .
-continued OC-staple-103		-continued OC-staple-116
(SEQ ID NO: 104) TGTCGTCATAAGTACAGAACCGCCACCCATTTTCACAGTACAAACTACAA		(SEQ ID NO: 117) GTGGGAAATCATATAAATATTTAAATTGAATTTTGACTGGCCTTCCTGT
CGCC	5	AGCC
OC-staple-104		OC-staple-117
(SEQ ID NO: 105) CGATTATAAGCGGAGACTTCAAATATCGCGGAAGCCTACGAAGGCACCAA		(SEQ ID NO: 118) CCCACGCGCAAAATGGTTGAGTGTTGTTGTGGGACTTGCTTTCGAGGTGA
ССТА	10	ATTT
OC-staple-105		OC-staple-118
(SEQ ID NO: 106) AACATGTACGCGAGTGGTTTGAAATACCTAAACACATTCTTACCAGTATA		(SEQ ID NO: 119) ATGACCACTCGTTTGGCTTTTGCAAAAGTTAGACTATATTCATTGAATCC
AAGC	15	ссст
OC-staple-106		OC-staple-119
(SEQ ID NO: 107) GTCTGGATTTTGCGTTTTAAATGCAATGGTGAGAAATAAAT		(SEQ ID NO: 120) TCCAAATCTTCTGAATTATTTGCACGTAGGTTTAACGCTAACGAGCGTCT
AGAG	20	ттсс
OC-staple-107	20	OC-staple-120
(SEQ ID NO: 108) GCCTTGAATCTTTTCCGGAACCGCCTCCCAGAGCCCAGAGCCGCCGC		(SEQ ID NO: 121) GGGTTATTTAATTACAATATATGTGAGTAATTAATAAGAGTCAATAGTGA
CATT	25	ATTT
OC-staple-108	25	Note:
(SEQ ID NO: 109) CGCTGGTGCTTTCCTGAATCGGCCAACGAGGGTGGTGATTGCCCTTCACC		To encapsulate AU NPS and ESA inside the OCS, add (SEQ ID NO: 122)
GCCT	30	red-marked sequences
OC-staple-109	50	ieu-maixeu sequences.
(SEQ ID NO: 110) TGATTATCAACTTTACAACTAAAGGAATCCAAAAAGTTTGAGTAACATTA		M13mp18 scaffold DNA sequence.
TCAT	35	>FOUNDATION_ssDNA_7249
OC-staple-110		(SEQ ID NO: 123) TGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGT
(SEQ ID NO: 111) ACATAACTTGCCCTAACTTTAATCATTGCATTATAACAACATTATTACAG		GGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCT
GTAG	40	TTTGATTTATAAGGGATTTTGCCGATTTCGGAACCACCATCAAACAGGATT
0C-staple-111		TTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGG
(SEQ ID NO: 112) GTAGCGCCATTAAATTGGGAATTAGAGCGCAAGGCGCACCGTAATCAGTA		GCCAGGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAA
GCGA	45	AAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCG
OC-staple-112		ATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGT
(SEQ ID NO: 113) TTATTTTTACCGACAATGCAGAACGCGCGAAAAATCTTTCCTTATCATTC		GAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCT
CAAG	50	TTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAA
OC-staple-113		CAATTTCACACAGGAAACAGCTATGACCATGATTACGAATTCGAGCTCGGT
(SEQ ID NO: 114) TTTCAATAGAAGGCAGCGAACCTCCCGATTAGTTGAAACAATAACGGATT	55	ACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTGGC
CGCC		CGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAA
0C-staple-114	55	TCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGC
(SEQ ID NO: 115)		CCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCG
GGGGGACCCCAAAAGIAIGIIAGCAAACIAAAGAGICACAAICAAI		CTTTGCCTGGTTTCCGGCACCAGAAGCGGTGCCGGAAAGCTGGCTG
AAAI	00	CGATCTTCCTGAGGCCGATACTGTCGTCGTCCCCTCAAACTGGCAGATGCA
OC-staple-115 (SEQ ID NO: 116)		CGGTTACGATGCGCCCATCTACACCAACGTGACCTATCCCATTACGGTCAA
AGCCGAAAGTCTCTCTTTTGATGATACAAGTGCCTTAAGAGCAAGAAACA		TCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTTACTCGCTCACATT

TGGCGTTCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAATGCG AATTTTAACAAAATATTAACGTTTACAATTTAAATATTTGCTTATACAATC TTCCTGTTTTTGGGGGCTTTTCTGATTATCAACCGGGGTACATATGATTGAC 5 ATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTC TCAGGCAATGACCTGATAGCCTTTGTAGATCTCTCAAAAATAGCTACCCTC TCCGGCATTAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGAT 10 TTGACTGTCTCCGGCCTTTCTCACCCTTTTGAATCTTTACCTACACATTAC TCAGGCATTGCATTTAAAATATATGAGGGTTCTAAAAATTTTTATCCTTGC GTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTTTT GGTACAACCGATTTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCT AATTCTTTGCCTTGCCTGTATGATTTATTGGATGTTAATGCTACTACTATT AGTAGAATTGATGCCACCTTTTCAGCTCGCGCCCCAAATGAAAATATAGCT AAACAGGTTATTGACCATTTGCGAAATGTATCTAATGGTCAAACTAAATCT ACTCGTTCGCAGAATTGGGAATCAACTGTTATATGGAATGAAACTTCCAGA CACCGTACTTTAGTTGCATATTTAAAACATGTTGAGCTACAGCATTATATT CAGCAATTAAGCTCTAAGCCATCCGCAAAAATGACCTCTTATCAAAAAGGAG CAATTAAAGGTACTCTCTAATCCTGACCTGTTGGAGTTTGCTTCCGGTCTG GTTCGCTTTGAAGCTCGAATTAAAACGCGATATTTGAAGTCTTTCGGGCTT CCTCTTAATCTTTTTGATGCAATCCGCTTTGCTTCTGACTATAATAGTCAG GGTAAAGACCTGATTTTGATTTATGGTCATTCTCGTTTTCTGAACTGTTT AAAGCATTTGAGGGGGGATTCAATGAATATTTATGACGATTCCGCAGTATTG GACGCTATCCAGTCTAAACATTTTACTATTACCCCCCTCTGGCAAAACTTCT TTTGCAAAAGCCTCTCGCTATTTTGGTTTTTATCGTCGTCTGGTAAACGAG GGTTATGATAGTGTTGCTCTTACTATGCCTCGTAATTCCTTTTGGCGTTAT GTATCTGCATTAGTTGAATGTGGTATTCCTAAATCTCAACTGATGAATCTT TCTACCTGTAATAATGTTGTTCCGTTAGTTCGTTTTATTAACGTAGATTTT TCTTCCCAACGTCCTGACTGGTATAATGAGCCAGTTCTTAAAATCGCATAA ggtaattcacaatgattaaagttgaaattaaaccatctcaagcccaattta 45 CTACTCGTTCTGGTGTTTCTCGTCAGGGCAAGCCTTATTCACTGAATGAGC AGCTTTGTTACGTTGATTTGGGTAATGAATATCCGGTTCTTGTCAAGATTA CTCTTGATGAAGGTCAGCCAGCCTATGCGCCTGGTCTGTACACCGTTCATC 50 TGTCCTCTTTCAAAGTTGGTCAGTTCGGTTCCCTTATGATTGACCGTCTGC GCCTCGTTCCGGCTAAGTAACATGGAGCAGGTCGCGGATTTCGACACAATT TATCAGGCGATGATACAAATCTCCGTTGTACTTTGTTTCGCGCTTGGTATA 55 ATCGCTGGGGGTCAAAGATGAGTGTTTTAGTGTATTCTTTTGCCTCTTTCG TTTTAGGTTGGTGCCTTCGTAGTGGCATTACGTATTTTACCCGTTTAATGG AAACTTCCTCATGAAAAAGTCTTTAGTCCTCAAAGCCTCTGTAGCCGTTGC TACCCTCGTTCCGATGCTGTCTTTCGCTGCTGAGGGTGACGATCCCCGCAAA AGCGGCCTTTAACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGC GTGGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGCTGTT TAAGAAATTCACCTCGAAAGCAAGCTGATAAACCGATACAATTAAAGGCTC

36

-continued

CTTTTGGAGCCTTTTTTTGGAGATTTTCAACGTGAAAAAATTATTATTCG CAATTCCTTTAGTTGTTCCTTTCTATTCTCACTCCGCTGAAACTGTTGAAA GTTGTTTAGCAAAATCCCATACAGAAAATTCATTTACTAACGTCTGGAAAG CTACAGGCGTTGTAGTTTGTACTGGTGACGAAACTCAGTGTTACGGTACAT GGGTTCCTATTGGGCTTGCTATCCCTGAAAATGAGGGTGGTGGCTCTGAGG GTGGCGGTTCTGAGGGTGGCGGTTCTGAGGGTGGCGGTACTAAACCTCCTG AGTACGGTGATACACCTATTCCGGGGCTATACTTATATCAACCCTCTCGACG 15 GCACTTATCCGCCTGGTACTGAGCAAAACCCCGCTAATCCTAATCCTTCTC TTGAGGAGTCTCAGCCTCTTAATACTTTCATGTTTCAGAATAATAGGTTCC GAAATAGGCAGGGGGCATTAACTGTTTATACGGGCACTGTTACTCAAGGCA 20 CTGACCCCGTTAAAACTTATTACCAGTACACTCCTGTATCATCAAAAAGCCA TGTATGACGCTTACTGGAACGGTAAATTCAGAGACTGCGCTTTCCATTCTG GCTTTAATGAGGATTTATTTGTTGTGAATATCAAGGCCAATCGTCTGACC GCGGCTCTGAGGGTGGTGGCTCTGAGGGTGGCGGTTCTGAGGGTGGCGGCT CTGAGGGGGGGGGGTTCCGGTGGTGGCTCTGGTTCCGGTGATTTTGATTATG 30 AAAAGATGGCAAACGCTAATAAGGGGGGCTATGACCGAAAATGCCGATGAAA ACGCGCTACAGTCTGACGCTAAAGGCAAACTTGATTCTGTCGCTACTGATT ACGGTGCTGCTATCGATGGTTTCATTGGTGACGTTTCCGGCCTTGCTAATG GTAATGGTGCTACTGGTGATTTTGCTGGCTCTAATTCCCAAATGGCTCAAG 35 TCGGTGACGGTGATAATTCACCTTTAATGAATAATTTCCGTCAATATTTAC CTTCCCTCCCTCAATCGGTTGAATGTCGCCCTTTTGTCTTTGGCGCTGGTA AACCATATGAATTTTCTATTGATTGTGACAAAATAAACTTATTCCGTGGTG 40 TTGCTAACATACTGCGTAATAAGGAGTCTTAATCATGCCAGTTCTTTTGGG TATTCCGTTATTATTGCGTTTCCTCGGTTTCCTTCTGGTAACTTTGTTCGG CTATCTGCTTACTTTTCTTAAAAAGGGCTTCGGTAAGATAGCTATTGCTAT TTCATTGTTTCTTGCTCTTATTATTGGGCTTAACTCAATTCTTGTGGGTTA TCTCTCTGATATTAGCGCTCAATTACCCTCTGACTTTGTTCAGGGTGTTCA GTTAATTCTCCCGTCTAATGCGCTTCCCTGTTTTTATGTTATTCTCTCTGT AAAGGCTGCTATTTTCATTTTTGACGTTAAACAAAAATCGTTTCTTATTT GGATTGGGATAAATAATATGGCTGTTTATTTTGTAACTGGCAAATTAGGCT CTGGAAAGACGCTCGTTAGCGTTGGTAAGATTCAGGATAAAATTGTAGCTG GGTGCAAAATAGCAACTAATCTTGATTTAAGGCTTCAAAACCTCCCGCAAG TCGGGAGGTTCGCTAAAACGCCTCGCGTTCTTAGAATACCGGATAAGCCTT 60 CTATATCTGATTTGCTTGCTATTGGGCGCGGTAATGATTCCTACGATGAAA ATAAAAACGGCTTGCTTGTTCTCGATGAGTGCGGTACTTGGTTTAATACCC 65 CTCGTAAATTAGGATGGGATATTATTTTTTTTTTTGTTCAGGACTTATCTATTG

25

30

35

TTGATAAACAGGCGCGTTCTGCATTAGCTGAACATGTTGTTTATTGTCGTC GTCTGGACAGAATTACTTTACCTTTTGTCGGTACTTTATATTCTCTTATAT CTGGCTCGAAAATGCCTCTGCCTAAATTACATGTTGGCGTTGTTAAATATG 5 GCGATTCTCAATTAAGCCCTACTGTTGAGCGTTGGCTTTATACTGGTAAGA ATTTGTATAACGCATATGATACTAAACAGGCTTTTTCTAGTAATTATGATT AACCATTAAATTTAGGTCAGAAGATGAAATTAACTAAAATATATTTGAAAA AGTTTTCTCGCGTTCTTTGTCTTGCGATTGGATTTGCATCAGCATTTACAT ATAGTTATATAACCCAACCTAAGCCGGAGGTTAAAAAGGTAGTCTCTCAGA 15 CCTATGATTTTGATAAATTCACTATTGACTCTTCTCAGCGTCTTAATCTAA ATTTACAGAAGCAAGGTTATTCACTCACATATATTGATTTATGTACTGTTT TTCTTGATGTTTGTTTCATCATCTTCTTTTGCTCAGGTAATTGAAATGAAT AATTCGCCTCTGCGCGATTTTGTAACTTGGTATTCAAAGCAATCAGGCGAA TCCGTTATTGTTTCTCCCCGATGTAAAAGGTACTGTTACTGTATATTCATCT GACGTTAAACCTGAAAATCTACGCAATTTCTTTATTTCTGTTTTACGTGCA AATAATTTTGATATGGTAGGTTCTAACCCTTCCATTATTCAGAAGTATAAT CCAAACAATCAGGATTATATTGATGAATTGCCATCATCTGATAATCAGGAA TATGATGATAATTCCGCTCCTTCTGGTGGTTTCTTTGTTCCGCAAAATGAT AATGTTACTCAAACTTTTAAAATTAATAACGTTCGGGCAAAGGATTTAATA CGAGTTGTCGAATTGTTTGTAAAGTCTAATACTTCTAAATCCTCAAATGTA TTATCTATTGACGGCTCTAATCTATTAGTTGTTAGTGCTCCTAAAGATATT TTAGATAACCTTCCTCAATTCCTTTCAACTGTTGATTTGCCAACTGACCAG $\mathtt{ATATTGATTGAGGGTTTGATATTTGAGGTTCAGCAAGGTGATGCTTTAGAT } ^{40}$ TTTTCATTTGCTGCTGGCTCTCAGCGTGGCACTGTTGCAGGCGGTGTTAAT TTTAATGGCGATGTTTTAGGGCTATCAGTTCGCGCATTAAAGACTAATAGC 45 CATTCAAAAATATTGTCTGTGCCACGTATTCTTACGCTTTCAGGTCAGAAG GGTTCTATCTCTGTTGGCCAGAATGTCCCTTTTATTACTGGTCGTGTGACT GGTGAATCTGCCAATGTAAATAATCCATTTCAGACGATTGAGCGTCAAAAT 50 GTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCA AGTGATGTTATTACTAATCAAAGAAGTATTGCTACAACGGTTAATTTGCGT 55 GATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCT CAGGATTCTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTG TTTAGCTCCCGCTCTGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTC 60 AAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGT GGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGC TCCTTTCGCTTTCTTCCCTTTCTCGCCACGTTCGCCGGCTTTCCCCCG 65

continued TCAAGCTCTAAATCGGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACG

GCACCTCGACCCCAAAAAACTTGATTTGGGTGATGGTTCACGTAGTGGGCC

ATCGCCC

Peptoid Synthesis and Purification.

Peptoids were synthesized by solid phase peptoid synthesis on the Symphony X (Gyros Protein Technologies) and the synthesis procedure followed the method previously described (1). All solvents and reagents were purchased from commercial sources and used without further purification. Briefly, 200 mg of Rink amide polystyrene resin (0.61 mmol/g, Novabiochem) was swelled in DMF and the Fmoc group was deprotected in 20% (v/v) 4-methylpiperidine/DMF prior to the submonomer cycle. The acylation step was performed on the amino resin by the addition of 1.0 mL of 0.8 M bromoacetic acid and 1.0 mL of 0.8 M N,N'-diisopropylcarbodiimide in DMF and agitated with N2 for 20 min. Displacement of the bromide with the submonomers was performed by adding 1 M solution of the primary amine in N-methyl-2-pyrrolidone followed by agitation for 30 min. The peptoids were cleaved from the resin by the addition of trifluoroacetic acid/triisopropylsilane/deionized water (95:2.5:2.5, v/v/v) solution for ~2 h, followed by evaporation using the Biotage V10 Evapoator and precipitation with an excess of cold diethyl ether. The crude peptoids were re-dispersed in deionized water followed by lyophilization. Finally, the peptoids were purified by reverse-phase high-performance liquid chromatography (HPLC, Shimadzu) using a linear gradient of 5-95% acetonitrile in water with 0.1% TFA. The Phenomenex C18 Gemini NX column was 150×21.2 mm and had a 5 m pore size and 100 Å particle size.

Preparation of peptoid-coated OCs. The synthesized peptoids were dissolved in deionized water at a concentration of 10 mM and stored at 4° C. For all experiments, peptoids at different concentrations based on the target ratios between the free peptoid amine and DNA phosphate (N/P) were mixed with OCs (5-45 nM) and incubated overnight (≥ 12 h) at 4° C. in TAE (1×) buffer.

The buffer is TAE $(1\times)$ buffer composed of 40 mM tris base, 20 mM acetic acid and 1 mM of ethylenediaminetetraacetic acid (EDTA) sodium salt dihydrate, and containing 12.5 mM magnesium chloride.

Negative-stained TEM imaging. The peptoid-coated OC structures were typically confirmed using negative-stained TEM imaging. In brief, 5 L of the peptoid-coated OC (5-10 nM) solution was dropped on a carbon film for 1-3 min and the residual liquid was removed with a piece of filter paper. After that, the grid was washed with 5 L of deionized water followed by staining with 5 L of 2 wt % uranyl acetate for 15 sec. The excess liquid was removed with filter papers. TEM imaging was performed on a JEOL 1400 TEM with an acceleration voltage of 120 kV.

Agarose Gel Electrophoresis (AGE).

In a typical experiment, agarose (0.8 wt %) was prepared in TBE (1×) buffer containing 12.5 mM MgCl₂ and 1×SYBR Gold dye. OCs (4.3 nM, ~40 L) were mixed with 1× BlueJuice gel loading buffer (Thermo Fisher Scientific) prior to loading into the gel. The gel electrophoresis was performed at 60 V on ice to prevent heating damage.

SYBR Green I (SG) fluorescence assay of OCs. OCs (1 nM) were mixed with peptoids in PBS (1×) buffer at an N/P of 0.125 and incubated overnight at room temperature. Prior to measuring fluorescence, 0.8×SG was added to the peptoid-coated OC solutions for 2 h at room temperature. The fluorescence signal was recorded from 37° C. to 85° C. at a step of 0.03° C./sec by LightCycler 480 (Roche).

SYBR Green I (SG) Fluorescence of Duplex DNA (dsDNA).

A15-bp dsDNA was designed with a sequence of 5'-AT- 5 TACCGTATAGCAT-3' (SEQ ID NO: 124) with a complementary sequence of 5'-ATGCTATACGGTAAT-3' (SEQ ID NO: 125). The dsDNA (500 μ M) was formed in PBS (1×) buffer and cooled from 70° C. to room temperature over 11 h. Next, the dsDNA (100 nM) solution was mixed with 10 different peptoid solutions at varied concentrations in PBS overnight at room temperature. Prior to measuring fluorescence, SG (1×) was added to the dsDNA/peptoid mixtures for 2 h at room temperature. The fluorescence signal was recorded from 37° C. to 85° C. at a step of 0.03° C./sec by 15 LightCycler 480. The concentrations of only peptoids in solution were the same as those in the N/P of 8, which were 3.43 μ M for PE1, PE3, PE4, PE5, and 1.85 μ M for PE2, respectively.

Molecular dynamics (MD) simulation of peptoid-DNA 20 interactions.

All-atom MD simulations were performed to investigate the mechanisms of interactions and binding of brush-type PE1 and block-type PE4 peptoids with DNA in explicit solvent. The 15-bp dsDNA (5'-ATT ACC GTA TAG CAT-3') 25 (SEQ ID NO: 126) structure was generated using the nab program available through AMBER18 (2). The peptoids were build using the Dassault Systemes BIOVIA Materials Studio package (3), and their atomic charges were calculated with B3LYP/6-31G* level of theory using the RESP proce- 30 dure (4) and Gaussian16 (5). The force field parameters for the peptoids, except the atomic charges, were generated using antechamber (6) and gaff (7). The ParmBSC1 force field (8) was employed to model the dsDNA. The molecular structures of the dsDNA, PE1 and PE4 peptoids are shown 35 in FIG. 19. Each peptoid was placed in a triclinic simulation cell ~11 Å away from the pre-equilibrated dsDNA structure to avoid any initial interactions. To solvate the systems, explicit water (TIP3P) molecules were added to the simulation cell to a corresponding water density of ~ 1.0 g/cm³. 40 Counter-ions (Na⁺) were included to neutralize the net negative charge of the system, and 150 mM NaCl to represent physiological environment.

All simulations were performed using the GROMACS simulations package (9). Particle mesh Ewald (PME) (10) 45 electrostatic summation was truncated at 11 Å, while a force-switched cut-off starting at 9 Å and ending at 10 Å was used for the Lennard-Jones non-bonded interactions. Cubic interpolation was used with 10 Å Fourier spacing and an Ewald tolerance of 10^{-6} . The MD simulations were per- 50 formed in the NPT (isothermal-isobaric) ensemble. The temperature of the system was coupled at 300 K using the Nosè-Hoover thermostat (11) and pressure was maintained at 1 bar using the Parinello-Rahman barostat (12). An integration time-step of 2 fs was applied with all hydrogen 55 bond lengths constrained using the LINCS algorithm (13). Each system was energy minimized using the steepest descent approach with a convergence criteria of 500 kJ mol⁻¹ nm⁻¹ to remove any steric clashes. Following the energy minimization, a 200 ps of MD simulation was 60 performed with position restraints applied to the solute to allow the solvent to equilibrate. Initial unrestrained MD simulations were performed on the dsDNA for 50 ns to equilibrate its structure. A peptoid was then added to the simulation box sufficiently apart to prevent any initial inter- 65 actions with the dsDNA. To further emulate spontaneous DNA-peptoid binding and explore wider conformational

space four different starting arrangements were simulated, where the peptoid was positioned at 0°, 90°, 180°, and 270° relative to the dsDNA. A 100 ns unrestrained MD was conducted for each peptoid arrangement where the peptoid was allowed to spontaneously adsorb onto the DNA from solution. The simulation trajectories from all four starting arrangements per dsDNA/peptoid complex were concatenated for further analysis. A total of 800 ns of simulation data was collected.

The different modes of interaction between the peptoids and dsDNA were investigated using contact analysis. The total time each peptoid was in contact with the dsDNA was determined, and these frames were extracted for further analysis. A contact was defined when any peptoid atom was within 4 Å of any DNA atom. The number of positively charged (Nae) residues and ethylene glycol (Nte) chains interacting with DNA and their contact stabilities was calculated. The preference of binding to specific structural features of DNA was also determined by calculating the total time each peptoid was interacting exclusively with the major or minor groove, or with both simultaneously (atomic definition for the DNA grooves is provided in the caption of Table S1). The average contact area between each peptoid and DNA was also determined. The average solvent accessible surface area of each peptoid while bound to dsDNA was calculated using a probe radius of 1.4 Å (water) and Lennard-Jones hard-shell radii for each atom to define the surface of the peptoid. The elongation or compactness of the peptoid was estimated by measuring the average distance between the outermost nitrogen atoms of the peptoid backbone. Visualization of the trajectories and analysis was performed using the VMD software (14).

TABLE S1

Peptoid-DNA interaction characterization and properties.						
Properties	PE1	PE4				
"Persistent Contact (%)	98.2%	98.7%				
^b Minor/Major groove interactions	-					
^c Minor Groove Contacts (%)	28.5%	24.0%				
^d Major Groove Contacts (%)	6.1%	39.6%				
Major and Minor Groove Contacts (%)	48.8%	18.5%				
^b Nte/Nae residue interaction time	_					
Nte Contact (%)	98.01%	70.39%				
Nte (1 residue)	12.55%	30.45%				
Nte (2 residues)	74.75%	24.94%				
Nte (3 residues)	31.79%	11.82%				
Nte (4 residues)	20.19%	2.90%				
Nte (5 residues)	8.07%	0.28%				
Nte (6 residues)	0.67%	0.00%				
Nae Contact Time (%)	98.08%	99.90%				
Nae (1 residue)	14.79%	0.66%				
Nae (2 residues)	25.53%	3.87%				
Nae (3 residues)	31.53%	12.74%				
Nae (4 residues)	19.87%	28.43%				
Nae (5 residues)	6.45%	35.86%				
Nae (6 residues)	0.41%	18.33%				
Average contact area (nm ²)	2.88 ± 1.11	2.54 ± 1.05				
Peptoid solvent accessible surface area	18.82 ± 1.47	17.81 ± 1.64				
(nm^2)						
Average separation distance of outermost	2.33 ± 0.6	2.20 ± 0.6				
nitrogens d _{N2-N19} (nm)						

Magnesium depletion assays.

Bare OCs and peptoid-coated OCs were diluted in TAE $(1\times)$ buffer, PBS $(1\times)$ buffer, Roswell Park Memorial Institute 1640 medium (RPMI, Thermo Fisher Scientific) and the Dulbecco's Modified Eagle Medium (DMEM, Gibco) such that the final concentrations of origami and MgCl₂ were 4.3

nM and 1.25 mM, respectively. The samples were incubated at 4° C. (TAE and PBS) or 37° C. (RPMI and DMEM) for 24 h and characterized by AGE and negative-stained TEM imaging. In all figures of AGE analyses, label "+" represents the final MgCl₂ concentration of 12.5 mM; label "-" represents depleted Mg²⁺ and the final MgCl₂ concentration was 1.25 mM. To prepare samples for TEM imaging, OCs were extracted from the agarose gels using the Freeze 'N SqueezeTM DNA Gel Extraction Spin Columns (Bio Rad) and centrifuged at 1000 rcf for 3 min at room temperature.

Dynamic light scattering (DLS). In FIG. 4E, bare (4 nM) and PE2-coated OCs (4 nM, N/P: 0.5) in TAE (1x) buffer containing 12.5 mM MgCl₂ were incubated with EDTA (10 mM) for ~30 min prior to DLS measurement. In FIG. 35, bare (4 nM) and PE2-coated OC solutions (4 nM, N/P: 0.5) were incubated with DN of 15 and 20 µg/mL at 37° C. for 30 min prior to measurement. The concentration of MgCl₂ in the TAE buffer was 12.5 mM. The samples were measured 3 times with Zetasizer Nano Z (Malvern Panalytical) with an 20 equilibrium time of 120 sec. Small-angle X-ray scattering (SAXS). Solution Scattering data was collected at the Life Sciences X-ray Scattering beamline (LiX) at NSLSII, Brookhaven National Laboratory, Upton, N.Y. LiX utilizes an undulator source and a Si(111) monochromator. KB 25 mirrors focus the beam on a secondary source and X-ray energy was 12 keV with a beamsize of ~400 um. An in-house solution scattering box houses a movable 3 channel flow cell such that proteins in solution flow through the beam during collection. Data is collected on 3 Pilatus 30 detectors (SAXS: Pilatus 1M, 2 offset WAXS detectors: Pilatus 300K) https://doi.org/10.1063/1.4952872. The data was merged, averaged, subtracted and packed into HDF5 format using our in-house py4xs software https://doi.org/ 10.1107/S0909049512048984, with data visualization in 35 jupyter notebook. Bare (28 nM) and PE2-coated OCs (28 nM, N/P: 0.5) in TAE (1x) buffer containing 12.5 mM MgCl₂ were mixed with EDTA (10 mM) and immediately loaded to the SAXS flow cell. The total processing time prior to measurement is ~20-30 min. For each sample exposed to 40 the X-ray beam, five frames, with an exposure time of 1 sec was collected and processed using the py4xs software. TAE (1×) buffer containing 12.5 mM MgCl₂ was used as reference and was subtracted from the samples.

Nuclease degradation assays.

Bare OCs (4.3 nM) and peptoid-coated OCs (4.3 nM, N/P: 0.5) were mixed with different concentrations of deoxyribonuclease I (DN) in TAE (1×) buffer containing 12.5 mM MgCl₂. The samples were incubated at 37° C. for 30 min at 650 rpm on a thermal cycler (Eppendorf) and characterized 50 using AGE and negative-stained TEM imaging. Encapsulation of 10 nm gold nanoparticles (Au NPs) in OCs.

(1) Peptide Synthesis.

Solid-phase peptide synthesis was performed to synthesize the azido peptide (CALDDK(N3)) for Au NP functionalization. Briefly, Rink Amide resins and the protected amino acids were added to the growing peptide chain with the activating reagent 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU). Following 60 addition of the submonomers, the Fmoc group was removed under 20% piperidine in DMF deprotection conditions. The peptides were cleaved by trifluoroacetic acid/triisopropylsilane/deionized water (95:2.5:2.5, v/v/v). The crude peptide was precipitated by cold ether several times and lyophilized. 65 The as-synthesized peptides were purified by reverse-phase high-performance liquid chromatography (HPLC, Shi-

madzu). The Phenomenex C18 Gemini NX column was 150×21.2 mm and had a 5 m pore size and 100 Å particle size.

(2) Au NP Functionalization.

First, 990 L of 10 nm Au NPs (9.5 nM, BBI solutions) were mixed with 10 L of peptide CALDDK(N3) (pep, 1 mM) overnight at room temperature (~12 h). The solution was washed 3 times with 10 mM phosphate buffer (pH 7.4) by centrifugation at 10,000 rcf and at 4° C. Next, DBCOmodified single-stranded DNA (ssDNA, 5'-TATGAAGT-GATGGATGAT/3DBCO/)) (SEQ ID NO: 1) was added to the Au NP-pep solution at concentration ratio of 300:1 in 10 mM phosphate buffer (pH 7.4) and incubated at least 4 h at room temperature. A final concentration of 100 mM of NaCl was added to the Au NP-solution and left incubating overnight. The solution was washed 3 times with 10 mM phosphate (pH 7.4) containing 100 mM NaCl by centrifugation at 10,000 rcf and at 4° C. UV-vis spectroscopy (Lambda 25, PerkinElmer) was used to calculate the final Au NP-pep-ssDNA concentration.

(3) Au NP-pep-ssDNA Encapsulation in OCs.

OCs (40 nM) were mixed with the Au NP-pep-ssDNA (48 nM) and cooled from 50° C. to room temperature over a time course of 40 h.

Doxorubicin (Dox) release from bare OCs and peptoidcoated OCs. OCs (10 nM) were incubated with doxorubicin (Dox, 0.1 mM) at room temperature for 24 h and purified 3 times with TAE (1x) buffer containing 12.5 mM MgCl₂ using a 100 kDa filter and centrifuged at 400 rcf and at 15° C. OCs were concentrated to 50 nM in the final centrifugation. PE2-coated OCs were prepared by mixing PE2 (27.7 µM) with Dox-loaded OCs (50 nM) overnight (~12 h) at room temperature. Dox-loaded bare and PE2-coated OCs were diluted in PBS (1×) at pH 7 or 5.5 and incubated at 37° C. for 48 h, followed by centrifugation with 50 kDa filters at 1000 rcf for 30 min at room temperature, of which the supernatant solution was collected. Fluorescence spectra were measured in a 384 well plate (Corning) using the Spark microplate reader (Tecan). The \lambda ex and \lambda em were 485 nm and 515-800 nm, respectively with a step size of 2 nm. Encapsulation of fluorescein-modified bovine serum albu-

min (BSA) in OCs.

First, NHS-fluorescein (240 μ M) and NHS-PEG-azide (60 μ M) was mixed with BSA (10 μ M) in PBS (1×) buffer for 3 45 h at room temperature. The solution was purified 8 times with PBS using a 50 kDa filter and centrifuged at 3000 rcf and at 4° C. Next, the DBCO-modified single-stranded DNA (ssHy, 5'-TATGAAGTGATGGATGGATGAT/3DBCO/, 250 μ M) (SEQ ID NO: 1) was mixed with the BSA solution (10 μ M) 50 overnight (~12 h) at 4° C. The solution was purified 8 times with PBS using a 50 kDa filter and centrifuged at 3000 rcf at 4° C. Finally, the surface-modified BSA (200 nM) was added to the OCs (40 nM) and the solution was cooled down from 45° C. to room temperature over a time course of 60 55 h. The solution was purified 2 times with TAE (1×) buffer containing 12.5 mM MgCl₂ using a 100 kDa filter and centrifuged at 400 rcf and at 4° C.

Fluorescence Assay for Tryptic Digestion of BSA.

(1) The fluorescein-modified BSA (80 nM) solution without OCs was incubated at 37° C. in the presence or absence of trypsin (50 nM) overnight ~12 h prior to fluorescence measurement. Fluorescence spectra were measured with excitation and emission wavelengths of 490 nm and 510-750 nm, respectively and a step size of 2 nm. (2) The fluoresceinmodified BSA encapsulated OCs (20 nM) were incubated at 37° C. in the presence or absence of trypsin (50 nM) in a 384 well plate. The fluorescence kinetics were measured at λ_{ex} and λ_{em} of 490 nm and 525 nm, respectively and time interval of 3 min. Fluorescence spectra were measured after 15 h at excitation and emission wavelengths of 490 nm and 510-800 nm, respectively and a step size of 2 nm. TAE $(1\times)$ buffer containing 12.5 mM MgCl₂ was used for both experi-5 ments.

Surface conjugation of peptoid-protected OCs with azide fluor 488.

Alkyne-modified peptoids (PE8 and PE9, 20 µM) were mixed with azide fluor 488 (60 µM), 0.1 mM CuSO₄, 0.5 10 mM THPTA, 5 mM aminoguanidine and 5 mM sodium ascorbate in 100 mM sodium phosphate buffer (pH=7.4) for 2 h at room temperature. The peptoid-fluorophore (PE8-FL and PE9-FL) conjugates were dialyzed against deionized water with 0.2 mM EDTA for 12 h at room temperature 15 using a 3,500 Da membrane, followed by dialysis against deionized water for 24 h at room temperature.

Synthesis of Trastuzumab-azide.

Trastuzumab expressed with two heavy chain C-terminal formylglycine residues (SMARTag antibody CT) was a gift 20 from David Rabuka (Catalent) (15). A small molecule azide linker with a hydrazino moiety was synthesized in 9 steps as described previously (16, 17). The trastuzumab-aldehyde was reacted with the azide via the hydrazino-iso-Pictet Spengler ligation as described previously (17). Briefly, 25 trastuzumab with C-terminal heavy-chain formylglycine residues was buffer exchanged via PD-10 column (GE Life Sciences, 17085101) into 50 mM sodium citrate (Millipore Sigma C8532). To trastuzumab fGly (182.7 nmol, 2.19 mL, 1 equiv.) in sodium citrate buffer was added the azide 30 molecule (4 µmol, 135 µL, 21.9 equiv.) freshly dissolved in DMSO in a falcon tube. The falcon tube was closed after flushing with argon gas, and the reaction was mixed 250 rpm in the dark at 37° C. for 22 h. Following this, the reaction was buffer exchanged via PD-10 desalting columns into PBS 35 (Corning, 21-040-CM), with ~90% recovery.

Trastuzumab-azide was analyzed by mass spectrometry to confirm the azide addition, with no detected unmodified trastuzumab-azide remaining. Trastuzumab-azide (20 L in PBS was treated with 0.75 L PNGaseF (NEB, P0704S) at 40 37° C. overnight in an eppendorf tube. After 16 h, the DTT was added (30 mM, 0.6 L from frozen stock solution in water) (Thermo Fisher Scientific, 15508013), and the antibody was heated at 65° C. for 5 min using a Thermomixer. Antibody was placed on ice and analyzed in the same day at 45 the SUMS facility at Stanford University by ESI-LC/MS on an Agilent 1260 HPLC and Bruker MicroTOF-O II timeof-flight mass spectrometer. A Waters BioResolve RP mAb Polyphenyl 450 Å 2.7 m 100×2.1 mm column was maintained at 50 $^{\circ}$ C. Five microliters of reduced, de-glycosylated 50 antibody conjugate were injected at a flow rate of 0.3 mL/min at 95% solvent A (0.05% trifluoroacetic acid in water) and 5% solvent B (0.1% formic acid in acetonitrile). This was held for 1.5 min, then ramped to 35% B at 2 min, 46% B at 10 min, and 95% B at 11 min, which was held for 55 1 min. Data was collected in full scan MS mode with a mass range of 400-4000 Da and Collision RF setting equal to 800 V.

Surface conjugation of peptoid-protected OCs with Trastuzumab.

Alkyne-modified peptoids (PE8 and PE9, 30 µM) were mixed with azide-modified Trastuzumab (10 µM), 0.1 mM CuSO₄, 0.5 mM THPTA, 5 mM aminoguanidine and 5 mM sodium ascorbate in 100 mM sodium phosphate buffer (pH=7.4) for 2 h at room temperature. The peptoid-65 Trastuzumab (PE8-Tz and PE9-Tz) conjugates were dialyzed against PBS (1×) buffer with 0.2 mM EDTA for 12 h

at 4° C. using a 100-500 Da membrane for 2 times, followed by dialysis against PBS (1×) buffer for 24 h at 4° C. Results and Discussion

Two types of polycationic peptoids were designed to protect DNA origamis by multivalent peptoid-DNA interactions and compact surface coating (FIGS. 1A and 13). In the brush-type peptoids (PE1-3), positively charged (2-aminoethyl)glycine (Nae) and neutrally charged N-2-(2-(2methoxyethoxy)ethoxy)ethylglycine (Nte) moieties were assembled alternately. In the block-type peptoids (PE4-5), Nae and Nte clustered together to form a peptoid having positively-charged submonomers clustered at the N-terminus and neutrally charged submonomers clustered at the C-terminus.

These polycationic peptoids are proposed to electrostatically bind to the anionic phosphate backbone of the DNA and compensate charge repulsions between DNA strands. In addition, incorporation of neutral oligo-Nte is expected to prevent aggregation of the DNA origami structures. The anti-fouling oligo-Nte can also prevent adsorption of biomolecules in physiological environments (51, 52) and enzymatic degradation of DNA origamis triggered by protease and nuclease.

In this disclosure, the interactions between a duplex DNA and peptoids were first studied by comprehensive spectroscopic approach and molecular dynamics simulations. The enhanced stability of 3D octahedra-shaped DNA origamis (OCs) was then investigated by surface coating with peptoids in physiological solutions, including the depletion of magnesium ions, the presence of nuclease and the addition of cell culture media. The effect of different peptoid structures on OC protection was discussed. Next, the functionality of peptoid-stabilized OCs was explored, where controlled release of anti-cancer drug and tryptic digestion of proteins encapsulated in OC nanostructures were examined. Finally, alkyne modified peptoids were used to conjugate functional biomolecules and present them on the surface of peptoid-coated OCs.

The effect of the two types (i.e., brush and block) of peptoids on stabilizing duplex DNA (dsDNA) was investigated by real-time SYBR Green I (SG) fluorescence assay. SG is known to have a stronger affinity toward dsDNA than to single-stranded DNA (ssDNA) due to the favored intercalation between base pairs and increased stability of the SG/dsDNA complex. The enhanced SG fluorescence in complex with dsDNA is due to the dampening of its intramolecular motions (53, 54). Here, a 15-base pair dsDNA with a melting temperature (Tm) of ~44° C. was designed to study dsDNA stability in the presence of peptoids at varied molar ratios of peptoid amines to phosphate groups of the DNA (i.e., N/P). As shown in FIGS. 2A and 14, fluorescence signals of SG/dsDNA complexes were observed to increase in the presence of peptoids, indicating enhanced stability of DNA base-pairing as the temperature approaches Tm of the dsDNA. The increase of fluorescence signal was believed to originate from the association of SG with dsDNA (53) since no signal was observed when mixing SG with peptoids only (FIG. 15). Tm of dsDNA/peptoid complexes was presented 60 by the derivatives of fluorescence intensities plotted against temperature. As shown in FIGS. 2B, 14 and 16, depending on the amount of peptoid added, Tm of the dsDNA increased 1-6° C. Among the sequences, PE2 exhibited the highest performance in raising the Tm of the dsDNA, where the Tm shifted from 44° C. to 50° C. as the N/P increased from 0.125 to 8 (FIGS. 2B and 16). Moreover, brush-type peptoids were observed to confer higher stability of the dsDNA

compared to block-type peptoids, where Tm (dsDNA/PE2)>Tm (dsDNA/PE1)>Tm (dsDNA/PE4) and Tm (dsDNA/PE3)>Tm (dsDNA/PE5).

Polycationic polymers and lipids often cause DNA to form polyplexes which can significantly quench the DNA-5 binding fluorophores (55). Here, the oligo-Nte motifs are expected to inhibit DNA condensation and polyplex formation. Indeed, the fluorescence of SG intercalated inside the dsDNA remained unchanged after the addition of PE2 at room temperature (25° C.) (FIG. **17**). This was confirmed by 10 agarose gel electrophoresis (AGE), where no aggregation of dsDNA/PE2 was noted at N/P from 0.125 to 8 (FIG. **18**). These indicated that the peptoid-dsDNA interactions did not induce DNA condensation at this level.

Explicit solvent molecular dynamics (MD) simulations 15 were performed to investigate the binding mechanisms of brush-type PE1 and block-type PE4 with dsDNA in solution (FIG. **3**A, **3**B, **19** and FIG. **13**). The simulations showed strong binding affinities of both peptoids to dsDNA, of which PE1 and PE4 exhibited persistent contacts (cut-off=4 20 Å) for 98.2% and 98.7% of the total simulation time, respectively. The peptoids experienced almost immediate binding to the dsDNA regardless of their starting structures in the simulations. This strong attraction was due to the electrostatic attractive forces between the positively charged 25 Nae residues of the peptoids and negatively charged phosphate groups of the DNA backbone.

PE1 and PE4 exhibited distinct differences in the binding mechanisms to dsDNA. PE1 demonstrated persistent interactions (~98% of the total contact time) with DNA via both 30 the Nae and Nte motifs, where at least 58% (Nae) and 61% (Nte) of the time, 3 or more residues were in close contact with the dsDNA. In addition, the "brush" arrangement facilitated PE1 to spread across the DNA backbone where it interacted with both major and minor grooves concurrently 35 (48.8% of the total contact time), while a preferred binding toward the minor groove (28.5%) exclusively over the major groove (6.1%) of the dsDNA was also observed.

In contrast, the PE4-dsDNA interactions dominated binding through the Nae moieties (~100% of the total contact 40 time), where 4 or more Nae residues were in close contact with the dsDNA for more than 85% of the time. Meanwhile, the Nte moieties exhibited significantly less persistent interactions with DNA, where only the closest two Nte residues were involved in binding for 55% of the total contact time. 45 In addition, the "block" arrangement facilitated the Nte end of PE4 to be solvent exposed, and therefore PE4 was observed to embed in either the major (39.6%) or minor (24%) grooves of the dsDNA, while simultaneous interactions with both major and minor grooves (18.5%) were less 50 favored. As expected, PE1 formed a larger contact area with $dsDNA (2.88 \pm 1.11 \text{ nm}^2)$ compared to PE4 (2.54 \pm 1.05 \text{ nm}^2), whereas PE4 had lower average solvent accessible surface area than PE1 due to a more compact structure overall while bound to DNA (PE1: 18.82±1.47 nm² and PE4: 17.81±1.64 55 nm²) (Table S). Interestingly, MD simulations showed the PE1 structure to be more flexible and dynamic while interacting with the dsDNA compared to PE4, which was frequently restrained due to the embedding of the Nae end within the DNA grooves (demonstrated by the larger occu- 60 pancy volume areas adopted by PE4 compared to PE1 in FIGS. 3A and 3B).

Without wishing to be bound by theory, it is believed that water plays an important role in the binding phenomena of the architecturally different peptoids with dsDNA. The 65 structuring of water surrounding the pristine dsDNA in respective to the dsDNA/peptoid complex was investigated

through radial distribution functions (RDFs). FIG. 3C-F showed a higher density of water molecules surrounding the AT base-pairs versus GC base-pairs with notable preference for the minor grooves of the AT base-pairs. The higher solvation of the minor groove vis-à-vis major groove of DNA was reported previously (56). Interestingly, the binding of PE4 contributed to significant expulsion of water from the dsDNA, with most evident reduction in water density at the minor grooves of the AT base-pairs and major grooves of the GC base-pairs. Without wishing to be bound by theory, it is believed that this was due to the "block" arrangement of PE4, where the "block" comprised osmotic ethylene glycol residues which could alter the surrounding dielectric constant, resulting in effective displacement of water molecules from the DNA structure (57, 58). On the other hand, PE1 was observed to have the least effect on the structuring of water surrounding the dsDNA, suggesting that such "brush" arrangement of PE1 did not affect the water uptake by dsDNA. At the same time, water facilitated the interactions of the polar Nte moieties to achieve a close (albeit dynamic) binding and larger contact area with the dsDNA. Since it is known that DNA hydration directly relates with the stability of duplex formation specifically through Watson-Crick base pairs (59), the observed differences in water structuring and binding mechanisms of PE1 and PE4 to dsDNA play important roles in the stability of dsDNA and thus DNA origamis, as observed from the SG fluorescence assays (FIG. 2).

The polycationic peptoids were then applied to protect OCs, which possessed six DNA bundles at each edge that confers rigidity of the 3D nanostructure (FIG. 1B). The structural stability of OCs in the presence of peptoids was evaluated. As shown in FIG. 20, transmission electron microscopic (TEM) imaging showed that the morphology of OCs was maintained when N/P was not higher than 0.5. Higher N/P could lead to aggregation, while this was improved by increasing the number of Nte residues, of which PE2 (Nae₁₂-Nte₁₂ brush) and PE3 (Nae₆-Nte₁₂ brush) coated OCs exhibited less aggregation than PE1 (Nae₆-Nte₆ brush). Similarly, increasing the number of Nte residues in the block-type peptoids, PE4 (Nae₆-Nte₆ block) and PE5 (Nae₆-Nte₁₂ block), to further of 16 Nte residues enabled more stable OC structures (FIGS. 20 and 21). This implied that incorporation of the hydrophilic Nte motifs could reduce aggregation of DNA origamis. On the other hand, PE6 and PE7 peptoids, where the positively charged Nae residues was substituted by neutrally charged N-(2methoxyethyl)glycine (Nme) residues on the peptoid backbone, exhibited no obvious structural changes at even higher N/P (i.e., 2, 1, and 0.5, FIGS. 22 and 23). This supported that the Nae moieties were the primary driving force for the peptoid-DNA interactions as demonstrated by MD simulations (FIG. 3). ξ -potential was also analyzed (n=3), where bare OCs, PE2- and PE3-coated OCs were measured at -13.3±0.34, -11.7±0.42, and -12.6±0.40, respectively. The low E-potential of OCs was likely due to the high ionic strength and Mg²⁺ content of the buffer, which effectively shielded the surface charge of OCs.

 Mg^{2+} is known to play the central role for the integrity of DNA origami nanostructures by stabilizing DNA base-pairing (28). Here, a Mg^{2+} depleted condition was generated by diluting the bare OCs and peptoid-coated OCs (OC/peptoid) so that the final concentration of magnesium chloride (MgCl2) in solution was 1.25 mM (FIG. 4). The structural integrity of OCs was first assessed by agarose gel electrophoresis (AGE). The peptoid-protected OCs show bands on the agarose gel similar to bare OCs, confirming the intact OC nanostructures (FIG. 24). However, when MgCl₂ con-

centration was reduced from 12.5 mM to 1.25 mM, a notable electrophoretic band shift in the agarose gel was observed (FIGS. 4B, 4C, and 25), indicating the damage of OCs. At N/P of 0.5, OC/peptoid showed less electrophoretic shift than bare OCs, indicating an improved stability in the 5 presence of peptoids (FIG. 4C). Among the peptoid sequences, OC/PE2 showed the least electrophoretic shift at N/P of 0.5, while the protection effect was significantly reduced at N/P of 0.1, supporting that higher concentration of positively charged moieties could compensate the deple- 10 tion of Mg²⁺. TEM imaging was further performed on bare OCs and OC/peptoid extracted from the agarose gel. As shown in FIG. 4D and S14A, the structure of bare OCs in a low Mg²⁺ condition was significantly distorted and expanded. At an N/P of 0.5, TEM imaging ensured the dense 15 coating of PE2 did not comprise the structural integrity of OCs in the Mg²⁺ depleted solution (FIGS. 4D and 26), while the protection effect was not observed in other peptoid sequences (FIG. 27). This stronger PE2-DNA interaction was consistent with result obtained from the SG fluores- 20 cence assay (FIG. 2). In fact, the assay was performed on OC/peptoid at an N/P of 0.125, in which only OC/PE2 exhibited a clear Tm shift from 48° C. to 52° C. (FIG. 28).

Dynamic light scattering (DLS) and in situ small angle X-ray scattering (SAXS) were used to analyze the overall 25 average size and structure of bare OCs and OC/PE2 in solution, respectively. Here, ethylenediaminetetraacetic acid (EDTA), a strong metal ion chelating reagent, was used to remove Mg²⁺ from the solution, where TEM images showed that the extent of damaged OCs increased with the concen- 30 tration of EDTA (FIG. 29). As shown in FIG. 4E, DLS revealed a broadened peak width when the bare OCs were treated with high concentration of EDTA (10 mM), indicating distorted OCs and increased structural heterogeneity. On the other hand, peak broadening was inhibited by PE2 35 coating, suggesting that OC stability was significantly improved in the presence of PE2. Similarly, SAXS showed that the q value at 0.021 Å¹, representing the shape factor of OCs, continued to shift toward the lower q-regime in the presence of EDTA (5 and 10 mM). While some destabili- 40 zation was observed in OC/PE2 at higher amount of EDTA, it is clear that the structural changes of OCs were effectively inhibited by PE2 coating (FIGS. 4F and 4G). The flexibility or "unfoldedness" of the OC structures obtained from SAXS were also assessed using the Kratky analysis. As shown in 45 FIG. 30, bare OCs became more flexible and did not plateau at higher a upon treatment with EDTA while this effect was inhibited by PE2 coating. These results were consistent with AGE and TEM imaging (FIG. 4A-C).

When bare OCs and OC/peptoid were dispersed in phosphate buffered saline (PBS) at low Mg^{2+} content, all OC/peptoid exhibited more stable structures compared to those observed in TAE buffer (FIG. **31**). This was likely due to the Na+ in PBS buffer compensated the loss of Mg^{2+} and assisted the stability of OC structures. 55

Next, the stability of OC/peptoid against enzymatic degradation was investigated in solution containing deoxyribonuclease I (DN). As shown in AGE, bare OCs could be degraded by DN at a concentration as low as 2.5 μ g/mL, where the increased electrophoretic mobility indicated dissociation of staple strands from the OCs (FIG. **32**). To demonstrate the protecting effect of peptoids, bare OCs and OC/peptoid were incubated with DN (15 μ g/mL) for 30 min at 37° C. and inspected by TEM imaging (FIGS. **5** and **33**). As expected, bare OC structures were degraded, and the 65 octahedra shape was damaged after incubating with DN. In the presence of peptoids, the OC/PE2 structure remained

intact and PE1, PE3, and PE4 show some extents of capability to preserve the origami structure. DLS also confirmed a smaller size reduction of the OC/PE2 at DN levels of 15 and 20 μ g/mL compared to bare OCs (FIG. **34**). Without wishing to be bound by theory, it is believed that the stronger multivalent interactions in the OC/PE2 system is required to prevent DN adsorption and degradation. The oligo-Nte of the peptoid sequences is also likely to provide steric shielding to reduce DN binding to the DNA backbone.

Since PE2 exhibited the best protection of OC structures, the stability of OC/PE2 in cell media was investigated, including the Dulbecco's Modified Eagle Medium (DMEM) (FIGS. 6C, 6D and 35) and Roswell Park Memorial Institute (RPMI) 1640 medium (FIGS. 6A and 6B) in a low Mg²⁺ condition. TEM images showed that OC/PE2 (N/P: 0.5) were protected after incubating in both the RPMI and DMEM media for 24 h at 37° C., while the OC structures were distorted without PE2 coating (FIGS. 6 and 35). In the presence of fetal bovine serum (FBS), the combination of Mg²⁺ depletion and FBS nuclease led to enhanced structural damages of bare OCs beyond recognition (FIG. 6C). On the other hand, TEM imaging showed presence of stable OC/PE2 in the DMEM-FBS media although reduced numbers of OCs were found after incubation for 24 h at 37° C. (FIG. 6D). The protection is expected to be further improved by increasing the length of PE2 sequence, enabling stronger peptoid-DNA interactions whilst preventing OC aggregation and condensation, which requires further experimentation. In an independent experiment, 10 nm gold nanoparticles (Au NPs) were encapsulated in the OC structures by surface functionalization of Au NPs with single-stranded DNAs (ssDNAs) that complemented eight ssDNA linkers located in the OCs prior to PE2 coating (FIG. 36). As shown in FIG. 37, the Au NPs remained encapsulated in the OC/PE2 after incubation in the DMEM and DMEM-FBS media for 24 h at 37° C., which supported the protection by PE2 coating. The resistance of OC/PE2 against Mg²⁺ depletion, change in buffer component and nuclease degradation makes it an attractive candidate for biomedical applications. In fact, OC has a size of ~60 nm which is ideal for encapsulation/ immobilization of biomolecules and drugs of a range of sizes. Doxorubicin (Dox), a common anti-cancer drug used in chemotherapy, was loaded to bare OCs and OC/PE2 (N/P: 0.5) and measured its release from the OC structures. Dox-loaded DNA origamis have been reported in the literature, where the molecule intercalates the DNA backbone and releases from the origamis structures over time (24-26). The intrinsic Dox fluorescence can be used to measure the loading and release from the OCs (24-26), where the fluorescence intensity was proportional to the Dox concentration in the sub-micromolar range (FIG. 38). In our case, -10% of Dox was loaded onto the OCs. As shown in FIG. 39, a reduction of the total Dox release from the OC/PE2 (~10% release) compared to bare OCs (~30% release) was observed 55 at both pH 7 and 5.5 after incubating for 48 hrs at 37° C. in PBS buffer. This property may be useful for modulating the desired release during the drug delivery processes.

It was demonstrated that surface coating of OCs with PE2 provides protease resistance to proteins encapsulated in the OC structures. Here, bovine serum albumin (BSA) was modified with fluorescein and encapsulated in the bare OCs and OC/PE2 via DNA hybridization (see Method). The fluorescence signal was self-quenched due to multiple fluorescein labeled on a single BSA (60). Fluorescence recovery was attained in the presence of trypsin, which catalyzed hydrolysis of BSA preferentially at sites of lysine and arginine (61), and subsequently released the fluorescein-

50

55

conjugated fragments (FIG. 7A). In the presence of trypsin, an 85% increase in the fluorescence intensity was observed in the fluorescein labeled BSA in solution (FIG. 40). This fluorescence enhancement representing trypsin digestion of the target BSA sequences was reduced to $\sim 40\%$ by protein ⁵ encapsulation inside the OCs and further reduced to ~14% by PE2 coating on the OC surface (FIG. 41). In addition, the fluorescence kinetics assay showed a slower trypsin digestion with PE2 coating (FIG. 7B). Peptoid coating can increase protection of biological cargos inside OCs from solution environments. Note that higher levels of trypsin (0.1-5 µM) in the OC solution were examined by TEM imaging and no observable effect to the OC structures was found (FIG. 42).

15 Peptoid-protected OCs can be modified with different biological moieties by incorporating reactive groups into the peptoid sequences. Toward this end, two clickable peptoids (brush and block types, PE8 and PE9) were synthesized (FIG. 8) and used to stabilize OCs. Azide fluor 488 was then 20 conjugated to OCs via copper-catalyzed click chemistry. As shown in FIG. 8C, the success of surface conjugation was confirmed by the increased fluorescence from OCs. The peptoid-protected OCs can also be functionalized with larger biomolecules such as Trastuzumab (Tz), an IgG1 monoclo- 25 15. Zhang Y, et al. (2018) Programmable and Multifuncnal antibody used to treat breast cancers that are HER2 receptor positive. To this end, Trastuzumab was expressed with two azide linkers at the C-terminal fGly residue of the Tz sequence prior to peptoid conjugation (62, 63). This allows us to perform site-specific antibody-peptoid conju-30 gation via alkyne-azide reaction (FIG. 43), where the active antibody domains are presented in an orientated fashion. As shown in FIG. 8D, the conjugation of Trastuzumab on OCs was confirmed by immunogold labelling, where the Tz was stained by Au NP (6 nm)-modified protein G and visualized 35 by TEM. The Tz-displaying property of OCs can be potentially combined with the capability of anti-cancer drug loading to provide a combinatory method toward cancer therapy.

SEQUENCE LISTING

A Sequence Listing conforming to the rules of WIPO Standard ST.25 is hereby incorporated by reference. The Sequence Listing has been filed as an electronic document 45 via EFS-Web in ASCII format. The electronic document, created on Sep. 25, 2020, is entitled "SEQ-369-304_ST25.txt", and is 37,860 bytes in size.

REFERENCES

- 1. Seeman N C (2003) DNA in a material world. Nature 421:427
- 2. Lin C, Liu Y, Yan H (2009) Designer DNA Nanoarchitectures. Biochemistry 48:1663-1674.
- 3. Pinheiro AV, Han D, Shih W M, Yan H (2011) Challenges and opportunities for structural DNA nanotechnology. Nat Nanotechnol 6:763-772.
- 4. Rothemund PWK (2006) Folding DNA to create nanoscale shapes and patterns. Nature 440:297.
- 5. Mirkin C A, Letsinger R L, Mucic R C, Storhoff J J (1996) A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 382:607-609.
- 6. Niemeyer C M, Burger W, Peplies J (1998) Covalent DNA-Streptavidin Conjugates as Building Blocks for 65 29. Kielar C, et al. (2018) On the Stability of DNA Origami Novel Biometallic Nanostructures. Angew Chemie Int Ed 37:2265-2268.

- 7. Keren K, et al. (2002) Sequence-Specific Molecular Lithography on Single DNA Molecules. Science (80-) 297:72 LP-75.
- 8. Ford W E, Harnack O, Yasuda A, Wessels J M (2001) Platinated DNA as Precursors to Templated Chains of Metal Nanoparticles. Adv Mater 13:1793-1797.
- 9. Alivisatos A P, et al. (1996) Organization of "nanocrystal molecules" using DNA. Nature 382:609-611.
- 10. Nykypanchuk D, Maye M M, van der Lelie D, Gang O (2008) DNA-guided crystallization of colloidal nanoparticles. Nature 451:549.
- 11. Zhang Y, Lu F, Yager K G, van der Lelie D, Gang O (2013) A general strategy for the DNA-mediated selfassembly of functional nanoparticles into heterogeneous systems. Nat Nanotechnol 8:865.
- 12. Chandrasekaran A R, Levchenko O (2016) DNA Nanocages. Chem Mater 28:5569-5581.
- 13. Schneider A-K, Niemeyer C M (2018) DNA Surface Technology: From Gene Sensors to Integrated Systems for Life and Materials Sciences. Angew Chemie Int Ed 57:16959-16967.
- 14. Zhu B, Wang L, Li J, Fan C (2017) Precisely Tailored DNA Nanostructures and their Theranostic Applications. Chem Rec 17:1213-1230.
- tional DNA-Based Materials for Biomedical Applications. Adv Mater 30:1703658.
- 16. Fu J, Liu M, Liu Y, Yan H (2012) Spatially-Interactive Biomolecular Networks Organized by Nucleic Acid Nanostructures. Acc Chem Res 45:1215-1226.
- 17. Li J, Fan C, Pei H, Shi J, Huang Q (2013) Smart Drug Delivery Nanocarriers with Self-Assembled DNA Nanostructures. Adv Mater 25:4386-4396.
- 18. Amir Y, et al. (2014) Universal computing by DNA origami robots in a living animal. Nat 20 Nanotechnol 9:353
- 19. Douglas S M, Bachelet I, Church G M (2012) A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads. Science (80-) 335:831 LP-834.
- 40 20. Bujold K E, Hsu JCC, Sleiman H F (2016) Optimized DNA "Nanosuitcases" for Encapsulation and Conditional Release of siRNA. J Am Chem Soc 138:14030-14038.
 - 21. Schüller V J, et al. (2011) Cellular Immunostimulation by CpG-Sequence-Coated DNA Origami Structures. ACS Nano 5:9696-9702.
 - 22. Grossi G, Dalgaard Ebbesen Jepsen M, Kjems J, Andersen E S (2017) Control of enzyme reactions by a reconfigurable DNA nanovault. Nat Commun 8:992.
 - 23. Ora A, et al. (2016) Cellular delivery of enzyme-loaded DNA origami. Chem Commun 52:14161-14164.
 - 24. Jiang Q, et al. (2012) DNA Origami as a Carrier for Circumvention of Drug Resistance. J Am Chem Soc 134:13396-13403
 - 25. Zhang Q, et al. (2014) DNA Origami as an In Vivo Drug Delivery Vehicle for Cancer Therapy. ACS Nano 8:6633-6643.
 - 26. Sun W, et al. (2014) Cocoon-Like Self-Degradable DNA Nanoclew for Anticancer Drug Delivery. J Am Chem Soc 136:14722-14725.
- 60 27. Douglas S M, et al. (2009) Self-assembly of DNA into nanoscale three-dimensional shapes. Nature 459:414.
 - 28. Hahn J, Wickham S F J, Shih W M, Perrault S D (2014) Addressing the Instability of DNA Nanostructures in Tissue Culture. ACS Nano 8:8765-8775.
 - Nanostructures in Low-Magnesium Buffers. Angew Chemie Int Ed 57:9470-9474.

10

- 30. Kim H, Surwade S P, Powell A, O'Donnell C, Liu H (2014) Stability of DNA Origami Nanostructure under Diverse Chemical Environments. Chem Mater 26:5265-5273.
- 31. Benson E, et al. (2018) Effects of Design Choices on the Stiffness of Wireframe DNA Origami Structures. ACS Nano 12:9291-9299.
- 32. Benson E, et al. (2015) DNA rendering of polyhedral meshes at the nanoscale. Nature 523:441.
- 33. Veneziano R, et al. (2016) Designer nanoscale DNA assemblies programmed from the top down. Science (80-) 352:1534 LP-1534.
- 34. Gerling T, Kube M, Kick B, Dietz H (2018) Sequenceprogrammable covalent bonding of designed DNA assemblies. Sci Adv 4:eaau1157.
- 35. Cassinelli V, et al. (2015) One-Step Formation of "Chain-Armor"-Stabilized DNA Nanostructures. Angew Chemie Int Ed 54:7795-7798. 21
- 36. Ponnuswamy N, et al. (2017) Oligolysine-based coating 20 protects DNA nanostructures from low-salt denaturation and nuclease degradation. Nat Commun 8:15654.
- 37. Kiviaho J K, et al. (2016) Cationic polymers for DNA origami coating-examining their binding efficiency and tuning the enzymatic reaction rates. Nanoscale 8:11674- 25 56. Guarnieri F, Mezei M (1996) Simulated Annealing of 11680.
- 38. Agarwal N P, Matthies M, Gur F N, Osada K, Schmidt T L (2017) Block Copolymer Micellization as a Protection Strategy for DNA Origami. Angew Chemie Int Ed 56:5460-5464.
- 39. Mikkilä J, et al. (2014) Virus-Encapsulated DNA Origami Nanostructures for Cellular Delivery. Nano Lett 14:2196-2200.
- 40. Auvinen H, et al. (2017) Protein Coating of DNA Nanostructures for Enhanced Stability and Immunocom- 35 patibility. Adv Healthc Mater 6:1700692.
- 41. Sun J, Zuckermann R N (2013) Peptoid Polymers: A Highly Designable Bioinspired Material. ACS Nano 7:4715-4732.
- 42. Figliozzi G M, Goldsmith R, Ng S C, Banville S C, 40 Zuckermann RNBT-M in E (1996) [25] Synthesis of N-substituted glycine peptoid libraries. Combinatorial Chemistry (Academic Press), pp 437-447.
- 43. Webster A M, Cobb S L (2018) Recent Advances in the Synthesis of Peptoid Macrocycles. Chem-A Eur J 45 24:7560-7573.
- 44. Miller S M, et al. (1994) Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers. Bioorg Med Chem Lett 4:2657-2662.
- evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci 97:13003-13008.
- 46. Rothbard J B, et al. (2002) Arginine-Rich Molecular Transporters for Drug Delivery: Role of Backbone Spac- 55 ing in Cellular Uptake. J Med Chem 45:3612-3618.
- 47. Schröder T, et al. (2008) Peptoidic Amino- and Guanidinium-Carrier Systems: Targeted Drug Delivery into the Cell Cytosol or the Nucleus. J Med Chem 51:376-379.
- 48. Murphy J E, et al. (1998) A combinatorial approach to 60 the discovery of efficient cationic peptoid reagents for gene delivery. Proc Natl Acad Sci 95:1517-1522
- 49. Tian Y, et al. (2015) Prescribed nanoparticle cluster architectures and low-dimensional arrays built using octahedral DNA origami frames. Nat Nanotechnol 10:637. 65
- 50. Tian Y, et al. (2016) Lattice engineering through nanoparticle-DNA frameworks. Nat Mater 15:654.

- 51. Statz A R, Meagher R J, Barron A E, Messersmith P B (2005) New Peptidomimetic Polymers for Antifouling Surfaces. J Am Chem Soc 127:7972-7973.
- 52. Xuan S, et al. (2017) Synthesis and Characterization of Well-Defined PEGylated Polypeptoids as Protein-Resistant Polymers. Biomacromolecules 18:951-964.
- 53. Dragan, A. I.; Pavlovic, R.; McGivney, J. B.; Casas-Finet, J. R.; Bishop E. S.; Strouse, R. J.; Schenerman M A. GCD (2012) SYBR Green I: Fluorescence Properties and Interaction with DNA. J Fluoresc 22:1189-1199.
- 54. Zipper H, Brunner H, Bernhagen J, Vitzthum F (2004) Investigations on DNA intercalation and surface binding by SYBR Green I, its structure determination and methodological implications. Nucleic Acids Res 32:e103-e103.
- 55. Krishnamoorthy G, Duportail G, M61y Y (2002) Structure and Dynamics of Condensed DNA Probed by 1,1'-(4,4,8,8-Tetramethyl-4,8-diazaundecamethylene)bis[4-[[3-methylbenz-1,3-oxazol-2-yl]methylidine]-1,4-dihydroquinolinium] Tetraiodide Fluorescence. Biochemistry 41:15277-15287.
- Chemical Potential: A General Procedure for Locating Bound Waters. Application to the Study of the Differential Hydration Propensities of the Major and Minor Grooves of DNA. J Am Chem Soc 118:8493-8494.
- 57. Spink C H, Chaires J B (1999) Effects of Hydration, Ion Release, and Excluded Volume on the Melting of Triplex and Duplex DNA. Biochemistry 38:496-508.
- 58. Tateishi-Karimta H, Sugimoto N (2014) Control of stability and structure of nucleic acids using cosolutes. Methods 67:151-158.
- 59. Miyoshi D, Karimata H, Sugimoto N (2006) Hydration Regulates Thermodynamics of G-Quadruplex Formation under Molecular Crowding Conditions. J Am Chem Soc 128:7957-7963.
- 60. Munkholm C, Parkinson D R, Walt D R (1990) Intramolecular fluorescence self-quenching of fluoresceinamine. J Am Chem Soc 112:2608-2612.
- 61. Hu L, et al. (2012) Highly sensitive fluorescent detection of trypsin based on BSA-stabilized gold nanoclusters. Biosens Bioelectron 32:297-299.
- 45. Wender P A, et al. (2000) The design, synthesis, and 50 62. Xiao H, Woods E C, Vukojicic P, Bertozzi C R (2016) Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Nat Acad Sci 113:10304 LP-10309.
 - 63. Gray, Melissa A.; Stanczak Michal A.; Xiao Han; Pijnenborg, Johan F. A.; Malaker, Stacy A.; Tanzo, Julia T.; Ahn, Green; Weidenbacher, Payton A.; Woods, Elliot C.; Laubli H, Bertozzi C R (2019) Targeted desialylation overcomes glyco-immune checkpoints and potentiates the anticancer immune response in vivo. https://doi.org/ 026434/chemrxiv8l87146.v1.

Thus while there have been described what are presently believed to be preferred embodiments of the invention, those skilled in the art will realize that changes and modifications may be made thereto without departing from the spirit of the invention, and it is intended to claim all such changes and modifications as fall within the true scope of the invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 127 <210> SEQ ID NO 1 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DBCOmodified ssDNA <400> SEQUENCE: 1 tatgaagtga tggatgat 18 <210> SEQ ID NO 2 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 2 tcaaagcgaa ccagaccgtt ttatatagtc 30 <210> SEQ ID NO 3 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 3 gctttgagga ctaaagagca acggggagtt 30 <210> SEQ ID NO 4 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 4 gtaaatcgtc gctattgaat aactcaagaa 30 <210> SEQ ID NO 5 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA oriqamis <400> SEQUENCE: 5 30 aageettaaa teaagaettg eggageaaat <210> SEQ ID NO 6 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 6

attttaagaa ctggcttgaa ttatcagtga
55

-continued

- 210- CEO TO NO 7	
<2IO> PEO ID NO /	
<211> LENGTH: 30	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<223> OTHER INFORMATION: Description of artificial sequence: DNA	
origamis	
<400> SEQUENCE: 7	
attaggetta agettatagg cataggetga	30
geeddaeee gedeeddaa egeddaeedg	50
<210> SEQ ID NO 8	
<211> LENGTH: 30	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of artificial sequence: DNA	
origamis	
CHOOP SEQUENCE. 0	
agcaccatta ccattacagc aaatgacgga	30
210 SEO ID NO 9	
<211> LENGTH: 30	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
origamis	
<400> SEQUENCE: 9	
	3.0
accycycaga coocoadaac agaccycocy	30
<210> SEQ ID NO 10	
<211> LENGTH: 30	
2010 TYDE, DNA	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctattttc gcattcattc	30
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctattttc gcattcattc	30
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEO ID NO 11	30
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30	30
<pre><212> TYPE: DNA <2113> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctattttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA</pre>	30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctattttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence Description Contemporture Description Contemporture Description Conte</pre>	30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctattttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA</pre>	30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctattttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctattttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	30
<pre><212> TYPE: DNA <2113> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11</pre>	30
<pre><212> TYPE: DNA <2113> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag</pre>	30
<pre><212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag</pre>	30
<pre><212> TYPE: DNA <2113> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag</pre>	30 30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag <210> SEQ ID NO 12 <211> LENGTH 20</pre>	30 30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <222> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag <210> SEQ ID NO 12 <211> LENGTH: 30 <212> TYPE: DNA</pre>	30 30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <222> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag <210> SEQ ID NO 12 <211> LENGTH: 30 <212> TYPE: DNA <212> ORGANISM: Artificial Sequence</pre>	30 30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag <210> SEQ ID NO 12 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: </pre>	30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag <210> SEQ ID NO 12 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <221> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA</pre>	30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgtt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag <210> SEQ ID NO 12 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <221> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	30
<pre><212> TYPE: DNA <211> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 10 taacctgttt agctatttc gcattcattc <210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 11 gtcagagggt aattgagaac accaaaatag <210> SEQ ID NO 12 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 12</pre>	30

ctccagccag ctttcccctc aggacgttgg

57

-continued

<210> SEQ ID NO 13 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 13 gtccactatt aaagaaccag ttttggttcc 30 <210> SEQ ID NO 14 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 14 taaaggtggc aacatagtag aaaataataa 30 <210> SEQ ID NO 15 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 15 30 gataagteet gaacaactgt ttaaagagaa <210> SEQ ID NO 16 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 16 ggtaatagta aaatgtaagt tttacactat 30 <210> SEQ ID NO 17 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 17 30 tcagaaccgc caccetetca gagtattage <210> SEQ ID NO 18 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 18 aagggaaccg aactgagcag acggtatcat 30

60

59

<210> SEQ ID NO 19 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 19 gtaaagattc aaaaggcctg agttgaccct 30 <210> SEQ ID NO 20 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 20 aggogttaaa taagaagaco gtgtogcaag 30 <210> SEQ ID NO 21 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 21 30 caggtcgact ctagagcaag cttcaaggcg <210> SEQ ID NO 22 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 22 cagageeace acceteteag aactegagag 30 <210> SEQ ID NO 23 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 23 30 ttcacgttga aaatcttgcg aatgggattt <210> SEQ ID NO 24 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 24 30 aagttttaac ggggtcggag tgtagaatgg

<210> SEQ ID NO 25

61

-continued

62

<211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 25 ttgcgtattg ggcgcccgcg gggtgcgctc 30 <210> SEQ ID NO 26 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 26 42 gtcaccagag ccatggtgaa ttatcaccaa tcagaaaagc ct <210> SEQ ID NO 27 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 27 ggacagagtt actttgtcga aatccgcgtg tatcaccgta cg 42 <210> SEQ ID NO 28 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 28 caacatgatt tacgagcatg gaataagtaa gacgacaata aa 42 <210> SEQ ID NO 29 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 29 42 aaccagacgc tacgttaata aaacgaacat accacattca gg <210> SEQ ID NO 30 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 30 tgacctacta gaaaaagccc caggcaaagc aatttcatct tc 42 <210> SEQ ID NO 31

<211> LENGTH: 42

63

-continued

64

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 31 tgccggaagg ggactcgtaa ccgtgcatta tattttagtt ct 42 <210> SEQ ID NO 32 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 32 agaaccccaa atcaccatct gcggaatcga ataaaaattt tt 42 <210> SEQ ID NO 33 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 33 42 gctccattgt gtaccgtaac actgagttag ttagcgtaac ct <210> SEQ ID NO 34 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEOUENCE: 34 agtaccgaat aggaacccaa acggtgtaac ctcaggaggt tt 42 <210> SEQ ID NO 35 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 35 cagtttgaat gtttagtatc atatgcgtag aatcgccata gc 42 <210> SEQ ID NO 36 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 36 42 aagattgttt tttaaccaag aaaccatcga cccaaaaaca gg <210> SEQ ID NO 37 <211> LENGTH: 42

<211> LENGTH: 42 <212> TYPE: DNA

65

-continued

66

<pre><213> ORGANISM: Artificial Sequence <200> PERTURE.</pre>	
<pre><220> FEATORE. <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	
<400> SEQUENCE: 37	
tcagagcgcc accacataat caaaatcaga acgagtagta tg	42
<210> SEQ ID NO 38 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 38	
gatggttggg aagaaaaatc caccagaaat aattgggctt ga	42
<210> SEQ ID NO 39 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 39	
ctccttaacg tagaaaccaa tcaataattc atcgagaaca ga	42
<210> SEQ ID NO 40 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 40	
agacacctta cgcagaactg gcatgatttt ctgtccagac aa	42
<210> SEQ ID NO 41 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 41	
gccagctagg cgatagetta gattaagaee tttttaaeet gt	42
<210> SEQ ID NO 42 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 42	
ccgacttatt aggaacgcca tcaaaaatga gtaacaaccc ca	42
<210> SEQ ID NO 43 <211> LENGTH: 42	

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence

6	7
~	

-continued

68

<pre><220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	
<400> SEQUENCE: 43	
gtccaatagc gagaaccaga cgacgatatt caacgcaagg ga	42
<210> SEQ ID NO 44 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 44	
ccaaaataca atatgatatt caaccgttag gctatcaggt aa	42
<210> SEQ ID NO 45 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 45	
aacagtactt gaaaacatat gagacgggtc ttttttaatg ga	42
<210> SEQ ID NO 46 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 46	
tttcaccgca ttaaagtcgg gaaacctgat ttgaattacc ca	42
<210> SEQ ID NO 47 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 47	
gagaatagag ccttaccgtc tatcaaatgg agcggaatta ga	42
<210> SEQ ID NO 48 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 48	
ataattaaat ttaaaaaact ttttcaaact tttaacaacg cc	42
<210> SEQ ID NO 49 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence	

<220> FEATURE:

70

69

-continued

<223> OTHER INFORMATION: Description of artificial sequence: origamis	DNA
<400> SEQUENCE: 49	
gcacccagcg tttttatcc ggtattctag gcgaattatt ca	42
<210> SEQ ID NO 50 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: origamis	DNA
<400> SEQUENCE: 50	
ggaagegeee acaaacagtt aatgeeeega eteeteaaga ta	42
<210> SEQ ID NO 51 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: origamis	DNA
<400> SEQUENCE: 51	
gtttgeetat teacaggeag gteagaegee aceaceae ee	42
<210> SEQ ID NO 52 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: origamis	DNA
<400> SEQUENCE: 52	
cgcgagctta gtttttccca attctgcgca agtgtaaagc ct	42
<pre><210> SEQ ID NO 53 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence:</pre>	DNA
<400> SEQUENCE: 53	
agaagcaacc aagccaaaag aatacactaa tgccaaaact cc	42
<210> SEQ ID NO 54 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: origamis	DNA
<400> SEQUENCE: 54	
attaagtata aagcggcaag gcaaagaaac taatagggta cc	42
<210> SEQ ID NO 55 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	

<223> OTHER INFORMATION: Description of artificial sequence: DNA

71

origamis	
<400> SEQUENCE: 55	
cagtgcctac atgggaattt accgttccac aagtaagcag at	42
<210> SEQ ID NO 56 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 56	
ataaggcgcc aaaagttgag atttaggata acggaccagt ca	42
<pre><210> SEQ ID NO 57 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	
<400> SEQUENCE: 57	40
<pre><210> SEQ ID NO 58 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	12
<400> SEQUENCE: 58	
cageettggt tttgtattaa gaggetgaet geetatatea ga	42
<210> SEQ ID NO 59 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 59	40
<pre>cggaataatt caacccagcg ccaaagactt attttaacgc aa <210> SEQ ID NO 60</pre>	42
<211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 60	
cgcctgaatt accctaatct tgacaagaca gaccatgaaa ga	42
<210> SEQ ID NO 61 <211> LENGTH: 42 <212> TYPE: DNA	

-continued

<400>	SEQUENCE: 61		
acgcga	aggct acaacagtac cttttacaaa tcgcgcagag aa	42	
<210> <211> <212> <213> <223>	SEQ ID NO 62 LENGTH: 42 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Description of artificial sequence: DNA origamis		
<400>	SEQUENCE: 62		
cagcga	aacat taaaagagag tacctttact gaatataatg aa	42	
<210> <211> <212> <213> <220> <223>	SEQ ID NO 63 LENGTH: 42 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Description of artificial sequence: DNA origamis		
<400>	SEQUENCE: 63		
ggacgt	ttaa tttcgacgag aaacaccacc actaatgcag at	42	
<210> <211> <212> <213> <220> <220>	SEQ ID NO 64 LENGTH: 42 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Description of artificial sequence: DNA origamis		
<400>	SEQUENCE: 64		
aaagco	gccaa agtttatctt accgaagccc aataatgagt aa	42	
<210> <211> <212> <213> <220> <220>	SEQ ID NO 65 LENGTH: 42 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Description of artificial sequence: DNA origamis		
<400>	SEQUENCE: 65		
gageto	cgttg taaacgocag ggttttocaa agcaataaag oo	42	
<210> <211> <212> <213> <220> <220> <223>	SEQ ID NO 66 LENGTH: 42 TYPE: DNA ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Description of artificial sequence: DNA origamis		
<400>	SEQUENCE: 66		
aattat	tgtt ttcatgcctt tagcgtcaga tagcacggaa ac	42	
<210> <211> <212> <213> <220>	SEQ ID NO 67 LENGTH: 42 TYPE: DNA ORGANISM: Artificial Sequence FEATURE:		

76

_

75

<400> SEQUENCE: 67	
aagtttcaga cageegggat egteaeeett etgtagetea ae	42
<210> SEQ ID NO 68 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DN origamis	IA
<400> SEQUENCE: 68	
acaaagaaat ttaggtaggg cttaattgta tacaacggaa tc	42
<210> SEQ ID NO 69 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DN origamis	A
<400> SEQUENCE: 69	
aacaaaaata actaggtctg agagactacg ctgagtttcc ct	42
<210> SEQ ID NO 70 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DN origamis <400> SEQUENCE: 70	A
cataacctaa atcaacagtt cagaaaacgt cataaggata gc	42
<pre><210> SEQ ID NO 71 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DN origamis</pre>	A
<400> SEQUENCE: 71	
cacgacgaat tcgtgtggca tcaattettt ageaaaatta eg	42
<210> SEQ ID NO 72 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DN origamis	IA
<400> SEQUENCE: 72	
cctaccaaca gtaattttat cctgaatcaa acagccatat ga	42
<210> SEQ ID NO 73 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DN origamis <400> SEQUENCE: 73	IA

7	7

<400> SEQUENCE: 79

-continued

gaturaneag aargocagt tacaaartt accaargota ga 12 *2005 SEQ ID NO 74 *2005 SEQ ID NO 74 *2005 SEQUENCE: 74 agtagatuga aaggacaa ggtagata gatugatuga tacatuga tagaartaga tagaaartagaa tagaartaga tagaa		
 club SED ID NO 71 club SED ID NO 74 club SEDURE: Artificial Sequence club SEDURE: Artificial Sequence club SEDURE: 74 club SEDURE: 75 tagatota aastattic coggotagat 1 club SEDURE: 75 tagatota aastattic coggotagat club SEDURE: 76 aasggotaa tagtatagat tagatagat tigtaga club SEDURE: 76 aasggotaa tagtatagat tigtaga citaattgat tigtototig gg club SEDURE: 76 aasggotaa tagtatagat citaattgat tigtototig gg club SEDURE: 77 caasaggata aggacaacgit tidgoga tactatatic coggotagat gg club SEDURE: 77 caasaggata aggacaacgit tidgoga tactatatic coggotagat gg club SEDURE: 77 caasaggat aggacaacgit tidgoga tactatatic coggotagat gg club SEDURE: 77 caasaggata aggacaacgit tidgoga tactatatic coggotagat gg club SEDURE: 71 gaaatogata acoggatac gatagtigt tacgotocaa cg club SEDURE: 71 gaaatogata acoggatac gatagtigt tacgotocaa cg club SEDURE: 70 gaaatogata acoggatac gatagtigt tacgotocaa cg club SEDURE: 70 gaaatogata acoggatac gatagtigt tacgotocaa cg club SEDURE: 74 club SEDURE: 74<td>gattataaag aaacgccagt tacaaaattt accaacgtca ga</td><td>42</td>	gattataaag aaacgccagt tacaaaattt accaacgtca ga	42
<pre>4400 SEQUENCE: 74 agtagattgs aaggatcat ggtcatagoc ggaagcata gt 42 4210 SEQUENCE: 75 tagatcot aaatottta acaattotot coggottagg t 42 420 SEQUENCE: 75 tagatcot aaatotts acaattotot coggottag t 42 420 SEQUENCE: 76 aaaggocaaa tagttgagg ctaattgat lgotcoatga gg 42 400 SEQUENCE: 76 aaaggocaaa tagttgagg ctaattgat lgotcoatga gg 42 400 SEQUENCE: 76 aaaggocaaa tagttgagg ctaattgat lgotcoatga gg 42 400 SEQUENCE: 77 coaaaggaa aggocaacg tttaggot gamence 400 SEQUENCE: 77 coaaaggaa aggocaacg tttaggogaa tagtattag coagga tagt gamence 400 SEQUENCE: 78 coasaggaa tagt ttaggogaa tagt tagt gamence 400 SEQUENCE: 78 coaaaggaa tagt ttaggogaa tagt tagt tagt t</pre>	<210> SEQ ID NO 74 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
agtagattga aaagaatta ggtcatagot ggaagata gt 42 2100 SEQ ID NO 75 2112 LENDTH: 42 2120 SEQUENCE: 75 2020 FEATURE: 4200 SEQUENCE: 75 2020 SEQUENCE: 75 2020 SEQUENCE: 75 2020 SEQUENCE: 76 2020 SEQUENCE: 77 2020 SEQUENCE: 78 2020 SEQU	<400> SEQUENCE: 74	
<pre>clos SRQ ID NO 75 clis IDNOT: 42 clis TROUMARTIFICIAL Sequence clis TROUME; clis TROUME; clis TROUME; clis TROUMARTIM: Description of artificial sequence: DNA crigamis close SRQ UENCE; 75 tagaatecat aaateatta acaattete coggettagg tt clis INFORMATION: Description of artificial sequence: DNA crigamis clis TROUME; clis TROUME;</pre>	agtagattga aaagaatcat ggtcatagcc ggaagcataa gt	42
<pre><400> SEQUENCE: 75 tagaatocat aaatoattta acaatttot ooggottagg tt tagaatocat aaatoattta acaatttot ooggottagg tt 210> SEQ ID N0 76 e211> LEMOTH; 12 e220> FEATURE: e220> OTHER INFORMATION: Description of artificial sequence: DNA crigamis e400> SEQUENCE: 76 aaaggocaaa tatgttagag ottaattgat tgotocatga gg e210> SEQ ID N0 77 e211> LEMOTH; 42 e212> TYPE: DNA e211> LEMOTH; 42 e212> TYPE: DNA e212> Content INFORMATION: Description of artificial sequence: DNA crigamis e400> SEQUENCE: 77 ccaaaaggaa aggacacag tttcagoga tcatcatatt cc e210> SEQ ID N0 78 e211> LEMOTH; 42 e212> TYPE: DNA e111> LEMOTH; 42 e12> T</pre>	<210> SEQ ID NO 75 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
tagaatcat aatoatta acaattat coggatag ti 42 2210- SEQ ID N0 76 2211- LENGURIS 42 2225- OTHER INFORMATION: Description of artificial sequence: DNA origamis 2400- SEQUENCE: 76 aaaggacaaa tatgttagag cttaattgat tgctcaatga gg 42 2210- SEQ ID N0 77 2211- LENGURI 42 2210- SEQUENCE: 77 ccaaaaggaa aggacaacg tttcagcgaa tcatcatat cc 42 210- SEQ ID N0 78 2213- OTHER INFORMATION: Description of artificial sequence: DNA origamis 2400- SEQUENCE: 77 ccaaaaggaa aggacaacg tttcagcgaa tcatcatatt cc 42 2110- SEQ ID N0 78 2213- OTHER INFORMATION: Description of artificial sequence: DNA origamis 2400- SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctcaa cg 42 2210- SEQ ID N0 78 2210- SEQ ID N0 79 2110- LENGURI 42 2110- LENGURI 42 2110- SEQ ID N0 79 2110- SE	<400> SEQUENCE: 75	
<pre><210 SEQ ID NO 76 <211 LENOTH: 42 <212 TYPE: DNA <213 ORGANISM: Artificial Sequence <220 FEATURE: <223 OTHER INFORMATION: Description of artificial sequence: DNA origamis <400 SEQUENCE: 76 aaaggccaaa tatgttagag cttaattgat tgctccatga gg 42 <210 SEQ ID NO 77 <211 LENOTH: 42 <212 TYPE: DNA <213 ORGANISM: Artificial Sequence <220 FEATURE: <223 OTHER INFORMATION: Description of artificial sequence: DNA origamis <400 SEQUENCE: 77 ccaaaaggaa aggacaacag tttcagcgaa tcatcatatt cc 42 <210 SEQ ID NO 78 <211 LENOTH: 42 <212 TYPE: DNA <213 ORGANISM: Artificial Sequence <220 FEATURE: <223 OTHER INFORMATION: Description of artificial sequence: DNA origamis <400 SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctccaa cg 42 </pre>	tagaatccat aaatcattta acaatttctc ccggcttagg tt	42
<pre>4400 S SEQUENCE: 78 aaaggccaaa tatgttagag cttaattgat tgctccatga gg 42 cllo SEQ ID NO 77 cll1 LENGTH: 42 cll2 TYPE: DNA cll3 CRCANISM: Artificial Sequence cl20 FEATURE: cl20 SEQUENCE: 77 ccaaaaggaa aggacaacag tttcagcgaa tcatcatatt cc 42 cllo SEQ ID NO 78 cll1 LENGTH: 42 cll2 TYPE: DNA cll3 CRCANISM: Artificial Sequence cl20 FEATURE: cll2 TYPE: DNA cll3 CRCANISM: Artificial Sequence cl10 SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctccaa cg cll0 SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctccaa cg cll0 SEQ ID NO 79 cll1 LENGTH: 42 cll2 SEQ ID NO 79 cll1 LENGTH: 42 cll3 SEQ ID NO 79 cll</pre>	<210> SEQ ID NO 76 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
aaaggccaa tatgttagag cttaattgat tgctccatga gg 42 	<400> SEQUENCE: /6	
<pre><210> SEQ ID NO 77 <211> LENGTH: 42 <212> TYPE: DNA <213> CRCANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 77 ccaaaaggaa aggacaacag tttcagcgaa tcatcatatt cc 42 </pre>	aaaggccaaa tatgttagag cttaattgat tgctccatga gg	42
<pre><400> SEQUENCE: 77 ccaaaaggaa aggacaacag tttcagcgaa tcatcatatt cc 210 SEQ ID NO 78 <211 LENGTH: 42 212 TYPE: DNA 213 ORGANISM: Artificial Sequence 220 FEATURE: <220 VIENT INFORMATION: Description of artificial sequence: DNA origamis <400 > SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctccaa cg 210 > SEQ ID NO 79 <211 > LENGTH: 42 <212 > TYPE: DNA <213 > ORGANISM: Artificial Sequence <220 > FEATURE: <223 > OTHER INFORMATION: Description of artificial sequence: DNA origamis </pre>	<210> SEQ ID NO 77 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<pre>ccaaaggaa aggacaacag tttcagcgaa tcatcatatt cc 42 cllo> SEQ ID NO 78 cllo SEQ ID NO 78 cllo SEQUENCE: TVFE: DNA cllo SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctccaa cg cllo> SEQ ID NO 79 cllo SEQ I</pre>	<400> SEQUENCE: 77	
<pre><210> SEQ ID NO 78 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctccaa cg <210> SEQ ID NO 79 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> FEATURE: <220> FEATURE: <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	ccaaaaggaa aggacaacag tttcagcgaa tcatcatatt cc	42
<400> SEQUENCE: 78 gaaatcgata accggatacc gatagttgta tcagctccaa cg 42 <210> SEQ ID NO 79 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	<210> SEQ ID NO 78 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<pre>gaaatcgata accggatacc gatagttgta tcagctccaa cg 42 <210> SEQ ID NO 79 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	<400> SEQUENCE: 78	
<210> SEQ ID NO 79 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	gaaatcgata accggatacc gatagttgta tcagctccaa cg	42
	<210> SEQ ID NO 79 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	

80

79

tgaatattat caaaataatg gaagggttaa tatttatccc aa	42
<210> SEQ ID NO 80	
<211> LENGTH: 42	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of artificial sequence: DNA	
origamis	
<400> SEQUENCE: 80	
	40
gaggaagcag gattcgggta aaatacgtaa aacacccccc ag	42
<210> SEO TD NO 81	
<211> LENGTH: 42	
<212> TYPE: DNA	
<213> ORGANISM· Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of artificial sequence: DNA	
origamis	
5	
<400> SEQUENCE: 81	
ggttgatttt ccagcagaca gccctcattc gtcacgggat ag	42
<210> SEQ ID NO 82	
<211> LENGTH: 42	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of artificial sequence: DNA	
origamis	
<400> SEQUENCE: 82	
	40
caagccccca cccttagccc ggaataggac gatctaaagt tt	42
<210 SEC ID NO 83	
<210> SEQ ID NO 03	
<213> ORGANISM: Artificial Sequence	
<220> FRATURE:	
<223> OTHER INFORMATION: Description of artificial sequence: DNA	
origamis	
01194m10	
<400> SEQUENCE: 83	
tgtagatatt acgcggcgat cggtgcgggc gccatcttct gg	42
<210> SEQ ID NO 84	
<211> LENGTH: 42	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of artificial sequence: DNA	
origamis	
<400> SEQUENCE: 84	
catcctattc agctaaaagg taaagtaaaa agcaagccgt tt	42
<210> SEQ ID NO 85	
<211> LENGTH: 42	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Description of artificial sequence. DNA	
origamis	
01190m10	
<400 SECHENCE, 25	
<400> SEQUENCE: 85	

81

-continued

<210> SEQ ID NO 86 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 86	
catgtcacaa acggcattaa atgtgagcaa ttcgcgttaa at	42
<210> SEQ ID NO 87 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 87	
agcgtcacgt ataagaattg agttaagccc tttttaagaa ag	42
<pre><210> SEQ ID NO 88 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>	
<400> SEQUENCE: 88	
tataaagcat cgtaaccaag taccgcaccg gctgtaatat cc	42
<210> SEQ ID NO 89 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 89	
atagecegeg aaaataattg tateggtteg eegacaatga gt	42
<210> SEQ ID NO 90 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 90	
agacagttca tataggagaa gcctttataa cattgcctga ga	42
<210> SEQ ID NO 91 <211> LENGTH: 42 <212> TYPE: DNA <2113> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 91	
aacaggtccc gaaattgcat caaaaagatc tttgatcatc ag	42

83

-continued

<210> SEQ ID NO 92 <211> LENGTH: 42		
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence		
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis</pre>		
<400> SEQUENCE: 92		
actgcccttg ccccgttgca gcaagcggca acagcttttt ct	42	
<210> SEQ ID NO 93 <211> LENGTH: 42		
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence		
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA</pre>		
origamis		
<400> SEQUENCE: 93		
tcaaagggag atagccctta taaatcaaga caacaaccat cg	42	
<210> SEQ ID NO 94 <211> LENGTH: 42		
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence		
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA </pre>		
origamis		
<400> SEQUENCE: 94		
gtaatacgca aacatgagag atctacaact agctgaggcc gg	42	
<210> SEQ ID NO 95		
<211> LENGIH: 42 <212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence <220> FEATURE:		
<223> OTHER INFORMATION: Description of artificial sequence: DNA origamis		
<400> SEQUENCE: 95		
gagataacat tagaagaata acataaaaag gaaggattag ga	42	
<210> SEQ ID NO 96		
<pre><212> TYPE: DNA </pre>		
<2213> ORGANISM: ATTITICIAI Sequence <220> FEATURE:		
<223> OTHER INFORMATION: Description of artificial sequence: DNA origamis		
<400> SEQUENCE: 96		
cagatattac ctgaatacca agttacaatc gggagctatt tt	42	
<210> SEQ ID NO 97		
<211> LENGTH: 42 <212> TYPE: DNA		
<213> ORGANISM: Artificial Sequence		
<pre><223> OTHER INFORMATION: Description of artificial sequence: DNA</pre>		
CIIGANIE		
catataacta atgaacacaa catacqaqct qtttctttqq qq	42	

85

-continued

<210> SEQ ID NO 98 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 98 atgttttgct tttgatcgga acgagggtac tttttctttt gataagaggt catt 54 <210> SEQ ID NO 99 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 99 ggggtgccag ttgagaccat tagatacaat tttcactgtg tgaaattgtt atcc 54 <210> SEQ ID NO 100 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 100 54 cttcgctggg cgcagacgac agtatcgggg caccgtcgcc attcaggctg cgca <210> SEQ ID NO 101 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEOUENCE: 101 tcagagetgg gtaaacgacg gccagtgega teeecgtagt ageattaaca teea 54 <210> SEQ ID NO 102 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 102 ttagcggtac agagcggggag aattaactgc gctaatttcg gaacctatta ttct 54 <210> SEQ ID NO 103 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 103 gatattctaa attgagccgg aacgaggccc aacttggcgc ataggctggc tgac 54

88

87

<211> LENGTH: 54 <212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 104 tgtcgtcata agtacagaac cgccacccat tttcacagta caaactacaa cgcc 54 <210> SEQ ID NO 105 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 105 cgattataag cggagacttc aaatatcgcg gaagcctacg aaggcaccaa ccta 54 <210> SEQ ID NO 106 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 106 aacatgtacg cgagtggttt gaaataccta aacacattct taccagtata aagc 54 <210> SEQ ID NO 107 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 107 gtctggattt tgcgttttaa atgcaatggt gagaaataaa ttaatgccgg agag 54 <210> SEQ ID NO 108 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 108 gcettgaate tttteeggaa eegeeteeea gageeeagag eegeegeeag eatt 54 <210> SEQ ID NO 109 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 109 54 cgctggtgct ttcctgaatc ggccaacgag ggtggtgatt gcccttcacc gcct <210> SEQ ID NO 110 <211> LENGTH: 54

89

-continued

90

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 110 tgattatcaa ctttacaact aaaggaatcc aaaaagtttg agtaacatta tcat 54 <210> SEQ ID NO 111 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 111 acataacttg ccctaacttt aatcattgca ttataacaac attattacag gtag 54 <210> SEQ ID NO 112 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 112 gtagcgccat taaattggga attagagcgc aaggcgcacc gtaatcagta gcga 54 <210> SEQ ID NO 113 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEOUENCE: 113 ttatttttac cgacaatgca gaacgcgcga aaaatctttc cttatcattc caag 54 <210> SEQ ID NO 114 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 114 tttcaataga aggcagcgaa cctcccgatt agttgaaaca ataacggatt cgcc 54 <210> SEQ ID NO 115 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis <400> SEQUENCE: 115 gggcgacccc aaaagtatgt tagcaaacta aaagagtcac aatcaataga aaat 54 <210> SEQ ID NO 116 <211> LENGTH: 54 <212> TYPE: DNA

92

<pre><213> ORGANISM: Artificial Sequence</pre>	
<220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 116	
agccgaaagt ctctcttttg atgatacaag tgccttaaga gcaagaaaca atga	54
<210> SEQ ID NO 117 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 117	
gtgggaaatc atataaatat ttaaattgaa tttttgtctg gccttcctgt agcc	54
<210> SEQ ID NO 118 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 118	
cccacgcgca aaatggttga gtgttgttcg tggacttgct ttcgaggtga attt	54
<210> SEQ ID NO 119 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 119	
atgaccactc gtttggcttt tgcaaaagtt agactatatt cattgaatcc ccct	54
<210> SEQ ID NO 120 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 120	
tccaaatctt ctgaattatt tgcacgtagg tttaacgcta acgagcgtct ttcc	54
<210> SEQ ID NO 121 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: DNA origamis	
<400> SEQUENCE: 121	
gggttattta attacaatat atgtgagtaa ttaataagag tcaatagtga attt	54
<210> SEQ ID NO 122 <211> LENGTH: 30	

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence

 ADDD FAUTURE AND AND AND AND AND AND AND AND AND AND		
A 40. SEQUENCE: 122 at cartact tratacts agtiggted 210. SEQUENCE: 123 210. SEQUENCE: 203 210. SEQUENCE:	 <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: encapsulating sequence 	
tecenterie testerie setterie granden i setterie	<400> SEQUENCE: 122	
All. END IN 123 Hill ENDTIN 724 Hill ENDIT Hill ENDIT Hil	atccatcact tcatactcta cgttgttgtt	30
4400> SEQUENCE: 113 tradapaogi tittitogooo titgaogitg gagtooacgi totttaadi tggaotottig 60 tittooaccig gaaccacci caaccaga attitugoot gotggaggaa accagotgig 120 accagotigoi goaactatti caaggocaagi oggigaaggi caatcagoti titgoorgici 240 accagotigai aagaaaacci accotgoogi cocaatcagoi accagotgi titgoorgicii 240 cactagotigai aagaaaacci accotgoogi cocaatcagoi accogotti cocogoogi 300 titgooratti attatigoig titgoorgica aggittoorg actiggaagi gggoggitagi 240 cactagotigai atgacagati accorgoogi cocaatcagoi ggooggitagi 240 cactagotigai taatgoogi titgoorgica aggittoorg actiggagai gggoggitagi 240 cactagotagi taatgoogi tagotogi accorgoggita accorgoogit 240 cactagotagi attacgoati gogoogataa aggittoorg actiggagat goactago 340 cattagoooti gattogittig tiggaattogi googgitaa accorgoogit gatogogita agoogata 260 gagcogatot ditocotti googacaci cocttogic agooggata googogita agoogata 260 cacacegaagi oggitococi caaacagi googogita agoogagaa tococogoogit 700 cacacegaagi titgoococi caaacagi gagoogita agoogogita accacego gagoogogita 960 cacacegaagi cogitococi caaacagi gagoogita accacegaagi agoogogita 960 cacacettagi digootoci caaacagi accacego gagoogo agoogogita 960 cacacettagi accocega cocacegaa cococogogita accoc	<210> SEQ ID NO 123 <211> LENGTH: 7249 <212> TYPE: DNA <213> ORGANISM: bacteriophage M13	
tgatagaegg titttegee titgaegtig gagtecaegt tetttaatag tggaetetig tteeaaaetg gaacaaet caaceetate tegggetat etttigatt ataagggat 120 tteeggettt eggaacaee ateaaeaegg atttegeet getgggeaa aceageetg 180 acegetiget geaaeteet eagggeeag eggtgaagg caateagetg tigeeegtet 240 caeteggigaa aagaaaaee aceetgege ceaataegea acegeete eeegeegt 300 tggeegate attaatgeg etggeeage aggtteeeg ateggaaage gggeagtgag 360 eggaacageaa ttaatgegg tiggeeagea aggtteeeg aceagagett aceetgegg 540 eggeaaegeaa ttaatgegg etggeeagea geggeaae aceegeett aceetgegg 540 eggeaaegeag tiggeeage eggegete acaegeeg eeetagggaa aceetgege 600 taeeegae tiggeeage eggegeete acaegeeg gaetgega ateggagaa aceetgege 700 eggeaegeae tiggeeage eggegeetg aatggegaa aceetgege 700 eggeaegeae tiggeeage eggegeetg aatggegaa deegggga 270 etggeegee gaeegeet eccaacagt gegeageet acaggega eggeettige 720 etggeegee gaeegeet eccaacagt gegeageet acgatgege caetaeae 840 eaaetgage titgeeteet eccaacage agetgeet teegaegge easterge 900 etgeteete geeteeet eccaacagt geetgeget taegatgege easteraee 840 eaaetgaee tateceatta eggteaga agetgetg eaggegaa ateceagag ateceagegg 900 etgetaetge teeeteet aggteage geetgetge taegatgege easterge 900 etgetaetge teeeteet aggteage geetgeetg taegatgege easterge 900 etgetaetge teeeteet aggteage deeggega atgeegga ateceagegg 900 etgetaetge teeeteet aggteage deeggeage atgeegge ageeggaat 960 taetttaeg agesteet tegataet taaatteg ettaacaat etteetetge 1200 gaettattee aaattaae getteacat taaatteg ettaacaat etteetetge 1200 gaettattee aaattaae getteetee ettaaatteg ettaacaa etgetgea eggtegata 1260 eatattaeg agetteet tegategee etteagea agegtea atgeetgat 1300 eatattaea aaattaege teeteegg etteetee etteagea getgeet 1200 gaattateg getteete taaatteet eatagetge etteage 140 eatattaea aaattaege taecegge ettee ettaegae gegteada 140 eatattaeg getgeetet taaatteet gaeggetet aaatttta teetgeega 140 eatattaeg getteetee aaaggetge attegeet teegaatge 140 eatattaeg atgetae taataat gaegaatge gaegeett teegaatge 140 eatattaeg ettaeget teagaatge gaegaeet teegaatge 140 eatataeg	<400> SEQUENCE: 123	
ttocaaactg gaacaact caacctat togggetat etttigatt ataagggat 120 ttgeegatt eggaacaac ateaacag atttoegee geggggaagg eateageg tgeegggg 180 acegettget geacteet eagggeege eggtgaaggg eateaget togeegget 240 caetggigaa aagaaaace aceetggege ceataegee aacegeete eeggggg 360 eggeaageaa ttaatgeag etggeaegg aggtteegg ateggaaage ggeagtgag 360 eggeaageaa ttaatgeag teggeeteg aggtteegg eegaage eggaaage ggeagtgag 360 eggeaageaa ttaatgeag teggeeteg aggtteegg aceetgaage eggaaage 480 tteggeett gatagtag teggeeteg aceegggga eetgaage eggaaage 480 tatgaeeatg attaegaat eggeetegg aceegggga eetegaage eggaaacage 480 tatgaeeatg attaegaat eggeetegg aceegggaa eeteggaa aceeggegg 560 geeatgeaage teggeeteg eegtegtt aceegggga eetegaag eggeegtgg 560 geeetgeaage teggeeteg eegtegtt aceeggegg egeteggaa aceetggegg 560 geeetgeaage teggeeteg eegtegtt aeaegeeg agetgegaa geegeette 720 eegtetege eegeeteg eegtegte eegeeteg ee	tgatagacgg tttttcgccc tttgacgttg gagtccacgt tctttaatag tggactcttg	60
<pre>ttgccgatt cggaacace atcaacagg attttcgct gctggggaa accagetgg 180 accgcttgt gcactct cggggccagg cggtgaaggg catcagetg ttgcccgtt 240 cattggtgaa aagaaaace accetgggg cgataggg catcagetg ttgcccgtt 240 cattggtgaa aagaaaace accetgggg cgataggg catgaaage gggcgtgag 360 cgcaacgaa ttaatgtag ttagetact cattaggca cccagggtt accetgaaage gggcagtgag 360 cgcaacgaa ttaatgtag ttagetact cattagge cgcaggtt accetgagaa eccggggt 480 cttgcgcgtt gatgttgt tggaattg ageggataa aatttaace aggaaacage 480 cttgcgcgat taacgaat cgagetegg acceggggat cectagag cgaceggaa eccggggt 660 ggcccgaace gategeett cccaacgt gecageteg aatggegat agegggaa accetggeg 720 ctggttceg gccgcga cggteggt geggeggt agegggaa agegggaa g660 ggcccgaace gategeett cccaacgg agtggegg gategegat tacegategg 720 ctggttceg gcccgaa cggtegga gategeggt agegggaa accegggg 900 ctggttceg gcccgaa geggeegga agetggegt gccgagege ageggegat 960 ctggttceg gcccaactg cggtagae gategeggt accaggag atcegaeggg 900 ctgttateg ttaccaatt agtggaa agetgget tcaagaage ageoggaa 960 ctattttag ggegteta tagetgaa agegggaa agetggat ttaacaaa atttaatge 1020 aattttaac aaatatae gtttacaat taatgttg cccaeggaa atceagegg 900 ctggtactg teccaatta agtggaa agetgget ctaacgaa acceggega 1020 aattttaac aaatatae gtttacaat taatgttg ccaacggaa agectggat 1200 aattttaac aaatatae gtttacaat taatgttg ccategga agecttgat 1200 ccatacag gcattgeat taaatata gaggetet aaatttat caegtagaa ggttgaatt 1260 ccatacag gcattgeat taaatata gaggetet aaatttta tectteget 1380 ggaataagg cttccceg aaaatgaa cittegeat agectagt atcaacegat 1440 ctagctta gcctggg catactat agtagaatt agecaatt tacaact 1320 catacaag gattgaat taagaatg agecaatt tuagaatg atcaacegat 1460 ccatacag gcattgeat taaattt ggagateg atcaact ttacgct 1500 ggaataagg cttccceg aaaatgac tattgeat agedaatg atcaacegat 1440 ctagctta gccatgge ataacgat aggecat tacgaatg atcaacegat 1660 agaacacga cttacget agetagat aggecat tacgaatg atcaacegat 1620 ccaactaat ctactgg caacacgg attgeact ttacaat tagggaatg atcaacegat 1620 ccaactaa ctactgg gaatagga cttacaac gtttagaa taggaaatg atcaacega 1620 ccaactaa ctactggt gaattag accectgt tgegaatg atca</pre>	ttccaaactg gaacaacact caaccctatc tcgggctatt cttttgattt ataagggatt	120
accgottgot goaactot cagggocagg oggtgaagg caatcagot ttgocogtot 240 cactggtga aagaaaac acctggog ccaatacga aaccgott tcocogogogt 300 tggocgatt attaatgtag ttggtcad cggogaa aggttcocg actggaaac gggcagtgag 360 cgcaacgcaa ttaatgtag ttagttoat cattaggaa cocaggott acactttat 420 cttocggot gtatgttgt ggaattgg agoggatac aattcoaca aggaaacagc 480 tatgaccatg attacgaat cgagcogg coctegtt acacggg accggggat catcatggg cgactgag 540 goatgoage ttggcatg cogtegtt acacggg accggggat cottagg cgactggg 540 goatgoage ttggcatg cogtegtt acacggg accggggat accggggaa accggggg 660 tacccaact aategoctg cagacace cocttege agotgggat agoggatag 360 ctggategag gatgoagg oggtgegg accggggg agggggat gggggat gggggat gggggt 720 ctggttcog gcaccagaa ggggcoga agotgggt gatgoaggt agoggat gggg 700 ctggttcog gcaccagaa gggtgoagg agggggg aategagg tacgagge cattaca fatego ttggtocet caaactgga gatgoagg tacgagge cattaca fatego ttggtocet tagttag aggtgoagg tacgagge agoggga 300 ctgttactg ctcacatta aggtgaate gocgttgt cocaggaga accggggg 900 ttgttactg ctcacatta aggtgaate gocgttgt cocaggaga atcggagg 900 ttgttactg gegtecet tuggtaaa aatggega atggacgg tagaagge 300 ttgttactg gegtecet tuggtaaa atggega atggacgga aggeggaa 300 ttggtgggtt totgattag aggtgocga atgacega aggeggaa 300 ttgttactg gegtecet tuggtaaa atggacga tuggaagge aggeggaa 300 ttggtgggtt tedgatag gggtecega atgacega aggetgaa 300 ttgggggtt tedgatag aggtgecega atgacega aggetgaa 300 ttgggggtt tedgatag ggttecea taggta atagga aggetga 300 ttgggggtt tedgatag aggetged atagga aggetga 300 ttgggggtt tedgatag tgttcocag attagt acatgga aggetga 300 ttgggggtt tedgatag tgttcocag attagt acatgga aggetga 300 ttgggggtt tedgatag tgttcocag attagt 400 gatetter aatagget gettece aaagget atagga aggetga 300 gatetter aatagget taaatat gagggtat atggtaga tgtttgg tagacacga 140 ttaggttag gettage tatatat aggagatg 400 caaatagg tettoceg aaagatat aggggta attagga tgacact 1100 gatettag tgttage tatatat agtaggat tgtgacat tgcgaatgg 400 sagacacga tettagge tatatata aggaggat tacagatt tacaggat 1500 gatettag agattag tatatag tataagg 400 caaatagga t	ttgoogattt oggaaccaco atcaaacagg attttogoot gotggggoaa accagogtgg	180
<pre>sactgytgya agaaaac acctgycg ccatacyca accycgocgt 300 tggcogatt attaatgya tggcacya agyttccy actgyaag ggycagtgag 360 cgcaacgca ttaatgya tggcacya catagyaa ccccagytt acactttat 420 cttccgyct gtatgttg tggaattgg agcggatac attccac aggaaacac 480 tatgaccatg attacgaat cgagctgg acccggggat cctctagag cgaccyag 540 gocdgcaeg ttggcactg cogtcgttt acacgtg gactgggat acctgggg agcggaa acccggggt 600 tacccaact attegetg cagcacate cccttage agcgggat acgggaaa acccggggt 600 tacccaact attegetg cagcacate cccttage agcgggat gggggaa acctggegt 720 ctggttccg gcaccagaa ggggcoga agcggcg gatggcgg atgggaa acctgggg 780 cggatactge gtggceet cccaacagge gatggcag gatgacggt tacgatggg ccattacc 840 caacgtgae tateotat oggeaace gocgttgt cccaacagg gatgacgg tacgaagg 390 ctgttactg ccaccata oggeaace gocgttgt cccacagag agtgggag atcogggg 390 ttgttactg ctaccatt atggtga aggtgga agcgggt atggaagg agacggaa 396 ttgttactg ctaccatt atggtga aggtgga aggtggg aatcogg agaaggg 390 ttgttactg ttgeteet taggtaa aggtgga aggtgga aggtggg agacgga 396 ttgttactg ttgeteet taggtaa aggtgga aggtggg agaa accggag 390 ttgttactg ttgeteet taggtaa aggtgga aggtgga aggtgga aggtgga 390 ttgttactg ttgeteet taggtaa aggtgga aggtgga agacgga 390 ttgttactg ttgeteet taggtaa aggtgga aggtgga agacgga 390 ttgttactg ttgeteet taggtaa aggtgga aggtgga agaegga 390 ttgttactg ttgeteet taggtaa aggtgga aggtgga aggtgga 300 ttgttactg ttgeteet taggtaa aggtgga aggtgga aggtgga 300 ttgttactg ttgeteet taggtaa aggtgga aggtgga aggagga 300 ttgttactg ttgeteet taggtaa aggtgga aggtgga aggagga 300 ttgttactg ttggta gggteegg atggagge 300 ttgttactg ttgeteet taggta aggtgga aggtgga aggagga 300 ttgttactg ttgeteet taggta aggtgga aggtgga aggtgga 300 ttgttactg ttggta gggteegg aggtgga aggtgga aggtgga aggtgga 300 ttgttactg ttggta gggteegg aggtgga aggtgga 300 ttgttact ttggtga aggtgga aggtgga aggtgga 300 ttgttact ttggta aggtgegg aggt</pre>	accgettget geaactetet cagggeeagg eggtgaaggg eaateagetg ttgeeegtet	240
tggccgatt attaatgcag etggcacgae aggttteeeg actggaaage gggeagtgag 360 cgcaacgeaa ttaatgtgag ttageteaet ettaggeae eccaggettt acaetttatg 420 ctteeggete gtatgttgt gggaattgg ageggaaaa atteeaee aggaaaeage 480 catagaeeag attaegaatt eggeeegg aceggggaa eeteggagaa aceetggeg 540 geatgeaage tiggeaetgg eegtegttt aceaeggeg geegggaa aceetggeg 600 taeeeaae atteegeett eegeeegg aeeggeegg aatggeggaa aceetggeg 720 ctggtteeg geaeeaga egggeegga aagetgget gagtgegaa ateggegaag 660 gegeeegeee geeeeee eegeegg aagetgeeg aatggegaa ateggegee 720 ctggtteeg geaeeaga egggeegga aagetgget gagtgegat etteetgagg 780 eegataetgt gtegteeet eeaaetggee gagtegegg aagetggeg eeatgagag 460 caaegtgaee taeeeatta eggteaate geegttigt eeeaggag ateegaegg 900 ttgttaeteg eteeeatt eggteaate geegttigt eeeaggag ateegaegg 900 ttgttaeteg eteeeatt eggteaate geegttigt eeeaggag ateegaegg 900 ttgttaeteg eteeeatt aggteaaa aatggetga ttagaagee agaegegaa 960 tattttaa aaatattaa gtttaeaat taaattig ettaeeaat etteetggt 1020 aaatttaae aaatattae gtteaeatt taaatattig ettaeeaat etteetgtt 1080 ttggggettt tetgattat aagetgga cetteagga atgeetga tgeetgat 1140 cegteaeg ateetetg tigeteeeg etteetee etteetgag aggetgaat 1260 caatatgatg gegtteet tigeteegg etteetee ettegge ataattta teetgegat 1220 gaatetee geatgeet taaaatata gagggete aaagetgat eagetaga ggetgaata 1260 caatatgatg geattgeat taaaatata gagggete aaagtgate ateettig taeaeegg 1140 ttagettea geetgage ttaatget aaggaget a atteettig taeaeegg 1560 gaataaag etteeege aaaagtata eggggetea attettig tegeaaeeg 1560 gaataaag etteeege aaaagtat eagagatt atgeeegt teegeatta 1500 gaattaatg aaaataage taaeeaggt attageeat teegeaatg ateeaaegt 1620 caaactaaa etaeegte gaaatagg gaateaeeg taaegeagt taetgaatge tgaaattee 1680 aggeeeega ettagetge aaaataage taaeeaggt attageeat gegaeatge ateaagtaet 1620 caaactaaa etaeetge gaaatage taettaeaa eaggageat aaggeaat aaaggtaet 1620 caaactaaa etaeetge gaaatage teetaeeaa gagaeata gagaeatee 1680 aggeeeega ettegee gaaatage teetaeeaa gagaeaata aaggeaat aaaggaeat 1880 cesaateeg aeetgeeg aaaatagee teetaee	cactggtgaa aagaaaaacc accctggcgc ccaatacgca aaccgcctct ccccgcgcgt	300
egoaacgcaa ttaatgtgag ttagctcac cattaggca cecaggctt acacttatag 420 ctteeggete gtatgttgt tggaattgt ageeggataa atteeace aggaaacage 480 catagaceag attaegaatt egagetegg accegggga ecteagge gaeegges 540 geatgeaage tiggeaetgg eegtegttt acaacgteg gaetgggaa accetggegt 600 taeceaacatt aategeettg eageeace ecetteege ageiggega atagegaaga 660 gegeeegeae gaeegeett eceaacagt gegeegga aagetggetg gagtgegate teeegagga eggeeegeae gaeegeett eceaacagt gegeegga aagetggetg gagtgegate teeegagga eggeteetg gegeeege eggeegga aagetggetg gagtgegate teeegaga 780 eegataetge gegeeeett eceaacagte gegetgett eceaggag ateegaegge 900 ttgetaeteg gegeeeett aggeeage gegeggaa aagetggetg eegagage ageeggaa 780 eegataetge gegeeeett aeggeeage gegeggeag aagetggetg eegagage ageeggaa 780 eegataetge etaeceatta eggteaatee geegttigt eceaeggaa ateegaeggg 900 ttgetaeteg etaeceatta eggteaatee geegttigt eceaeggaa ateegaeggg 900 ttgetaeteg etaeceatta eggteaate geegttigt eceaeggaa ateegaeggg 1020 aattttaae aaatattae gtttaeaat taaatattig ettaacaat etteetgitt 1080 ttegggeettt tetgattat aagetgga ecteaggea atgeetga titaeeaat attaatgeg 1020 aattttaee aaatattae gtttaeeatt taaatattig ettaacaat etteetgitt 1080 ttegggeettt tetgattat aacegggga ecteedgea atgeetga titaeeaat 1140 cegtteat gigegtteet tigeteegg etteeteege etteeteete 1320 cattaeteag geattgeat tideeetee atteeteete 1320 cattaeteag geattgeat teaaatata gagggette aaatttite teetgeetg 1380 gaaataaagg etteeteega aaatgata eagggetea atgettig ateettige tigeetgata 140 ttagetta geetgage titatget aattteet atgetgaattge tigeetgeete 1560 geeecaaatg aaatatage taaeagtt atgeeagt taatgeag ateeatget ateetage 1620 caaattaat etaetegte geagaatgg gaateacet titategaa tigaaattee 1680 aggeeeega ettagetge gaaatgge teaeagatt aaggagaat aaggataet ateatgetg 1620 caaactaaa etaetege aaaatgae tettaeeaa aggageaatt ataaggatet 1620 caaactaaa etaetege aaaatgae tettaeeaa aggageaatt ataaggataet 1620 caaactaaa etaetege gaaatgge gaateaeet taaeeaat taaeggaat 1620 caaactaaa etaetege gaaatgge gaateaeet tetaeeaa aggageaatt aaaggtaet 162	tggccgattc attaatgcag ctggcacgac aggtttcccg actggaaagc gggcagtgag	360
<pre>cttccggtc gtatgttgtg tggattgtg agcggtaac aatttcacac aggaaacag 480 tatgaccatg attacgaatt cgagctcgg acccggggt acccggggt octtcagagt cgaccggag 540 gcatgcaag ttggcactg cgtcgttt acaacgtcg gatggggaa acccggcggt 600 tacccaact aatcgcctg cagcactc cccttccge agtggggta atagcaggg 660 cggcccgcac gatcgcctt cccaacagt gcgcagctg atggcgga tggcggta tggcgggg 720 ctggttccg gcaccagaa cggtgccgga aagtggcg gatggggt tccgaggg 780 cgatactag ctcccatta agtgggat aggcgggt tacgagge caccagag 900 ttgttaccg ctcacttt agtgtgag aactggcg gatggggd tacgaggg aggcgggg 900 ttgttaccg ctcactta agtgggat aggcgggt aggcggga accgaggg 900 ttgttact ggggtcct ttggttaa aggtgggat aggcggga aggcggga 900 ttgttact ggggttct tggttaaa agggggat aggaggg aggcgga 900 ttgttact gggggtt taggtggg aaggcggg tacgaggg aggcggga 900 ttgttact gggggtt taggtggg aggtggg tacgaggg aggcgga 900 ttgttact gggggtt taggtggg aaggcggg tacgaggg aggcgga 900 ttgttact gggggtt taggtggg acataggg tacgaggg aggcggga 900 ttgttact gggggtt taggtggg acatagg ggt ggg tagg aggcg aggcggaat 960 tactttgg gggttct ttggttaaa aggagtgg ttaacaaa atttaatgg 1020 aaatttaac gtttacaat taatgggg tacatgg aggcgga gggtggg tacggg aggcgga 1020 aaatttaac aaatatac gtttacaat taaatatt gcgtagaa aggctgga gggtgga 1200 gaatttag ggggtttg tgtcccg actcccgg attagatg aggctgga aggctgga 1200 gaattagg ggtgtgg ttgtccg tgtccgg attaggg aggggga gggtgga 1200 gaattagg ggattgg tgttcgg tgtccgg attaggg aggggga 1200 caaattagg ggtgtgg ttga tggcggg attgggg agggggg ggtggg 120 catactcag gcatgga tgtccgg attaggg aggggga 120 caaattag gggggtgg ttag tgggggg attgggg aggggggg 120 caaattag ggggggggggggggggggggggggggggggg</pre>	cgcaacgcaa ttaatgtgag ttagctcact cattaggcac cccaggcttt acactttatg	420
tatgaccatg attacgaatt cgageteggt acceggggat octotagagt ogacetgoag 540 goatgoaag ttggcaetgg oegtegttt acaacggeg gatgggaaa accetggegt 600 tacceaacatt actgocetg cagcacate ocottegge agtggggaa accetggggt 720 cetggtteeg gaccagaag oggegegga ageeggett geggggett toegagge 720 cetggtteeg goaccagaag oggegegga ageegget gatggggat teeteetgagge 780 cegatactge gegeceet caaaceggea gatgeaeggt taegagege catetacae 840 ceaaegggae taeceaatt oegeeaatee geegttegt oecaeeggaga atceagegg 900 tegtacetg oecaecaata atgetgaga ageeggeta caagaaggee agaegegaat 960 tettgttace geegteeta teggtaaaa aatgeggeta taagaagee agaegegaat 960 tattetteg tgegteeta teggtaaaa agagetgga ttaacaaa atteaatgeg 1020 aaatttaaca aaatattaae gettacaat taaatattg oetatacaa oetteetgagt 1100 aattttaaca aaatattaae gettacaat taaatattg oetatacaat oeteetgtt 1080 teggggett teeggatee tgeeegge acceegga atgeeegga ageeetgat 1140 ceggteetg getgeetge teeteegge attaceat taagatge ageetgaat ggeettigta 1140 cegteetga getgeetge teeteegge etteetee cettiggaat ggeettigta 1220 gaatttae aaatgeetg oetteeegg attaceae etteggaa ageetgget 1380 gaaattaae getgeet taaaatat gaggetea atagteetg teeteegget 1380 gaaattaae getgeget taaatata gaggetea attettege titgeetgat 1380 gaaattaaeg etteeegg aaatgat degggetaa attettige titgeetgat 1560 geeeaatg gatgtaag taaacaggt attegeeat teeggaagt atteagetg 1620 caaattaat geetegge titategat ageggetaa attettige teegatgget 1620 caaattaat geetegge titateget attegeat tigggaatg atteagetg 1620 caaattaat geetegge titateget agegetea attettige tiggeeatt teeggetge 1660 geeeaata geetegge taatata gatgateg taecaetg titateggaa tgaaactee 1680 aggeacega aaatatag taacaggt attgaceat tigggaaat aggetee titaagetg 1620 caaattaat deetegge gaattag gaateaeetg titataggaa tgaaactee 1680 aggeacega cittagte gaaattgg gaatcaactg titataggaa tgaaactee 1680 aggeacega cittagte gaattage tettacaaa aggageatt aaggaactt aaggaactta ageegaactee 1800 tetaateetg accetgeg attgetee gettigget eettaaaa aggagete teagaataa aggagetee 1800 tetaateetg accetge gattegee tettacaaa aggageatt aaggaatt	cttccggctc gtatgttgtg tggaattgtg agcggataac aatttcacac aggaaacagc	480
<pre>geatgcaage ttggeactgg cogtegttt acaacgtegt gactgggaaa accetggegt 600 tacceaactt aategeettg cageacatee ceettegee agetggegta atagegaaga 660 gggeeegeace gategeeett eceaacagtt gegeageetg aatggegat gggegttege 720 cetggttteeg geaceagaa eggtgeegga aagetgget gagtgeegate tteetagge 780 cegataetgte gtegteeeet eaaaetggea gatggeeggt taegatgege ceatetaeae 840 ceaaegtgaee tateceatta eggteaatee geegttgtt eceaeggaa ateegaeggg 900 ttgttaeteg geegteeet atggtaaga aagetgget acagaaggee agaegegaat 960 tatttttgat ggegteeta ttggtaaaa aatgagetga ttaacaat attaatgeg 1020 aaatttaaca aaatataae gtttaeaat taaatattg ettaacaat etteetggtt 1000 ttggteete aaeteggggta eaagetgget eettegaag ageetggat 1200 gatetetaa aaatatae eetteegge attaatta eagetagat gaegetgat ttaeeaat etteetgett 1000 ttggtaeteg geattegat tegeteeeg etteeteae atggetgat atgetgate 1260 ceatattgatg gtgatttgae tgeteeegge etteeteae atgetgeta atgetgget 1200 gattaattg geattgae tgeteeegge etteeteae atgetgeta atgetgget 1200 gattattag gedttegat taaaatata gagggteta aaatttta cegtegat 1220 gattaeteg geattgae tgeteeegge etteeteae 1320 ceatattgatg gtgatttgae tgeteeegge etteeteae ettegett 1380 gaaataaagg etteeeega aaagtatta eggggetea aaatttta teettgeegt 1560 ggeeceaaag aaaatage taacaaggt atggegatt gaegeaet tteeggetge 1560 gaactaat gaeaataage taacaaggt atggegatt tgegaaatg ateeaaetg 1620 ceaaactaaa etaetegte geagaatgg gaaceaetg ttaatgga tgaaactee 1680 aageeaeta eteetegte geagaatgg gaacaactg taatatgaa tgaaattee 1680 aageeaeta eteetege aaaatgae etettaaaa aggageaat aaggageat aaggtae 1840 ttaageetea ageeateeg aaaaagae etettaaaa aggageaat aaggageat aaagtaete 1840 ttaageetta ageeateeg aaaatgae etettaaaa aggageat aaggtae taataegaa 1740 ttaageetta geeeteeg aaaaagae etettaaaa aggageat aaggageat aaaggtaet 1840 ttaageetta geeeteeg aaaaagae etettaeaa aggageaat aaggtaete 1840 ttaageetta geeeteeg aaaaagae etettaeaa aggageatt aaggageatt aaggtaet 1840 ttageetta geeeteeg aaaaagae etettaeaa aggageaata aaggtaete 1840 ttagetta geeeteege aaaaagaete etettaeaa aggageaata aaggtaete 1840 ttageetee eeteegeaatge eaeaeatge</pre>	tatgaccatg attacgaatt cgagctcggt acccggggat cctctagagt cgacctgcag	540
tacccaactt aategoettg eageacatee eecttegee agetggegta atagegaaga 660 ggeeegeace gategoett eecaaactg gegeageetg aatggegat ggegettege 720 etggtteeg geaccagaag eggtgeegga aagetggetg gagtgegate teeetgage 780 eegatactge gtegteeet eaaactggea gatgeaegt acggatgeg eeatetaae 840 ecaacgtgaee tateceatta eggteaatee geegttgtt eecaeggag ateegaeggg 900 ttgttacteg etaecatta atgttgatga aagetggeta eaggaagee agaegegaat 960 ttgttacteg etaecatta atgttgatga aagetggeta eaggaagee agaegegaat 960 tatttttga ggegteeta teggtaaaa aatgagetga ttaacaaa attaatgeg 1020 aatttaaca aaatataae gtttaeaat taaatattg ettaacaaa etteatgg 1020 aattttaae aaatataae gtttaeaat taaatattg ettaacaat etteetgtt 1080 ttggggettt tetgatta acaeggggta eatagatga ageetgaat 1140 eegtteetg atteetgt tegeeegg etteetgaae etteetgate 1200 gatetetea aaatagetae eetteegge etteetgaae ggttgaata 1260 eatattgatg gtgattgae tgeteeegg etteetea ettegate ttaacaae ggttgaatat 1260 eatattgatg gtgattgae tgeteeegg etteetea ettegate ttacedea 1320 eatatatega gedattegae tgeteeegg etteetea ettegate ttacedea 1320 eatatateg gedattgae tgeteeegg etteetea atgegetea atgeeettg 1380 gaaataaagg etteeegg aaagget atagtgat atgeeett tteegegt 1560 gaettaattgg atgttaage taetaetat agtagaatg atgeeaett teegetgaa 1620 eaaatatagg agaataage taacaaggt attgeeaa tgeeaett teegeetge 1560 gaettaattgg atgttaage taetaetat agtagaatg atgeeaett teegeetge 1680 aggeeaetaa etaetgte geagaatgg gaateaaet taatagga tgaaattee 1680 aggeaaetaa etaetgte gaaatage tettateaa eatgtgege taeageatt atategga 1740 ttaageetta ageeateeg aaaaagaee tettaeaaa aggageatt aaaggtaet 1860	gcatgcaagc ttggcactgg ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt	600
gggccgcacc gatcgcctt cccaacagtt gcgcagcctg aatggcgat ggggtttge 720 ctggtttccg gcaccagaa cggtcggga aagctggct gatggcgga ctctcctgaggg 780 cgatactgc gtcgccct caactggca gatgccggt tacgatggc ccatctacac 840 caacgtgacc tatcccatta cggtcaatcc gcgtttgt cccacggaga atccgaggg 900 ttgttactcg ctcacatta atgttgatga aagctggct caggaagcc agacggaat 960 caattttag ggcgttccta ttggttaaaa aatgagcga tttaacaaa atttaatgcg 1020 aattttaaca aaatataac gtttacaat taaatattg cttaacaat cttcctgttt 1080 ttgggggttt tctgattat aaccgggga cctccagga atgaccgga agccgaat 1140 cogttcatcg attocttgt ttgcccaga ctctcagga atgaccgaa ggttgaatat 1200 ggatactcag gcattgcat tagatga ctctcagga atgaccggt agccggtt 1320 1380 caatatgatg gtgatttga tgactccgg ctttccacc ctttggat ttaccacaa 1440 catattgatg gcattgcat taaaatat gagggtca atggccaa tggtcgaat gtcctggt 1560 1560 ggacccaaatg aaaatatag taacacaggt atggaattg atgccactt tccagccag 1620 ggacccaaatg aaaatatage taacaggt atgggaca atggcaatg atgcaactg ttacacgat 140 140 ttagcttat gctcggge ttattgct aatttge aatgttga tgccaccga ttacctacaa 1500 ggaataagg atgtaatga tacacaggt atggaatg atgccactt ttcagctcgg 1620 caaactaaat ctactgtt gcagaatgg gaatcaactg ttataggaa tgaaacttc 1680 aagacaccgt ctttagtga atgtgac tcttacaa aggagcat aaggtaactg 1740 caaactaaat ctactgtt gaagttg atgccactt tgcgaaatg atgcacagaa 1740 caaactaaat ctactgtg actgttga gttgget cctatcaaa aggagcatt aaggtact 1800 caaactaaat ctactgg agttgge tcct cttacaaa aggagcat caaggtata 1800	tacccaactt aatcgccttg cagcacatcc ccctttcgcc agctggcgta atagcgaaga	660
<pre>ctggttccg gcaccagaag cggtgccgga aagctggctg gagtgcgatc ttcctgagg 780 cggtactgtc gtogtccct caactggca gatgcacggt tacgatgcgc ccatctacac 840 caacgtggac tatccatta cggtcaatce gccgtttgt cccacggaga atccgacggg 900 ttgttactcg ctcacattta atgttgatga aagctggcta caggaaggcc agacgcgaat 960 tattttgat ggcgttcct ttggttaaa aatgagctga tttaacaaa atttaatgcg 1020 aattttaaca aaatataac gtttacaatt taaatattg cttatacaat cttcctgttt 1080 ttggggcttt tctgattat aacggggta catatgattg acatgctagt ggttgatat 1140 cogttcateg attccttgt ttgctccaga ctctaggca atgaccgat aggttgatat 1260 catattgatg gtgattgac tgtcccgge ctttctcace cttttgate tttacctaca 1320 catattgatg gtgattgac tgtcccgge ctttctcace cttttggt tacaacggt 1440 ttagctta gcctgagge ttaatgatt agaggatct acggtgaatgt atcctaggtg 1560 ggattattgg atgttaatge tacacatt agtagaatg atgccacct ttcagctcg 1560 ggatttattgg atgttaatge taacaaggt attgaccatt tggaaatgt atcaatggt 1620 caaactaaat ctactcgtte gcagaattgg gaatcaactg ttatatggaa tgaaacttce 1680 agacaccgta ctttagttge atattaaa cagtgtge tacaggatt aagggtcat aagggtact 1680 agacaccgta cttagtge gattgctec ggtcggtte gcttgaage tcgaattaa 1860 accgggatatt tgaagtett cgggcttcc ctaatctt ttgatgcaat ccgcttgge 1920</pre>	ggcccgcacc gatcgccctt cccaacagtt gcgcagcctg aatggcgaat ggcgctttgc	720
egatactgte gtegteceet eaaactggea gatgeaeggt taegatgege eeatetaeae 840 caaegggaee tateeeatta eggteaatee geegtttgt eeeaeggaga ateegaeggg 900 ttgttaeteg eteaeatta atgttgatga aagetggeta eaggaaggee agaegegaat 960 tattttgat ggegtteet ttggttaaaa aatgageega tttaacaaaa atttaatgeg 1020 aattttaaca aaatattae gtttaeaat taaatattg ettaacaaa atttaatgeg 1020 aattttaaea aaatattae gtttaeaat taaatattg ettaacaaa etteetgett 1080 ttggggettt tetgattate aaeeggggta eatagattg acatgetagt tttaegatta 1140 eeggteetg atteetetg ttgeeeaga eteeeaggea atgaeetgat ageettgta 1200 gateeteea aaatagetae eeeteegge attaattat eagetagaae ggttgaatat 1260 catattgatg gtgatttgae tgeeteegge etteeteae etteggett 1380 gaaataaagg etteeege aaaagtatta eaggggetaa atgeeeaga 1440 ttagetttat geeetgagge ttattgett aatttgeet attettgee ttgeeegget 1560 geeeeaaagt ageettee taetaetat agtagaattg atgeeeaett tteegeteg 1560 geeeeaaagt atteteegg egaattge gaateeaetg ttatatggaa tgaaeettee 1680 agaeaaetaaat etaetegte geagaattg gaateeaetg ttatatggaa tgaaeettee 1680 agaeaetaaat etteegge aaaatgage teetaeaaa aggageata taatgaatta tatteegeaa 1740 ttaageetta ageeateeg aaaatgaee teettaeaa aggageatat aaaggtaet 1860 agaeateeg acetgega gtttgettee ggteggettee gettgage teegaattaa 1860 aggegatatt tgaagtett egggetteee ettaatett tggagaet gettgaage tegaattaa 1860	ctggtttccg gcaccagaag cggtgccgga aagctggctg gagtgcgatc ttcctgaggc	780
caacgtgace tateecatta eggteaatee geegtttgt eecaeggaga ateegaegg 900 ttgttacteg etcacattta atgttgatga aagetggeta caggaaggee agaegegaat 960 tatttttgat ggegtteeta ttggttaaaa aatgagetga tttaacaaa atttaatgeg 1020 aattttaaca aaatataae gtttacaatt taaatattg ettaacaaa atttaatgeg 1020 ttggggettt tetgattate aaceggggta eatagattg eetatgatg tttaegatta 1140 cogtteateg atteetetgt ttgeteeaga eteteaggea atgaeetgaa aggettgaatat 1200 gateeteea aaatagetae eeteeggee attaattta eagetagaae ggttgaatat 1260 catattgatg gtgatttgae tgeteegge etteeage etteteage 1120 gaaataaagg etteeege aaaagtatta eagggeteta aaaatttta teettgeett 1380 gaaataaagg etteeege aaaagtatta eagggetaa atgetetgg tacaacegat 1440 ttagetttat geeetgagge titattget aatttgeta attettgee ttgeetgeta 1500 gaettattgg atgttaatge taetaetatt agtagaattg atgeeacett tteageteg 1560 geeeeaaag aaaatatage taaeaaggt attgaeeat tgegaaagt ateataggt 1620 caaaactaaat etaetegte geagaattgg gaateaactg ttatatggaa tgaaacttee 1680 agaecaecgta etttagttge atatttaaaa eatgttgage taeageatta tatteageaa 1740 ttaageetta ageeateeg aaaaatgaee tettacaaa aggageaatt aaaggtaet 1860 agaecaecgta etttagteg agutgettee ggtetggte gettgaage tegaattaa 1860 aegegaatt tgaagtett egggetteee ettaatett tgatgeaat eegetttget 1920	cgatactgtc gtcgtcccct caaactggca gatgcacggt tacgatgcgc ccatctacac	840
tigttactog otoacatta atgtigatga aagotggota caggaaggoc agaogogaat 960 tatttigat ggogtocta tiggttaaaa aatgagotga titaacaaaa atttaatgog 1020 aatttaaca aaatattaac gittacaatt taaatattig ottatacaat ottootgitt 1080 tiggggotti totgattate aacoggggta catatgattg acatgotagt titacgatta 1140 cogticateg attoottig tigotocaga otoocagoa atgacetgat agoottigta 1200 gateteteaa aaatagotae cotoccogge attaattita cagetagaac ggtigaatat 1260 catattgatg gigattigae igitocogge ottoocace ottitgaate titacetaca 1320 catattagatg gigattigae igitocogge ottootaece ottitgaate titacetaca 1320 gaaataaagg ottoocege aaaagtatta caggggteata atgittigg tacaacegat 1440 titagetitat gototgagge titattgeti aattetigeta attettige tigocoge 1560 gacceaaatg aaaatatage tacacatat agtagaattg atgocacett ticagetega 1560 gacceaaatg aaaatatage taaacaggt attgaceat tigogaaatg tacaagetg 1620 caaaactaaat ciactegtte geagaatgg gaatcaacig tiatatggaa tgaaactice 1680 aggacacegta ettiagtige atattiaaaa catgitigage tacageatta tatteageaa 1740 titaageteta agecateceg aaaaatgace tottateaaa aggagcaatt aaaggtace 1800 tetaaacctg accegtigga gittigetice ggteggtie gettigaage tigaatta aaagtata aaggagatat tigaagtott egggetiee dettatetti tigatgeaat eegettiget 1820	caacgtgacc tatcccatta cggtcaatcc gccgtttgtt cccacggaga atccgacggg	900
tattttgat ggegtteeta ttggttaaaa aatgagetga tttaacaaaa atttaatgeg 1020 aattttaaca aaatataac gtttacaatt taaatatttg ettatacaat etteetgttt 1080 ttggggettt tetgattate aaceggggta catatgattg acatgetagt tttaegatta 1140 eegtteateg atteetetg ttgeteeaga eteteaggea atgaeetgat ageetttgta 1200 gateteetea aaatagetae eeteeegge attaatttat eagetagaae ggttgaatat 1260 eatattgatg gtgatttgae tgeteegge etteeteace etttgaate tttaeetaea 1320 eatattegag geattgeat taaaatatt gagggtteta aaaatttta teettgegtt 1380 gaaataaagg etteeteegage ettattget aatttgeta atgetttgg taeaacegat 1440 ttagetttat getetgagge tttattgett aatttgeta atgetttge tgeetget 1560 geeeeeaaat gaaatatage taaacaggtt attgaeeatt tgegaaatgt atetaatggt 1620 eaaactaaat etaetegte geagaattg ggaatega tgegaatgt atetaatggt 1620 eaaactaaat etaetegte geagaattg gaateaaetg ttatatggaa tgaaacttee 1680 agaacacegta etttagteg aaaatagee tettateaaa eagggegaatt atgageatta tatteageaa 1740 ttaageteta ageeateege aaaaatgaee tettateaaa aggageaatt aaaggtaete 1800 ettaageteta geetgtgga gtttgettee ggtetggtte geettgaage tegaattaa 1860 aagegatatt tgaagtett egggetteet ettaatett ttgatgeaat eegetttget 1920	ttgttactcg ctcacattta atgttgatga aagctggcta caggaaggcc agacgcgaat	960
aattttaaca aaatattaac gtttacaatt taaatatttg cttatacaat ctteetgttt 1080 ttggggettt tetgattate aaceggggta catatgattg acatgetagt tttaegatta 1140 cegtteateg atteettg ttgeteeaga eteteaggea atgaeetgat ageetttgta 1200 gateteetea aaatagetae eeteeegge attaatttat eagetagaae ggttgaatat 1260 catattgatg gtgatttgae tgeteegge etteeteace ettttgaate tttaeetaea 1320 catateegg geattgeatt taaaatatt gagggeteta aaaatttta teettgegtt 1380 gaaataaagg etteeeege aaaagtatta eagggetata atgettttgg taeaacegat 1440 ttagetttat geteeggge tttattgett aattttgeta attettgee ttgeeetgta 1500 gaettaattgg atgttaatge taetaetatt agtagaattg atgeeaeett tteageteg 1560 geeeeaaatg aaaatatage taaacaggtt attgaeeatt tgegaaatgt ateeaatggt 1620 caaaaetaaat etaetegtte geagaattg gaateaaetg ttatatggaa tgaaaettee 1680 agaeacegta etttagttge atattaaaa eatgttgage taeageatta tatteagea 1740 ttaageteta ageeateege aaaatgaee tettateaaa aggageaatt aaaggtaete 1800 tetaateetg acetgttgga gtttgettee ggtetggte getttgaage tegaattaa 1860 aceeggatatt tgaagtettt egggetteet ettaatettt ttgatgeaat eegetttget 1920	tatttttgat ggcgttccta ttggttaaaa aatgagctga tttaacaaaa atttaatgcg	1020
ttggggettt tetgattate aaceggggta eatatgattg acatgetagt tttaegatta 1140 eegiteateg attetetigt ttgeteeaga eteteaggea atgaeetgat ageettigta 1200 gateteetaa aaatagetae eeteteegge attaatttat eagetagaae ggttgaatat 1260 eatattgatg gtgatttgae tgteteegge ettteteaee etttgaate tttaeetaea 1320 eattaeteag geattgeatt taaaatatat gagggteeta aaaatttta teetiggett 1380 gaaataaagg etteeegee aaaagtatta eagggteata atgttttgg taeaaeegat 1440 ttageettat geteigagge tttattgett aattetigee atteetigee tteegeege 1560 geeeeaaagt aaaataage taaeaeggtt attgaeeatt tgegaaatgt ateeaaeggt 1620 eaaaaetaaat etaetegte geagaattgg gaateaaeetg ttaatggaa tgaaaettee 1680 agaeeaeega etttagtige aaaaatgaee teettaeaaa aggageaatt aaaggtaete 1800 ttaageetea ageeateege aaaaatgaee teettaeaaa aggageaatt aaaggtaete 1800 teetaateeeg acetgtigga gttigettee ggteggtte gettigaage tegaattaaaa 1860	aattttaaca aaatattaac gtttacaatt taaatatttg cttatacaat cttoctgttt	1080
eegtteateg atteettigt tigeteeaga eteteaggea atgaeetiga ageettigta 1200 gateteetaa aaatagetae eeteteegge attaatttat eagetagaae ggttgaatat 1260 eaatattgatg gigattigae tigeteegge etteeteaee ettitgaate titaeetaaa 1320 eaataatagg geattgeat taaaatata gagggteeta aaaattetta teetigegtt 1380 gaaataaaagg etteeegge aaaagtatta eagggteata atgettitgg taeaaeeggat 1440 etageettat geteegagge titattgeet aattetigeta attettigee tigeeetgat 1500 gattattigg atgetaatge taeaeeaggtt attgaeeatt tigegaaatgt ateeaaeggt 1620 eaaaeeaaat etaeeegte geagaattgg gaateaaeetg titaataggaa tigaaaeettee 1680 agaaeaeegga etttagete aaaatgaee teetateaaa aggageeatt atagegeaa 1740 etaageeteta ageeateegg agattgetee ggteeggte geettigaage tegaattaaa 1860	ttggggcttt tctgattatc aaccggggta catatgattg acatgctagt tttacgatta	1140
<pre>gateteteaa aaatagetae eeteteegge attaatttat eagetagaae ggttgaatat 1260 catattgatg gtgatttgae tgteteegge ettteteace ettttgaate tttaeetaea 1320 cattaeteag geattgeat taaaatatat gagggtteta aaaattttta teettgegtt 1380 gaaataaagg etteteegge aaaagtatta eagggteata atgttttgg taeaaeegat 1440 ttagetttat getetgagge tttattgett aatttgeta attetttgee ttgeetgtat 1500 gatttattgg atgttaatge taetaetatt agtagaattg atgeeaeett tteagetege 1560 geeeeaaatg aaaatatage taaaeaggtt attgaeeatt tgeegaaatgt atetaateggt 1620 caaaeetaaat etaetegtte geagaattgg gaateaaeetg ttatatggaa tgaaaeettee 1680 agaeeeegta etttagttge atatttaaaa eatgttgage taeeageatta tatteegeaa 1740 ttaageteta ageeateegg agttgettee ggtetggtte getttgaage tegaattaaa 1860 aegeegatatt tgaagtettt egggetteet ettaatettt ttgatgeaat eegettget 1920</pre>	cogttcatog attotottgt ttgotocaga ototoaggoa atgaootgat agootttgta	1200
catattgatg gtgatttgac tgteteegge etteteace ettetgaate tttaectaca 1320 cattaeteag geattgeatt taaaatatat gagggtteta aaaatttta teettgegtt 1380 gaaataaagg etteteegge aaaagtatta cagggteata atgttttgg taeaacegat 1440 ttagetttat getetgagge tttattgett aattttgeta attetttgee ttgeetgtat 1500 gatttattgg atgttaatge taetaetatt agtagaattg atgeeaeett tteagetege 1560 geeeeaaatg aaaatatage taaacaggtt attgaeeatt tgegaaatgt atetaatggt 1620 caaaaetaaat etaetegtte geagaattgg gaateaaetg ttatatggaa tgaaaettee 1680 agaeeeegta etttagttge atatttaaaa eatgttgage taeageatta tatteageaa 1740 ttaageteta ageeateege aaaaatgaee teetatteaa aggageaatt aaaggtaete 1800 tetaateetg acetgttgga gttgettee ggtetggtte getttgaage tegaattaaa 1860	gateteteaa aaatagetae eeteteegge attaatttat eagetagaae ggttgaatat	1260
cattactcag gcattgcatt taaaatatat gagggttcta aaaattttta tccttgcgtt 1380 gaaataaagg cttctcccgc aaaagtatta cagggtcata atgtttttgg tacaaccgat 1440 ttagctttat gctctgaggc tttattgctt aattttgcta attctttgcc ttgcctgtat 1500 gattattgg atgttaatgc tactactatt agtagaattg atgccacctt ttcagctcgc 1560 gccccaaatg aaaatatagc taaacaggtt attgaccatt tgcgaaatgt atctaatggt 1620 caaactaaat ctactcgttc gcagaattgg gaatcaactg ttatatggaa tgaaacttcc 1680 agacaccgta ctttagttgc atatttaaaa catgttgagc tacagcatta tattcagcaa 1740 ttaagctcta agccatccgc aaaaatgacc tcttatcaaa aggagcaatt aaaggtactc 1800 tctaatcctg acctgttgga gtttgcttcc ggtctggttc gctttgaagc tcgaattaa 1860 acgcgatatt tgaagtcttt cggggcttcct cttaatcttt ttgatgcaat ccgctttgct 1920	catattgatg gtgatttgac tgtctccggc ctttctcacc cttttgaatc tttacctaca	1320
<pre>gaaataaagg cttctcccgc aaaagtatta cagggtcata atgtttttgg tacaaccgat 1440 ttagctttat gctctgaggc tttattgctt aattttgcta attctttgcc ttgcctgtat 1500 gatttattgg atgttaatgc tactactatt agtagaattg atgccacctt ttcagctcgc 1560 gccccaaatg aaaatatagc taaacaggtt attgaccatt tgcgaaatgt atctaatggt 1620 caaactaaat ctactcgttc gcagaattgg gaatcaactg ttatatggaa tgaaacttcc 1680 agacaccgta ctttagttgc atatttaaaa catgttgagc tacagcatta tattcagcaa 1740 ttaagctcta agccatccgc aaaaatgacc tcttatcaaa aggagcaatt aaaggtactc 1800 tctaatcctg acctgttgga gtttgcttcc ggtctggttc gctttgaagc tcgaattaaa 1860 acgcgatatt tgaagtcttt cgggcttcct cttaatcttt ttgatgcaat ccgctttgct 1920</pre>	cattactcag gcattgcatt taaaatatat gagggttcta aaaattttta tccttgcgtt	1380
ttagetttat getetgagge tttattgett aattttgeta attetttgee ttgeetgtat 1500 gatttattgg atgttaatge taetaetatt agtagaattg atgecaectt tteagetege 1560 geeeceaaatg aaaatatage taaacaggtt attgaceatt tgegaaatgt atetaatggt 1620 caaaeetaaat etaetegtte geagaattgg gaateaaetg ttatatggaa tgaaaettee 1680 agaeaeegta etttagttge atatttaaaa eatgttgage taeageatta tatteageaa 1740 ttaageteta ageeateege aaaaatgaee tettateaaa aggageaatt aaaggtaete 1800 tetaateetg aeetgttgga gttgettee ggtetggtte getttgaage tegaattaaa 1860 acgegatatt tgaagtettt egggetteet ettaatettt ttgatgeaat eegetttget 1920	gaaataaagg cttctcccgc aaaagtatta cagggtcata atgtttttgg tacaaccgat	1440
yatttattgg atgttaatge taetaetatt agtagaattg atgeeaeett tteagetege 1560 geeeeaaatg aaaatatage taaacaggtt attgaeeatt tgegaaatgt atetaatggt 1620 caaaeetaaat etaetegtte geagaattgg gaateaaetg ttatatggaa tgaaaettee 1680 agaeaeegta etttagttge atatttaaaa eatgttgage taeageatta tatteageaa 1740 etaageteta ageeateege aaaaatgaee tettateaaa aggageaatt aaaggtaete 1800 tetaateetg aeetgttgga gttgettee ggtetggtte gettgaage tegaattaaa 1860 aegeegatatt tgaagteett egggetteet ettaateett ttgatgeaat eegetttget 1920	ttagetttat getetgagge tttattgett aattttgeta attetttgee ttgeetgtat	1500
geeecaaatg aaaatatage taaacaggtt attgaceatt tgegaaatgt atctaatggt 1620 caaactaaat etaetegtte geagaattgg gaateaaetg ttatatggaa tgaaaettee 1680 agacaeegta etttagttge atatttaaaa eatgttgage taeageatta tatteageaa 1740 ctaageteta ageeateege aaaaatgaee tettateaaa aggageaatt aaaggtaete 1800 cetaateetg aeetgttgga gtttgettee ggtetggtte getttgaage tegaattaaa 1860 aegeegatatt tgaagtettt egggetteet ettaateett ttgatgeaat eegetttget 1920	gatttattgg atgttaatgc tactactatt agtagaattg atgccacctt ttcagctcgc	1560
caaactaaat ctactcgttc gcagaattgg gaatcaactg ttatatggaa tgaaacttcc 1680 agacaccgta ctttagttgc atatttaaaa catgttgagc tacagcatta tattcagcaa 1740 ctaagctcta agccatccgc aaaaatgacc tcttatcaaa aggagcaatt aaaggtactc 1800 cctaatcctg acctgttgga gtttgcttcc ggtctggttc gctttgaagc tcgaattaaa 1860 acgcgatatt tgaagtcttt cgggcttcct cttaatcttt ttgatgcaat ccgctttgct 1920	geoceaaatg aaaatatage taaacaggtt attgaceatt tgegaaatgt atetaatggt	1620
agacaccgta ctttagttgc atatttaaaa catgttgagc tacagcatta tattcagcaa 1740 ttaagctcta agccatccgc aaaaatgacc tcttatcaaa aggagcaatt aaaggtactc 1800 tctaatcctg acctgttgga gtttgcttcc ggtctggttc gctttgaagc tcgaattaaa 1860 acgcgatatt tgaagtcttt cgggcttcct cttaatcttt ttgatgcaat ccgctttgct 1920	caaactaaat ctactcgttc gcagaattgg gaatcaactg ttatatggaa tgaaacttcc	1680
ttaageteta ageeateege aaaaatgaee tettateaaa aggageaatt aaaggtaete 1800 tetaateetg aeetgttgga gtttgettee ggtetggtte getttgaage tegaattaaa 1860 aegegatatt tgaagtettt egggetteet ettaatettt ttgatgeaat eegetttget 1920	agacaccgta ctttagttgc atatttaaaa catgttgagc tacagcatta tattcagcaa	1740
tctaateetg aeetgttgga gtttgettee ggtetggtte getttgaage tegaattaaa 1860 aegegatatt tgaagtettt egggetteet ettaatettt ttgatgeaat eegetttget 1920	ttaagctcta agccatccgc aaaaatgacc tottatcaaa aggagcaatt aaaggtactc	1800
acgegatatt tgaagtettt egggetteet ettaatettt ttgatgeaat eegetttget 1920	tctaatcctg acctgttgga gtttgcttcc ggtctggttc gctttgaagc tcgaattaaa	1860
	acgcgatatt tgaagtettt egggetteet ettaatettt ttgatgeaat eegetttget	1920

95

-continued

tetgaetata atagteaggg taaagaeetg atttttgatt tatggteatt etegttttet 1980 gaactgttta aagcatttga gggggattca atgaatattt atgacgattc cgcagtattg 2040 gacgetatec agtetaaaca ttttactatt acceetetg geaaaaette ttttgeaaaa 2100 gcctctcgct attttggttt ttatcgtcgt ctggtaaacg agggttatga tagtgttgct 2160 cttactatgc ctcgtaattc cttttggcgt tatgtatctg cattagttga atgtggtatt 2220 2280 cctaaatctc aactgatgaa tctttctacc tgtaataatg ttgttccgtt agttcgtttt attaacgtag atttttcttc ccaacgtcct gactggtata atgagccagt tcttaaaatc 2340 gcataaggta attcacaatg attaaagttg aaattaaacc atctcaagcc caatttacta 2400 ctcgttctgg tgtttctcgt cagggcaagc cttattcact gaatgagcag ctttgttacg 2460 ttgatttggg taatgaatat ccggttcttg tcaagattac tcttgatgaa ggtcagccag 2520 cctatgcgcc tggtctgtac accgttcatc tgtcctcttt caaagttggt cagttcggtt 2580 cccttatgat tgaccgtctg cgcctcgttc cggctaagta acatggagca ggtcgcggat 2640 ttegacacaa tttateagge gatgatacaa ateteegttg taetttgttt egegettggt 2700 ataatcgctg ggggtcaaag atgagtgttt tagtgtattc ttttgcctct ttcgttttag 2760 gttggtgddt togtagtggd attacgtatt ttacoogttt aatggaaadt tootcatgaa 2820 aaaqtettta qteetcaaaq eetetqtaqe eqttqetace eteqtteeqa tqetqtett 2880 cqctqctqaq qqtqacqatc ccqcaaaaqc qqcctttaac tccctqcaaq cctcaqcqac 2940 cgaatatatc ggttatgcgt gggcgatggt tgttgtcatt gtcggcgcaa ctatcggtat 3000 caagctgttt aagaaattca cctcgaaagc aagctgataa accgatacaa ttaaaggctc 3060 cttttggagc ctttttttg gagattttca acgtgaaaaa attattattc gcaattcctt 3120 tagttgttcc tttctattct cactccgctg aaactgttga aagttgttta gcaaaatccc 3180 atacagaaaa ttcatttact aacgtctgga aagacgacaa aactttagat cgttacgcta 3240 actatgaggg ctgtctgtgg aatgctacag gcgttgtagt ttgtactggt gacgaaactc 3300 agtgttacgg tacatgggtt cctattgggc ttgctatccc tgaaaatgag ggtggtggct 3360 ctgagggtgg cggttctgag ggtggcggtt ctgagggtgg cggtactaaa cctcctgagt 3420 acggtgatac acctattccg ggctatactt atatcaaccc tctcgacggc acttatccgc 3480 3540 ctggtactga gcaaaacccc gctaatccta atccttctct tgaggagtct cagcctctta atactttcat gtttcagaat aataggttcc gaaataggca gggggcatta actgtttata 3600 cgggcactgt tactcaaggc actgaccccg ttaaaactta ttaccagtac actcctgtat 3660 catcaaaagc catgtatgac gcttactgga acggtaaatt cagagactgc gctttccatt 3720 ctggctttaa tgaggattta tttgtttgtg aatatcaagg ccaatcgtct gacctgcctc 3780 aaceteetgt caatgetgge ggeggetetg gtggtggtte tggtggegge tetgagggtg 3840 3900 gtggetetga gggtggeggt tetgagggtg geggetetga gggaggeggt teeggtggtg gctctggttc cggtgatttt gattatgaaa agatggcaaa cgctaataag ggggctatga 3960 ccgaaaatgc cgatgaaaac gcgctacagt ctgacgctaa aggcaaactt gattctgtcg 4020 ctactgatta cggtgctgct atcgatggtt tcattggtga cgtttccggc cttgctaatg 4080 gtaatggtgc tactggtgat tttgctggct ctaattccca aatggctcaa gtcggtgacg 4140 gtgataattc acctttaatg aataatttcc gtcaatattt accttccctc cctcaatcgg 4200

ttgaatgtcg cccttttgtc tttggcgctg gtaaaccata tgaattttct attgattgtg

97

acaaaataaa	cttattccgt	ggtgtctttg	cgtttcttt	atatgttgcc	acctttatgt	4320
atgtatttc	tacgtttgct	aacatactgc	gtaataagga	gtcttaatca	tgccagttct	4380
tttgggtatt	ccgttattat	tgcgtttcct	cggtttcctt	ctggtaactt	tgttcggcta	4440
tctgcttact	tttcttaaaa	agggcttcgg	taagatagct	attgctattt	cattgtttct	4500
tgctcttatt	attgggctta	actcaattct	tgtgggttat	ctctctgata	ttagcgctca	4560
attaccctct	gactttgttc	agggtgttca	gttaattctc	ccgtctaatg	cgcttccctg	4620
tttttatgtt	attctctctg	taaaggctgc	tattttcatt	tttgacgtta	aacaaaaaat	4680
cgtttcttat	ttggattggg	ataaataata	tggctgttta	ttttgtaact	ggcaaattag	4740
gctctggaaa	gacgctcgtt	agcgttggta	agattcagga	taaaattgta	gctgggtgca	4800
aaatagcaac	taatcttgat	ttaaggcttc	aaaacctccc	gcaagtcggg	aggttcgcta	4860
aaacgcctcg	cgttcttaga	ataccggata	agccttctat	atctgatttg	cttgctattg	4920
ggcgcggtaa	tgattcctac	gatgaaaata	aaaacggctt	gcttgttctc	gatgagtgcg	4980
gtacttggtt	taatacccgt	tcttggaatg	ataaggaaag	acagccgatt	attgattggt	5040
ttctacatgc	tcgtaaatta	ggatgggata	ttatttttct	tgttcaggac	ttatctattg	5100
ttgataaaca	ggcgcgttct	gcattagctg	aacatgttgt	ttattgtcgt	cgtctggaca	5160
gaattacttt	accttttgtc	ggtactttat	attctcttat	tactggctcg	aaaatgcctc	5220
tgcctaaatt	acatgttggc	gttgttaaat	atggcgattc	tcaattaagc	cctactgttg	5280
agcgttggct	ttatactggt	aagaatttgt	ataacgcata	tgatactaaa	caggettttt	5340
ctagtaatta	tgattccggt	gtttattctt	atttaacgcc	ttatttatca	cacggtcggt	5400
atttcaaacc	attaaattta	ggtcagaaga	tgaaattaac	taaaatatat	ttgaaaaagt	5460
tttctcgcgt	tctttgtctt	gcgattggat	ttgcatcagc	atttacatat	agttatataa	5520
cccaacctaa	gccggaggtt	aaaaaggtag	tctctcagac	ctatgatttt	gataaattca	5580
ctattgactc	ttctcagcgt	cttaatctaa	gctatcgcta	tgttttcaag	gattctaagg	5640
gaaaattaat	taatagcgac	gatttacaga	agcaaggtta	ttcactcaca	tatattgatt	5700
tatgtactgt	ttccattaaa	aaaggtaatt	caaatgaaat	tgttaaatgt	aattaatttt	5760
gttttcttga	tgtttgtttc	atcatcttct	tttgctcagg	taattgaaat	gaataattcg	5820
cctctgcgcg	attttgtaac	ttggtattca	aagcaatcag	gcgaatccgt	tattgtttct	5880
cccgatgtaa	aaggtactgt	tactgtatat	tcatctgacg	ttaaacctga	aaatctacgc	5940
aatttcttta	tttctgtttt	acgtgcaaat	aattttgata	tggtaggttc	taacccttcc	6000
attattcaga	agtataatcc	aaacaatcag	gattatattg	atgaattgcc	atcatctgat	6060
aatcaggaat	atgatgataa	ttccgctcct	tctggtggtt	tctttgttcc	gcaaaatgat	6120
aatgttactc	aaacttttaa	aattaataac	gttcgggcaa	aggatttaat	acgagttgtc	6180
gaattgtttg	taaagtctaa	tacttctaaa	tcctcaaatg	tattatctat	tgacggctct	6240
aatctattag	ttgttagtgc	tcctaaagat	attttagata	accttcctca	attcctttca	6300
actgttgatt	tgccaactga	ccagatattg	attgagggtt	tgatatttga	ggttcagcaa	6360
ggtgatgctt	tagatttttc	atttgctgct	ggctctcagc	gtggcactgt	tgcaggcggt	6420
gttaatactg	accgcctcac	ctctgtttta	tcttctgctg	gtggttcgtt	cggtatttt	6480
aatggcgatg	ttttagggct	atcagttcgc	gcattaaaga	ctaatagcca	ttcaaaaata	6540
ttgtctgtgc	cacgtattct	tacgctttca	ggtcagaagg	gttctatctc	tgttggccag	6600
aatgtccctt	ttattactgg	tcgtgtgact	ggtgaatctg	ccaatgtaaa	taatccattt	6660
			- 0	-		

99

100

-continued

cagacgattg agcgtcaaaa tgtaggtatt tccatgagcg tttttcctgt tgcaatggct 6720 ggcggtaata ttgttctgga tattaccagc aaggccgata gtttgagttc ttctactcag 6780 gcaagtgatg ttattactaa tcaaagaagt attgctacaa cggttaattt gcgtgatgga 6840 cagactettt tacteggtgg eetcaetgat tataaaaaca etteteagga ttetggegta 6900 ccgttcctgt ctaaaatccc tttaatcggc ctcctgttta gctcccgctc tgattctaac 6960 gaggaaagca cgttatacgt gctcgtcaaa gcaaccatag tacgcgccct gtagcggcgc 7020 attaagegeg gegggtgtgg tggttaegeg eagegtgaee getaeaettg eeagegeeet 7080 agegeeeget cetttegett tetteeette etttetegee aegttegeeg gettteeeeg 7140 tcaageteta aateggggge teeettagg gtteegattt agtgetttae ggeaeetega 7200 ccccaaaaaa cttgatttgg gtgatggttc acgtagtggg ccatcgccc 7249 <210> SEQ ID NO 124 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: fluorescence assay sequence <400> SEQUENCE: 124 attaccgtat agcat 15 <210> SEQ ID NO 125 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: fluorescence assay sequence <400> SEQUENCE: 125 15 atgctatacg gtaat <210> SEQ ID NO 126 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: MD simulation nucleic acid <400> SEQUENCE: 126 15 attaccgtat agcat <210> SEQ ID NO 127 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: AuCoated OC structure <400> SEQUENCE: 127 Cys Ala Leu Asp Asp Lys 5 1

102

What is claimed is: 1. A composition for stabilizing a biomaterial, said com-position comprising a compound of Formula (I), wherein Formula (I) comprises:























113 2. A stabilized nanoparticle, wherein the nanoparticle comprises a compound of Formula (I) as described in claim **1**.

* * * * *